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Abstract 
 
Telomerase activity can be detected in about 80% of non-small cell lung cancers (NSCLC). 
Inhibition of telomerase is a specific approach for treatment of NSCLC. The oligonucleotide 
2´-O-methyl-RNA (OMR) binding to the RNA component of telomerase acts as a selective 
telomerase inhibitor. Chitosan-coated poly(lactide-co-glycolide) (PLGA) nanoparticles which 
are capable to form nanoplexes with OMR are one promising carrier system for OMR 
delivery. This thesis is mainly focused on the therapeutic potential of OMR based on different 
in vitro and ex vivo models. In cell culture models, delivery of OMR by nanoparticles 
exhibited 50%-70% telomerase inhibition 72h after treatment. In A549 cells telomerase 
activity was continuously reduced by 80% and the telomere length shortened about 50% 
during a treatment for 102 days with nanoplexes. In a new tissue slice model, nanoplexes can 
penetrate into tumor tissue slices, deliver OMR and subsequently inhibit telomerase activity 
by about 40% without changing tissue architecture. An isolated perfused rat lung model was 
successfully applied to investigate the inhalative delivery of nanoplexes to the lung without 
altering lung physiology. In 40 NSCLC tumor samples, stem cell marker CD133 positive 
tumor cells tend to have a lower telomerase activity. These experiments provide evidence that 
telomerase inhibitors delivered by nanoparticles have a great potential for in vivo application 
to render a more selective anticancer therapy. 
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Kurzzusammenfassung 
 
Etwa 80% aller nicht-kleinzelligen Lungentumoren (NSCLC) weisen Telomerase-Aktivität 
auf. Hemmung der Telomerase wäre eine spezifische Tumortherapie. Das Oligonukleotid 2'-
O-Methyl-RNA (OMR) bindet an die RNA Komponente der Telomerase und ist ein selektiver 
Telomerase-Inhibitor. Chitosan beschichtete Polylaktat-coglykolat (PLGA)-Nanopartikel, die 
mit OMR Nanoplexe bilden, sind ein vielversprechendes Trägersystem. Diese Arbeit setzt 
verschiedene in vitro Modelle ein, um das therapeutische Potenzial von OMR zu untersuchen. 
Eine Nanopartikel-vermittelte Aufnahme von OMR in NSCLC Zelllinien und primäre 
humane Lungenkarzinomzellen führte nach 72 Stunden zu einer 50% bis 70%igen Hemmung 
der Telomerase. Eine 102-tägige Behandlung von A549 Zellen mit Nanoplexen reduzierte die 
Telomerase-Aktivität kontinuierlich um 80% und verkürzte die Telomere auf etwa 50%. 
Nanoplexe drangen in ex vivo kultiviertes Tumorgewebe ein. Die so eingeschleuste OMR 
hemmte die Telomerase-Aktivität um etwa 40%, ohne die Gewebe-Struktur zu verändern. Im 
Modell der isoliert perfundierten Rattenlunge wurden Nanoplexe inhalativ verabreicht, ohne 
die Lungenphysiologie zu verändert. OMR konnte in diesen Lungen nachgewiesen werden. In 
40 NSCLC Proben zeigten die Tumorzellen mit positiver Expression des Stammzell-Markers 
CD133 eine Tendenz zu einer geringeren Telomerase-Aktivität. Diese Experimente zeigen, 
dass die Nanoplexe ein großes Potenzial für die in vivo Anwendung und eine selektivere 
Krebstherapie haben.  
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Parts of this chapter have been published as an editorial commentary in European 
Journal of Clinical Pharmacology: 
Dong M, Mürdter TE, Klotz U.  
Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in 
Physiology or Medicine. Eur J Clin Pharmacol. 2010 Jan;66(1):1-3. 
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1.1 Lung 
The lung is one of the largest organs in the human body where respiration takes place. It is 
divided into lobes by interlobular fissures. The left lung consists of two lobes (upper and 
lower lobes). The right lung consists of three lobes (upper, middle and lower lobes). They are 
separated into several bronchopulmonary segments and further into many lobules. In humans, 
the trachea splits into two main bronchi that enter the lungs. The bronchi continue to divide 
within the lung and give rise to bronchioles. At the level of terminal bronchioles, the alveolar 
sacs are made up of clusters of alveoli (Fig.1). The individual alveoli are tightly wrapped in 
blood vessels where gas exchange occurs [http://www.theodora.com/anatomy/the_lungs.html]. 
Each lobe is supplied by a secondary bronchus. Each segment is supported by a tertiary 
bronchus that is a branch of the secondary bronchus. Each lobule has a lymphatic vessel, an 
arteriole, a venule, and a branch from terminal bronchioles (Fig.1). Terminal bronchioles are 
subdivided into tiny branches called respiratory bronchioles and further into several (2 to 11) 
alveolar ducts.  
Fig. 1: The structure of lung 
(Modified from http://commons.wikimedia.org/wiki/File: Lungs_ (animated).gif; http://en.wikipedia. 
org/wiki/File:Alveolus_diagram.svg, accessed 23rd Nov. 2010) 
The substance of the lung is a light, porous, spongy texture. The normal human lungs weigh 
about 1kg containing 40% to 50% blood. Nearly 50 distinct types of cells have been identified 
in the lungs, at least 12 types of cells can be found in the airways. The lung composes of 
about 300 million alveoli providing a surface area of 90m2 [Effros, 2006]. An adult alveolus 
has a mean diameter of 200 to 300 µm. The alveoli consist of an epithelial layer and 
extracellular matrix surrounded by capillaries. Three major alveolar cell types in the alveolar 
wall are shown in Fig.2. The first cell type is alveolar type I cells also called squamous 
alveolar cells. They are very flat and thin (about 0.2µm in width) cells making up 97% of the 
alveolar surfaces. The second cell type is alveolar type II cells are also called great alveolar 
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cells. They cover the remaining 3% of the alveolar surface and are interspersed among the 
type I cells. The type II cells are more round shaped and secrete pulmonary surfactant by 
excytosis to reduce surface tension. These cells can maintain alveolar integrity by dividing 
and differentiating into type I cells [Crapo et al., 1982]. It is possible to isolate primary 
human type II cells for in vitro studies but it is not possible to isolate primary type I cells 
[Kemp et al., 2008]. The third cell type, alveolar macrophages are important in removing 
any debris that escapes the mucus and cilia in the conducting portion of the system. 
They are also responsible for destroying pathogens such as bacteria. 
 
 
 
 
 
Fig. 2: The structure of an alveolar 
 
1.1.1 Lung cancer  
Lung cancer is the second most frequently diagnosed cancer in both men and women, and the 
leading cause of cancer-related death worldwide [Jemal et al., 2010]. Symptoms suggesting 
lung cancer include cough, chest discomfort or pain, dyspnea, wheezing and hemoptysis. 
However, no cancer specific symptoms can be found at the early stage of the disease. Most 
patients present the symptoms with advanced disease. The main causes of lung cancer include 
smoking, genetic factors, radon gas, asbestos, viruses and air pollution [Gorlova et al., 2007; 
Kabir et al., 2007]. Smoking is still the major risk factor for this type of cancer [Collins et al., 
2007]. 
According to histological findings lung cancers can be classified as small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). NSCLC is most prevalent and constitutes 
about 80% of all lung cancers. SCLC is less common and accounts for about 15%. NSCLC 
can be further differentiated into adenocarcinoma, squamous cell carcinoma and large cell 
carcinoma to facilitate treatment [Collins et al., 2007]. The histological images of these 
subtypes of NSCLC can be seen in Chapter 7: Fig.2. The details of the histologic 
classification of lung cancer are summarized in Table 1. 
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Table 1: Histological type  and frequency of lung cancer according to the World Health 
Organization (Information from Collins et al., 2007; Mountain 1997; Brambilla et al., 2001) 
Histological type Histological sub-type Frequency 
Adenocarcinoma 40% 
Squamous cell carcinoma 25% 
Large cell carcinoma 10% 
                                       
                                       
Non-small cell lung cancer 
Adenosquamous carcinoma < 5% 
 
 
80% 
Small cell lung cancer             15% 
Carcinoid  
Sarcomatoid  
Salivary-gland carcinoma  
Unclassified carcinoma 
 
 
 
          
             < 5% 
Adenocarcinoma is the predominant histological subtype of NSCLC and accounts for 40% of 
lung cancers [Travis, 2002]. It is the most common type of lung cancer in "never smokers". 
They are histologically heterogeneous peripheral masses that metastasize early and usually 
originate in peripheral lung tissue [Collins et al., 2007]. The subclassification of 
adenocarcinoma is not easy because it is highly heterogeneous. The subtypes show a mixed 
pattern of acinar, papillary, bronchioloalveolar, and solid adenocarcinoma with mucin 
formation [Brambilla et al., 2001]. 
Squamous cell carcinomas are centrally located endobronchial masses and generally 
metastasize late in the course of the disease [Collins et al., 2007]. Hemoptysis, 
postobstructive pneumonia, or lobar collapse may be present at the same time. They are 
closely correlated with a history of smoking and more common in men than in women.  
Large cell carcinomas are poorly differentiated large peripheral masses associated with early 
metastases [Collins et al., 2007]. It is actually a "diagnosis of exclusion" for tumor cells that 
lack light microscopic characteristics which classify the neoplasm as other lung cancer types. 
SCLC arising mostly in the larger airways (primary and secondary bronchi), grow rapidly and 
aggressively [Collins et al., 2007]. Smoking is a significant etiological factor for SCLC, 
which is more metastatic than NSCLC and often has a poor prognosis [Barbone et al., 1997].  
The diagnosis of lung cancer includes tissue diagnosis, a staging process including metastases 
and a functional patient evaluation. Histological diagnosis can be performed with sputum 
cytology, accessible lymph node biopsy, thoracentesis, bronchoscopy, transthoracic needle 
aspiration, thoracotomy [Collins et al., 2007]. The metastasis evaluation relies on patient 
history, physical examination, laboratory tests and clinical presentation. The functional 
evaluation is the last step before discussing treatment options [Collins et al., 2007].  
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In lung cancer therapy staging is an important issue to determine prognosis and potential 
treatment. Lung cancer staging is the assessment of the degree to which a lung cancer has 
spread from its original source. The international tumor node metastasis (TNM) system is 
used for staging NSCLC [Mountain, 2000]. In this system T stands for the extent of the 
primary tumor (T0-T4), N describes the involved regional lymph nodes (N0-N3) and M 
indicates the absence (M0) or presence (M1) of distant metastasis. The numerals I, II, III, and 
IV (plus 0) are used to describe the progression of cancer. Using this system, NSCLC is 
classified into five stages from 0 to IV. Stage 0 refers to carcinoma in situ, stages I, II and III 
are further subdivided into A and B according to different situations [Collins et al., 2007; 
Mountain, 1997; Mountain, 2000]. Normally, the higher the stage, the poorer the prognosis. 
The staging for SCLC is different from NSCLC; it is divided into limited and extensive 
disease according to the spread of the tumor to distant sites. Limited stage tumors are 
confined to the ipsilateral hemithorax, extensive stage tumors are associated with metastases 
and are located beyond the ipsilateral hemithorax.  
1.1.2 Lung cancer therapy   
The most common treatments for lung cancer include surgery, chemotherapy, radiotherapy or 
a combination of these options. Treatment varies according to the cell type, the stage of the 
lung cancer and functional evaluation of the patient [Collins et al., 2007]. Adjuvant therapy is 
given after the primary treatment to lower the risk of cancer relapse. It may include 
chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. 
Table 2 shows an overview of the treatment for different stages of NSCLC. SCLC is more 
sensitive to chemotherapy and radiation therapy. 
Table 2: Treatment strategies for NSCLC  
(Information from Collins et al., 2007; Merck Manual Professional) 
NSCLC stage Treatment 
I and II Surgery with or without adjuvant chemotherapy or radiotherapy 
IIIA (resectable) Surgery with or without preoperative chemotherapy, adjuvant 
chemotherapy with or without radiotherapy 
IIIA (unresectable) Chemotherapy or subsequent radiotherapy without adjuvant  
IIIB Radiotherapy  with or without chemotherapy 
IV 
Chemotherapy with or without palliative radiation therapy or resection 
of primary brain metastasis and primary T1 tumor 
The overall five-year survival rate for all patients diagnosed with lung cancer is about 15% 
and it decreases by cancer stage [Spiro et al., 2010]. About 40 to 70% of patients at stage I 
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and II survive more than 5 years from the time of diagnosis but for patients of stage IV with 
metastasis, the five-year survival rate is less than 1% [Collins et al., 2007].  
Table 3: Adverse effects and modes of action of drugs used currently in lung cancer 
chemotherapy 
The adverse effects mentioned are the most common occurring in more than 30% of patients. 
(Information from Eldridge 2010, Taetz 2008, http://www.chemocare.com/ Chemotherapy Drugs) 
Drug  Adverse effects Mechanism 
Cisplatin  Low blood cell count, nausea, vomiting,  
renal toxicity, blood test abnormalities 
Carboplatin  Similar to Cisplatin 
Platinum-based, interacts 
with DNA, causes cell 
apoptosis. 
Docetaxel  Low blood cell count,  nausea, hair loss, diarrhea, swelling, infection, nail changes 
Paclitaxel  
Low blood cell count, nausea, vomiting, 
hair loss, diarrhea, arthralgias, myalgias, 
mouth sores, fever, chills, skin rash 
Vinorelbine  Low blood cell count, nausea, vomiting, 
muscle weakness, constipation 
Vinblastine  Low blood cell count, reactions at injection site, fatigue, weakness 
Anti-mitotic medication 
interferes with cell 
division. 
Gemcitabine  Low blood cell count, nausea, vomiting, flu-like symptoms, fever, fatigue, skin rash 
Pemetrexed  Low blood cell counts, nausea, vomiting, diarrhea, fatigue, skin rash, constipation 
Folate antimetabolites 
Mitomycin C  Low blood cell counts, fatigue, poor 
appetite, mouth sores 
  
Doxorubicin  Low blood cell count, nausea, vomiting, hair loss, mouth sores 
Antitumor antibiotics, 
incorporated into cell 
DNA strand and stops 
cell growing 
Ifosfamide  
Low white blood count, low platelet count, 
hair loss, nausea, vomiting, blood in urine 
Alkylating agent, 
effective in the resting 
phase of the cell. 
Etoposide  Low white blood cell count, nausea, 
vomiting, hair loss, loss of fertility 
Irinotecan  Low blood cell count, nausea, vomiting, hair loss, diarrhea, fever, weight loss 
Topotecan  Low blood count, nausea, vomiting, hair loss, diarrhea 
Topoisomerase inhibitor, 
unwinds DNA and 
causes DNA strands to 
break. 
Chemotherapy mainly works by killing rapidly dividing cells. Most of the used medications 
are given intravenously, some are also given as tablets. Chemotherapy can cause adverse 
effects. Table 3 summarizes the currently administered drugs, their common adverse events 
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and their mode of action. In clinical practice, two or more drugs are often given at the same 
time to improve therapeutic efficiency. 
Targeted therapy as a newer form of cancer treatment is used in combination with 
chemotherapy or when other options fail. This therapy applies a drug which attacks more 
specifically cancer cells, resulting in less damage to normal cells. So far only few drugs are 
approved for advanced NSCLS treatment. Most of the agents are still under clinical 
investigation to characterize their safety and effectiveness. In Table 4 some targeted drugs are 
listed which are tested in clinical trials. 
Table 4: Targeted drugs and their mode of action 
* Still in clinical trials for NSCLC therapy. (Information from Sun et al., 2007; 
http://www.chemocare.com/ Chemotherapy Drugs, http://clinicaltrials.gov/ Clinical trails) 
Drug  Mode of action 
Gefitinib  
Erlotinib  
Epidermal growth factor 
receptor (EGFR) tyrosine 
kinase inhibitor 
Cetuximab  
Panitumumab * 
Anti-EGFR monoclonal 
antibody 
Inhibitors of EGFR pathway  
Bevacizumab  Vascular endothelial growth factor (VEGF) inhibitor 
Tipifarnib * 
Lonafarnib * 
Inhibitors of Ras pathway  
p53 adenovirus * Tumor suppressor gene  
Bortezomib * Proteasome inhibitor 
GRN163L * Telomerase inhibitor 
Recent evidence has suggested that cancers may arise from a rare subpopulation of stem cell-
like tumor cells [Reya et al., 2001]. Like normal stem cells, these cancer stem cells have 
several properties: self-renewal, extensive proliferation, differentiation to other malignant 
cells, active telomerase activity, activation of antiapoptotic pathways, increased membrane 
transporter activity and the ability to migrate and to metastasize[Wicha et al., 2006]. Several 
stem cell markers have been used to isolate cancer stem cells from lung cancer [Eramo et al., 
2008; Wicha et al., 2006; Sun et al., 2007]. As the same markers were found in the developed 
tumors and the lung stem cells a strong link between stem cells and carcinogenesis in the lung 
was assumed [Sun et al., 2007]. The small subpopulation of cancer stem cells may be resistant 
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to the cytotoxic effects of the presently used drugs. The failure of current cancer therapies 
may be due to the inefficacy of drugs on cancer stem cells [Dean et al., 2005]. Several 
selective therapies targeting cancer stem cells are under development. Stem cell self-renewal 
pathways such as Hedgehog, Notch, and Wnt signalling pathways can be used as potential 
targets [Sun et al., 2007]. Applying immunotherapy-based vaccines against antigens present 
on cancer stem cells offers another option. Furthermore, inducing cancer stem cells 
differentiation with soluble factors, inhibiting DNA repair enzymes or inhibiting telomerase 
activity of cancer stem cells represent modern targeting tools [Sun et al., 2007]. As given in 
Table 4, one telomerase inhibitor GRN163L is currently in phase II trials. Thus, telomerase 
inhibition is a promising strategy in treating lung cancer more selectively.  
1.1.3 Inhalation therapy 
The human lung has a large absorptive surface area (up to 100m2), extremely thin (0.1µm – 
0.2µm) alveolar capillary membranes and a very good blood supply. Due to this unique 
structure and its transport function between the external environment and systemic circulation, 
the pulmonary route has the potential for the systemic delivery of therapeutic agents. Drug 
administration by inhalation has been used commonly for the treatment of asthma, chronic 
obstructive pulmonary disease and cystic fibrosis [Anabousi, 2006]. There is also an 
expanding role of aerosols in systemic drug delivery such as insulin for diabetes [Laube, 
2005]. Nowadays increasing attention was also attributed to the potential of inhalative 
administration for lung cancer treatment. 
Pulmonary administration of drugs can be achieved by aerosol which is generated either from 
a liquid drug solution in a nebuliser, a dry powder inhaler, or a pressurised metered dose 
aerosol [Vidgren et al., 1988]. Inhaled particles have different distribution patterns in the lung 
depending on their sizes and deposited regions. Large particles (~20µm) impacting in the 
throat are swallowed soon after inspiration. Smaller particles (0.2-2.0µm) are the respirable 
fractions and can finally enter the respiratory bronchioles and alveoli. The medium-sized 
particles can deposit within the tracheal-bronchial tree and might be swept out of the lung by 
mucociliary clearance [McCalden, 1990]. It is not easy to deposit aerosols in high yield into 
the alveoli. From a pressurised metered dose aerosol, only about 10% of the administered 
materials are able to reach the terminal airways. All the rest is deposited into the upper 
airways [Vidgren et al., 1988]. Thus a better pharmacokinetic distribution to the targeted area 
should be achieved in inhalation therapy. 
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Direct drug administration by inhalation for cancer treatment offers several theoretical 
advantages. The drug can be delivered topically to the tumor area thus increasing the local 
drug concentration and limiting systemic drug exposure with fewer systemic side effects. 
Problems with poor oral bioavailability and intestinal/hepatic first-pass metabolism of the 
drug would be avoided by the pulmonary application and the use of a noninvasive needle-free 
delivery system [Gagnadoux et al., 2008; Anabousi, 2006]. On the other hand, this method 
also has some disadvantages. Patients might have difficulties by administering a drug via 
inhaler, which could directly influence the applied drug quantity. Only a small portion of the 
inhaled drugs can reach the intended target in the lower respiratory system [Anabousi, 2006]. 
Local administration of high doses of a cytotoxic drug by inhalation may increase the risk of 
drug-induced lung disorders. Several chemotherapeutic agents such as doxorubicin, 
gemcitabine and paclitaxel have been studied in animal models for their safety, 
pharmacokinetic advantages and antitumor effects [Gagnadoux et al., 2008]. However, 
inhalation therapy is not yet a clinical standard treatment of lung cancers. Efficiency of drug 
delivery, pulmonary and systemic toxicity need to be further evaluated. 
1.2 Telomere and Telomerase  
The 2009 Nobel Prize in Physiology or Medicine was awarded to Elizabeth H. Blackburn, 
Carol W. Greider, and Jack W. Szostak for their discovery of “how chromosomes are 
protected by telomeres and the enzyme telomerase” which solved a major problem in biology: 
how chromosomes can be properly copied during cell division and how they are protected 
from degradation by a highly conserved telomeric DNA sequence synthesized through a 
unique reverse transcriptase called telomerase. 
Telomeres are DNA-protein complexes that contain repeating nucleotide sequences and cap 
the end of linear chromosomes of most eukaryotic organisms. It can protect the chromosomes 
from recombination, degradation and fusion with other chromosomes [Zimmermann et al., 
2007]. Human telomeric DNA consists of a 2-15kb duplex repeats of TTAGGG/AATCCC 
sequences ending with a 100-200 nucleotides single-stranded G-rich 3´overhang. Several 
proteins bind specifically to telomeric DNA, and these recruit other proteins to the 
chromosome end as shown in Fig.3. The human telomere length shortens at a rate of 50 to 
200bp during each cell cycle because of the end replication problem [Zimmermann et al., 
2007; Blackburn, 1991]. Most somatic cells stop dividing when their telomeres reach a certain 
point, and eventually the cells die. The maintenance of functional telomeres is crucial for cell 
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proliferation. Almost all eukaryotic cells use the reverse transcriptase telomerase for telomere 
elongation. 
 
Fig. 3: Proposed schematic structure of the human telomere 
Telomeres are shown as red points at the end of chromosome. The telomere DNA can turn back on 
itself forming the so called telomere loop (T-loop). The 3´ overhang can invade and anneal with part 
of the duplex telomeric repeats forming a displacement loop (D-loop).The protecting protein of 
telomeres-1 (POT1) binds to the single-stranded DNA. Two double-stranded telomeric repeat binding 
factors (TRF1 and TRF2) are associated with the duplex repeats. TRF1 and TRF2 may also form 
multiple complexes and recruit other proteins, such as the tankyrases 1/2 (TANK1/2); double-strand 
break repair protein complexes consisting of MRE11; RAD50 and NBS1; TRF1-interacting factor-2 
(TIN2); Ras-proximate-1 (RAP1); Protein Ku that binds to DNA double-strand break ends. Some 
other proteins are also involved in the telomeric complexes which are shown as other proteins in the 
figure (Information from Neumann et al., 2002; Griffith et al., 1999; de Lange, 2004). 
 
 
Fig.4: Telomerase components 
Human telomerase is comprised of the template 
telomerase RNA (hTR), the telomerase reverse 
transcriptase catalytic subunit (hTERT), and some 
associated proteins. The sequence of the template 
region on hTR is 3´-CAAUCCCAAUC-5´. 
(Information from Keith et al., 2002; Shay et al., 
2006). 
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Telomerase is a ribonucleoprotein complex that synthesizes telomeric DNA. As illustrated in 
Fig.4 human telomerase contains two major components: human telomerase RNA (hTR) 
which serves as a template for production of telomeric repeats to the telomere DNA and 
human telomerase reverse transcriptase (hTERT) that works as the catalytic protein subunit 
[Nakamura et al., 1997; Feng et al., 1995; Meyerson et al., 1997]. The mode of action of 
telomerase on telomeric DNA synthesis is illustrated in Fig.5. 
 
Fig. 5 : The mechanism of telomerase on telomeric DNA synthesis 
The RNA template on hTR contains two domains. The alignment domain hybridised to the 3´ end of 
the telomere. The telomere is subsequently extended by reverse transcription of the elongation domain. 
Three steps are involved in telomere synthesis: (1) telomere binding, in which the 3´ end of telomeric 
single strand binds to the alignment domain of the template; (2) elongation, in which nucleotides are 
sequentially added to the telomere; (3) translocation, in which the telomere shifts 6 nucleotides and 
moves to the alignment domain for next round of elongation. Oligonucleotides with sequence 
complementary to the template region of hTR can act as a telomerase inhibitor and hybridise with 
RNA template, block telomere binding and prevent telomere elongation. (Information from Gavory et 
al., 2002; Harley, 2008). 
1.2.1 Telomerase as a target for cancer therapy  
In most human cells telomerase activity is down-regulated during embryogenesis, which leads 
to successive telomere shortening. When the telomere length erodes to a critical length 
(~5kbp) cells reach mortality stage 1 or senescence stage (Fig. 6) and cell proliferation is 
arrested. However this can be bypassed by inactivation of tumor suppressor genes or 
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mutations [Shay et al., 1991]. By escaping senescence, cells continue to proliferate leading to 
critically telomere shortening. They reach mortality stage 2 or crisis stage with massive cell 
death. Very rare cells can escape this stage by developing a mechanism to maintain the 
telomeres becoming immortal cancer cells (Fig. 6). Generally, tumor cells can survive from 
crisis by reactivation of telomerase [Kim et al., 1994].  
 
Fig. 6 : Telomere and telomerase activity dynamics and telomerase inhibition function 
Germline cells show high telomerase activity maintaining long and stable telomere length. Telomerase 
is down-regulated during embryonic development, which leads to telomere shortening with cell 
divisions in most somatic cells. When the telomere length is reduced to lower than 3 kbp, massive 
genomic instability is triggered and eventually cells die. Adult stem cells have relatively higher 
telomerase activity, but they still undergo slowly telomere shortening. Bypassing the crisis barriers 
and reactivating high telomerase activity, about 90% of tumor cells get immortal. Inhibition of 
telomerase activity for a certain period of time (grey area) can cause telomere shortening on all 
telomerase positive cells. As germline cells and adult stem cells have longer telomere length and lower 
proliferation rates, the effects on these cells are moderate. Their telomeres are extended after the 
treatment when telomerase activity is recovered. Tumor cells will be selectively killed because of their 
predominantly shorter telomere length and their fast proliferation rate (Information from Zimmermann 
et al. 2007; Harley et al. 2008). 
In contrast to normal somatic cells, the vast majority of tumor cells exhibit short telomere 
length and high telomerase activity. This makes telomerase an attractive drug target for cancer 
therapy. The major advantage of targeting telomerase is its specificity for cancer cells, 
including the putative cancer stem cells which are considered to be responsible for the current 
failure of anticancer therapy [Harley, 2008].  
Chapter 1: General Introduction and Aim of the Thesis 
13 
Different strategies have been employed to inhibit telomerase in all kinds of tumor cells 
[Rankin et al., 2008; Kleideiter et al., 2007; Chen et al., 2009]. A large-scale screen of a 
chemical library has been performed to identify highly selective isothiazolone-derived 
telomerase inhibitors. The nonnucleosidic compounds (e.g. BIBR 1532 [Pascolo et al., 2002] 
or TELIN [Kakiuchi et al., 2004]) can bind directly to hTERT; the G-quadruplex-interactive 
compounds (e.g. BRACO19) can fix the single-stranded telomeric end as a G-quadruplex 
structure [Taetz et al., 2008]. Unfortunately, the development of nonnucleosidic telomerase 
inhibitors has not yet generated compounds which can induce significant telomerase 
inhibition in vivo over a longer time period [Zimmermann et al., 2007]. However, the 
oligonucelotide-based therapeutic agents have reached clinical trials [Harley, 2008]. 
 
Table 5: Approaches and mechanisms of telomerase-based anticancer therapy (Information from 
Zimmermann et al., 2007; Harley, 2008) 
Approach Mode of action Features 
   
Telomerase inhibition Direct enzyme inhibition  
Targeting hTERT 
• Target hTERT mRNA expression 
• Mutant hTERT 
• hTERT phosphorylation inhibitors 
• Repress hTERT transcription 
           Targeting hTR 
• Antisense oligonucleotides target hTR template 
• Small interfering RNAs (si RNAs) target hTR 
• Ribozymes 
• Mutant hTR template 
          Targeting additional  
          telomerase components 
• Targeting telomerase-associated protein 1 
• Blocking the interaction of hTERT with chaperones 
The products may not be 
subject to common drug-
resistance mechanisms. 
A lag phase is noted 
between the initiation of 
telomerase inhibition and 
the effect on tumor cell 
growth.  Long treatment 
duration might be 
necessary. 
Telomerase immunotherapy 
Stimulating immune system to attack cancer cells that 
express hTERT. The antigen-presenting cells are 
exposed to relatively high levels of TERT peptides, 
mRNA, plasmid or viral DNA. 
 Life-long effects with 
periodic boosting possible. 
Many patients may have 
weak TERT response. 
Suicide gene therapy 
Telomerase promoter is placed upstream of a toxic 
gene or gene that triggers a toxic downstream event. 
Cells will be killed when the products are expressed. 
Rapid killing of telomere- 
se positive tumor cells. 
Effective delivery to the 
tumor area is changing. 
Telomere-disrupting agents Alter the structure of the telomere leading to inability 
of telomerase to access the telomere. 
Rapid induction of cell 
death. Assumed toxicity to 
normal cells and tissue. 
Targeting telomere-
associated proteins 
Target the telomere-associated proteins (e.g. HSP90, 
TRF1, TRF2) and influence the stability and function 
of telomere 
Rapid function on 
telomeres. Possibility of   
influencing the normal 
cell telomere function. 
 
Several strategies have been employed in oligonucelotide-based inhibition of telomerase 
activity. They are summarized in Table 5. Either hTERT or hTR can be targeted by different 
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molecules. Stabilized antisense oligonucleotides directed against hTR, such as peptide nucleic 
acids (PNAs) or RNA oligomers with methyl-substituted ribose sugar rings (2´-O-methyl-
RNA) prevent telomere elongation by hybridizing to hTR [Dong et al., 2009].  
Agents being in clinical trials are mainly focusing on telomerase enzyme inhibitors and active 
immunotherapy. GRN163L is an hTR template antagonist with covalent lipid(L) modification. 
In vivo it shows sufficient cellular uptake and biodistribution at very low concentrations and 
has moved to phase II clinical trials [Harley, 2008]. Furthermore, GV-1001 is a biological 
telomerase peptide vaccine which is undergoing phase III clinical trials [Harley, 2008].  
Inhibition of telomerase activity will induce progressive telomere shortening resulting in 
reduced proliferation and apoptosis after a certain time delay. Therefore, telomerase inhibitor-
based therapy will be a long-term treatment. This requires high demands on the profile of 
drug safety [Dong et al., 2009]. In addition, tumor cells have variable telomere length. It is 
necessary to identify telomere length and telomerase activity before treating the patients with 
telomerase inhibitors. Patients with short telomeres in their tumors may benefit more from 
this kind of therapy. 
A major obstacle with all potential oligonucleotide-based anticancer agents is their safe and 
efficient delivery to the tumor cells and their uptake at the site of action. Whereas a covalently 
bound lipid residue will enhance the cellular uptake of the antisense oligonucleotide 
GRN163L, biodegradable nanoparticles might also serve as an efficient carrier system for 
intracellular delivery of the various oligonucleotide-based telomerase inhibitors [Herbert et al., 
2005; Beisner et al., 2010].  
1.3 Nanoparticles 
Nanoparticles are microscopic particles normally measured in nanometers (nm). In 
nanotechnology, particles are defined as fine and ultrafine particles according to their sizes. 
The diameter of fine particles cover the range between 100 and 2500 nm, while the ultrafine 
particles have diameters between 1 and 100 nm. The up to date definition of nanoparticles is 
similar to ultrafine particles having a maximum feature size of 100nm. Nanoparticles may 
exhibit some size-related physical properties that differ from those of bulk materials when 
their sizes do not reach a limiting value. However, such size thresholds vary with the material 
types and may not be the only determinant for nanoparticle classification. An accepted 
definition extends this upper size limit to 1 micron, the sub-micron range being classified as 
nano [Buzea et al., 2007]. 
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1.3.1 Nanoparticles as drug delivery systems 
Two important aspects have to be considered when developing a new drug delivery system 
for cancer therapy. First, the delivery system must be able to carry the drug to the tumor tissue 
with minimal loss of the active agent. Second, the drug can target and kill the tumor cells with 
a controlled release mechanism of the active form [Cho et al., 2008].  Nanoparticles can be 
used as a drug delivery system to meet these two requirements. They can use both active and 
passive targeting strategies to concentrate drugs in cancer cells [Maeda, 2001] and they can 
bypass P-glycoprotein mediated drug efflux which is an important mechanism of drug 
resistance [Larsen et al., 2000]. Table 6 illustrates the types of nanoparticles used as carrier 
system for drug delivery. 
Size and surface characteristics are important factors to determine the application of 
nanoparticles. Uptake of nanoparticles into cells is size dependent. Smaller nanoparticles have 
significantly higher uptake efficiency than larger nanoparticles [Prabha et al., 2002]. For a 
suitable drug delivery system, the size of nanoparticles must be large enough to prevent rapid 
leakage into blood capillaries but small enough to avoid rapid filtration by the spleen and to 
pass through the fenestra of the Kuffer cells in the liver ranging between 150 to 200nm 
[Wisse et al., 1996]. The gap junction between endothelial cells of the leaky tumor 
vasculature has a range between 100 to 600nm [Yuan et al., 1995]. Therefore the perfect size 
of nanoparticles should be greater than 100nm allowing an efficient delivery of drugs to 
tumor tissues. 
Surface characteristic is another important factor to influence nanoparticles drug delivery. 
Nanoparticles coated with hydrophilic polymers (e.g. PEG) can escape macrophage capture 
and they have prolonged half-lives [Moghimi et al., 2003]. Nanoparticles with hydrophobic 
surfaces are more easily taken up by liver, spleen and lung [Brigger et al., 2002]. The surface 
charge of nanoparticles is a crucial property for drug delivery and cytotoxicity [Nafee, 2008]. 
Positively charged nanoparticles are often used in oligonucleotides delivery. Since DNA and 
RNA are negatively charged, a positive charge of the nanoparticle can provide better 
interaction with oligonucleotides. The charge of nanoparticles can be modified with different 
materials. Poly(lactide-co-glycolide) (PLGA) nanoparticles are negatively charged and 
therefore interaction with negatively charged oligonucleotides is restricted. Chitosan has a 
strong affinity for DNA and it is against the degradation by DNAse [Nafee, 2008]. Thus, 
chitosan coated PLGA nanoparticles can exhibit a positive charge and will efficiently bind to 
the negatively charged oligonucleotides representing a promising drug delivery system. 
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Table 6: Classification of different nanocarriers for drug delivery  
(Information from Cho et al., 2007 ; Gradishar et al., 2005 ; Sabbatini et al., 2004 ; Maik et al., 1999). 
Type Structure Nanoparticle
-drug 
interaction 
Raw materials Characteristics 
Polymeric 
nanoparticles 
 
 
 
 
Conjugation or 
encapsulation 
• Natural polymers: 
albumin, chitosan, alginate; 
• Synthetic polymers: 
Poly(lactide-co-glycolide) 
(PLGA),  
N-(2-hydroxypropyl) 
methacrylamide copolymer 
(HPMA); 
polyethylene glycol (PEG); 
poly-L-glutamic acid (PGA). 
• Biodegradable 
• Surface modification 
• Specific targeting the cancer 
cells 
• Selective accumulation and 
retention in tumor tissue 
Polymeric 
micelles 
 
Encapsulation 
or covalent 
attachment  
Amphiphilic block 
copolymers: 
PEG-poly(D,L-lactide)-
paclitaxel 
• Hydrophilic shell stabilizes 
hydrophobic core and makes 
the polymers water-soluble 
• Biocompatible and 
biodegradable 
• Self-assembling structure 
Dendrimers 
 
Encapsulation  
or covalent 
attachment  
or  ionic 
interaction  
Polyamidoamine 
(PAMAM) 
• Monodispersity 
• Water solubility 
• Functionalizable peripheral 
groups 
• Multifunctionality 
Liposomes Encapsulation Lipid bilayers • Self-assembling structures 
composed of lipid bilayers 
• Amphiphilic, biocompatible 
• Easy to be modified 
 Carbon 
nanotubes 
 
 
 
Covalent 
attachment  
Carbon • Water solubility and 
biocompatible by chemical 
modification 
• Toxicity problems 
• Multifunctionality 
Metal 
nanoparticles 
 
Electrostatic 
forces 
Gold (iron, silver, 
platinum, titanium) 
 
 
• Gold has high chemical 
stability 
• Optical properties 
• Low toxicity 
Viral-based 
nanoparticles 
Gene 
expression  
or protein 
conjugation 
Viruses: cowpea mosaic 
virus, bacteriophages, 
adenovirus, lentivirus 
• Surface modification 
• Biological compatibility 
• Specific tumor targeting 
• Multifunctionality 
1.3.2 Nanoparticles as delivery system for telomerase inhibitors 
The antisense oligonucleotide 2´-O-methyl-RNA (OMR) with a phosphorothioate backbone 
has been reported as a potent and sequence-selective telomerase inhibitor [Pitts et al., 1998; 
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Herbert et al., 2006]. However, the poor cellular uptake of oligonucleotides limits a 
successful application of OMR [Loke et al., 1989]. Chitosan-coated PLGA nanoparticles have 
been shown to be an efficient drug delivery system [Kumar et al., 2004]. Fig.7 demonstrates 
the principle of the chitosan-coated nanoparticles delivery of the telomerase inhibitor OMR 
into cells.  
 
Fig. 7 : Schematic representation of chitosan-coated PLGA nanoparticles delivery of the 
telomerase inhibitor 2´-O-methyl-RNA(OMR) into cells 
Positively charged nanoparticles bind to negatively charged OMR to form nanoplexes that pass 
through the cell membranes and enter cells. In the cells telomerase inhibitors are released and 
specifically block telomerase RNA template region (Information from Kumar et al., 2004). 
Delivery of OMR with chitosan-coated PLGA nanoparticles induced efficient telomerase 
inhibition and telomere shortening in human NSCLC [Beisner et al., 2009]. Therefore they 
offer a new therapeutic option for lung cancer treatment. The special anatomy and transport 
function of the lung would suggest that inhalation could accomplish an optimal approach for 
nanoparticle- based drug delivery. The chitosan-coated PLGA nanoparticles and OMR 
formed nanoplexes can be inhaled in form of an aerosol by a nebuliser device and the tumor 
cells in the lung would be directly targeted. Inhalation therapy for lung cancer patients has 
several advantages. The administration of anticancer drugs by inhalation of nebulised aerosols 
has been reported to be highly effective with low systemic drug distribution [Tatsumura et al., 
1993]. Concerning nanoparticles for lung cancer inhalation therapy, particle size, drug-
particle ratio, appropriate dosage and consequently the median aerodynamic diameter of the 
aerosols should be considered. Therefore, there is still a long way to go before this promising 
approach will enter clinical trials for lung cancer therapy. 
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1.4 Aim of the thesis 
The aim of the thesis was to evaluate the potential of a telomerase inhibitor, the antisense 
oligonucleotide 2´-O-methyl-RNA (OMR), for non-small cell lung cancers (NSCLC) therapy 
based on in vitro and ex vivo models. Biodegradable and chitosan-coated poly(lactide-co-
glycolide) (PLGA) nanoparticles which can form nanoplexes with OMR were intensively 
studied as OMR carrier system. The thesis can be divided in the following parts: 
- Assays for telomerase activity and telomere length: Methods optimization to provide 
quantitative data for various biological specimens. 
- in vitro cell culture model: Telomerase inhibition and telomere shortening induced by 
OMR and delivered by different carrier systems were assessed in human NSCLC cell lines 
and primary lung cancer cells to prove especially the potential of nanoparticles as OMR 
delivery system for lung cancer treatment.  
- ex vivo tissue slice model: Using 0.2 mm thick tissue slices from freshly excised tumor 
samples of NSCLC patients to investigate whether nanoplexes formed from nanoparticles and 
OMR can penetrate into tumor tissue, efficiently deliver OMR to the tumor cells and 
subsequently inhibit telomerase. Relationships between telomerase expression and activity, 
cell proliferation and cancer stem cells population were evaluated. 
- ex vivo isolated perfused rat lung model: An inhalation system for the delivery of 
nanoplexes to the lung was established by an isolated perfused rat lung model. The pulmonary 
transport and distribution of the inhaled nanoplexes and their influence on the physiological 
function of the lung was assessed.  
The experiments were performed in cooperation with several groups and financially 
supported by the German Cancer Aid (Grant no. 107541) and the Robert Bosch Foundation 
(Stuttgart, Germany). The chitosan-coated PLGA nanoparticles were produced and supplied 
by the group of Professor Dr. Claus-Michael Lehr from the Department of Biopharmaceutics 
and Pharmaceutical Technology, Saarland University, Saarbrücken. The lung tumor tissue 
specimens were provided as surgical waste by Prof. Dr. Godehard Friedel from the 
Department of Thoracic Surgery, Schillerhöhe Hospital, Gerlingen. The inhalation 
experiments of the isolated perfused rat lung model were done in cooperation with PD Dr. 
Susanne Ammon-Treiber from the Department of Clinical Pharmacology University Hospital 
Tübingen, Tübingen. 
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2.1 Abstract 
 
Background: Telomerase is present in 80-90% of all human cancers. It adds special 
telomeric repeats (TTAGGG in vertebrates) to the end of linear eukaryotic chromosomes. 
Telomeres are protective structures located at the end of linear chromosomes. Telomerase 
activity and telomere shortening are considered as important factors in some human diseases. 
The most widely used methods to measure these two factors are the telomeric repeat 
amplification protocol (TRAP) for telomerase activity and the Southern blot of mean terminal 
restriction fragment (TRF) length measurement for telomere length. However both methods 
are time-consuming and do not provide precise quantitative analysis. In the present study we 
compared different assays and optimized the methods for telomerase activity and telomere 
measurements with quantitative real-time PCR. 
Methods: We compared the real-time quantitative TRAP (Q-TRAP) assay with the capillary 
electrophoresis-based TRAP (TRAP-CE) assay with lung carcinoma cell lines and primary 
lung cancer tissues. The Q-TRAP assay was optimized in 384-well plate with 7900HT Fast 
Real-Time PCR System. For telomere length measurement, we compared the real-time 
quantitative PCR (Q-PCR) method with traditional Southern blot of TRF measurement with 
different lung carcinoma cells. 
Results: Compared to TRAP-CE, Q-TRAP analyzes the exponential amplification phase of 
the PCR reaction avoiding plateau-related events. It is specific, highly sensitive, permits rapid 
analysis with lower costs and less contamination potentials. For the telomere length 
measurement, the Southern blot of TRF measurement is time-consuming and requires large 
amounts of DNA. In contrast, the Q-PCR method is a rapid, simple, and accurate 
measurement for large sample sets. 
Conclusion: Our data suggest that both real-time quantitative PCR based assays for 
telomerase activity and telomere length measurements are simple and specific. The rapid and 
reliable quantifications can be used in a large range of applications.  
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2.2 Introduction 
Telomerase adds special telomeric repeats to the end of linear eukaryotic chromosomes. The 
enzyme activity is present in 80-90% of all human cancers [Harley, 2008]. In recent years 
telomerase has been considered as a new marker for cancer diagnosis and a promising drug 
target for anti-cancer therapy ,Hiyama et al., 2002; Harley, 2008; Shay et al., 2006]. 
Evaluation of telomerase activity is essential to better understand telomerase biology and its 
clinical impact. A standard method, termed telomeric repeat amplification protocol (TRAP) 
was established for determining telomerase activity [Kim et al., 1994]. This PCR-based 
method was widely used for measurement of telomerase activity and was further modified to 
improve quantification and to simplify the post-PCR steps. These modified TRAP assays 
include gel-based TRAP assay [Kim et al., 1997; Piotrowska K et al., 2005], ELISA-based 
TRAP assay [Wu et al., 2000], capillary electrophoresis-based TRAP assay [Atha et al., 2003] 
and several other methods. Some of the assays are also available as commercial kits. However, 
these methods are based on the end-point PCR product which provides insufficient 
quantitative information and allows only a relatively low throughput. The post-PCR process is 
time-consuming and more susceptible to contaminations. Recently, a real-time quantitative 
TRAP assay has been developed to overcome these problems [Hou et al., 2001; Herbert et al., 
2006]. This method using the PCR reaction with SYBR Green PCR master mix kit allows a 
rapid and reliable quantification of telomerase activity. In our experiments we compared 
capillary electrophoresis-based TRAP assay (TRAP-CE) with the real-time quantitative 
TRAP assay (Q-TRAP) for the measurement of telomerase activity and optimized a 
simplified Q-TRAP assay for an accurate measurement of telomerase activity with large 
sample sets and low costs. 
Telomere is a protective element, which contains repeating nucleotide sequences (TTAGGG 
in vertebrates), located at the end of linear chromosomes of most eukaryotic organisms. 
Human telomeres shorten naturally at a rate of 50 to 200bp during each cell cycle [Blackburn, 
1991]. A correlation has been reported between telomere shortening and age-related diseases 
and cancers [Blasco, 2005]. There are several techniques to measure telomere length in 
eukaryotic cells such as fluorescence in situ hybridization (FISH) and flow cytometry 
[Hultdin et al., 1998]. The most widely used method of measuring telomere length in genomic 
DNA analyzes the mean terminal restriction fragment (TRF) length by Southern blot [Allshire 
et al., 1989]. This method involves hybridization of a labeled telomere specific 
oligonucleotide probe to digested genomic DNA which was fractionated by electrophoresis 
and transferred to a membrane, and further exposed to X-ray film for analyzing. It needs large 
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amounts of DNA (about 5µg) and is very time-consuming (3 to 5 days). The results can vary 
depending on different restriction enzymes and the blot has a large variability. A real-time 
quantitative PCR based method (Q-PCR) for telomere measurement has been established 
[Cawthon et al., 2002]. This Q-PCR method is a fluorescence - based assay which needs less 
DNA amount without enzyme digestion. It is a rapid and high throughput method. In this 
study, we compared the traditional Southern blot with the Q-PCR method for the 
measurement of telomere length and proved that the Q-PCR method is a powerful tool for 
investigating telomere biology in a large range of applications.  
 
2.3 Part 1: Telomerase activity measurement 
2.3.1 Materials and methods 
2.3.1.1 Preparation of cell extracts 
Human lung carcinoma cell lines A549, NCI-H23 (H23), NCI-H460 (H460) and primary lung 
carcinoma cells 5705 were used for telomerase extraction. Cultured cells were harvested, 
counted and 106 cells were pelleted and washed with PBS. The cell pellets were either stored 
at -80°C or immediately resuspended in 200µl ice-cold 3-[(3-cholamidopropyl) dimethyl-
ammonio]-1-propanesulfonate (CHAPS) lysis buffer and incubated on ice for 30min. The 
lysates were centrifuged at 12 000×g for 20min at 4°C and the supernatants were aliquoted, 
snap-frozen and stored at -80°C.  
2.3.1.2 Preparation of tumor tissue extracts 
Tumor tissues (50-100mg) were isolated by FastPrep methods. 300µl CHAPS buffer with 
200U recombinant RNase inhibitor (RNaseOUTTM, Invitrogen, Carlsbad, CA) were added 
into a Lysing Matrix D tube with spheres (MP Biomedical, Solon, OH). The frozen tissues 
were minced into slices and transferred into the tube. Slices in the buffer were homogenized 
using a FastPrep FP120 cell disrupter (Thermo Savant Bio101, Cedex, France) for 20sec at 
speed setting of 6.0 at 4°C. After short centrifugation the tubes were left on ice for 30min. 
The upper phase was transferred to new tubes and centrifuged at 12 000×g for 20min at 4°C. 
The supernatants were aliquoted, snap-frozen and stored at -80°C.  
2.3.1.3 Protein concentration determination 
The amount of cellular protein in the lysates was determined with bicinchoninic acid (BCA) 
assay which is based on reduction of the cupric (Cu2+) ion to cuprous (Cu1+) ion by protein 
[Smith et al., 1985]. The BCA assay was performed using a Sigma Protein Assay kit (Sigma-
Aldrich Chemie, Steinheim, Germany). CHAPS buffer was used as dilution buffer and blank 
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for the measurement. 1mg/ml bovine serum albumin (BSA) was used as standard solution and 
a serial dilution (0, 200, 400, 600, 800, 1000µg/ml) was used for the calibration curve. Protein 
lysates were diluted to concentrations between 200 to 1000µg/ml. Bicinchoninic acid and 
copper (II) sulphate were mixed in a ratio of 50 to 1 and formed the mixed reaction solution. 
200µl of mixed reaction solution and 10µl test solution were added into 96-well plates and 
incubated at 37°C for 1h. The plate was measured in a microtiter plate reader (Victor 
Multilabel Counter 1420, Wallac-PerkinElmer, Waltham, MA, USA) at 562nm. The 
concentration of protein in the lysates was determined from the calibration curve. All 
measurements were performed in triplicates. 
2.3.1.4 Telomerase activity assay using capillary electrophoresis   
Telomerase activity was measured using a modified protocol of the TRAPEZE Telomerase 
Detection Kit (Chemicon International, Hampshire,UK). The manufacturer’s protocol was 
modified as follows: TS primer labeled with 6-carboxy-fluorescein (FAM) (TS Primer, 
MWG-Biotech AG) and CX primer (CX Primer, MWG-Biotech AG) were used instead of 
unlabeled TS primer and TRAP primer mix provided in the TRAPEZE kit. TRAP reaction 
was performed in a final reaction volume of 50µl containing 2µl cell extract (0.05µg protein), 
100nM of labeled TS primer and CX primer, 50µM of each deoxynucleotide triphosphate 
(dATP, dCTP, dGTP and dTTP), 2U Taq polymerase (Qiagen, Hilden, Germany), 10µl of 
solution Q (Qiagen, Hilden, Germany), 10fg internal telomerase assay standard (ITAS) and 
TRAP reaction buffer (20mM Tris-HCl (pH 8.3), 1.5mM MgCl2, 63mM KCl, 0.05% Tween 
20, 1mM EGTA) as shown in Table 1. Solution Q was added to achieve a better amplification. 
ITAS represents a 150bp fragment of the rat myogenin cDNA that is amplified using TS and 
CX primer. Thermal cycling conditions were as follows: 30°C for 30min for the telomerase 
mediated extension reaction (if present), 95°C for 5min followed by 35 cycles of 95°C for 
30sec, 57°C for 30sec with a final extension step at 57°C for 30sec. TSR8, which is an 
oligonucleotide with a sequence identical to telomere primers, was used as positive control. 
CHAPS-buffer was used as negative control. After cycling was finished the PCR products 
were immediately frozen. Fluorescence capillary electrophoresis (ABI PRISM 310 Genetic 
Analyzer) was used for separating PCR products. 2µl of the amplified PCR products were 
added to 11µl of highly deionized formamide and 0.5µl GeneScan-500 ROX size standard 
(Applied Biosystems, Foster City, CA, USA). Samples were denatured for 5min at 95°C and 
chilled on ice. Denatured PCR fragments were separated on the genetic analyzer using 
Applied Biosystems GeneScanTM capillary and POP6 polymer system. Fragment sizes were 
determined using the internal size standard GeneScan-500 ROX and collected data were 
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analyzed with GeneScan Analysis software ABI PrismTM and GeneScanTM Version 3.1. The 
quantity of extension product was calculated for each sample as the total integral (area under 
the curve) of FAM-labeled peaks corresponding to the extension products in relation to the 
area of the ITAS peak. TA= Peak area
 total / Peak area ITAS. 
Table 1: Primers, sequences and 1× PCR reaction components of TRAP-CE                           
Primer Sequence 
TS-FAM 5´-FAM-AATCCGTCGAGCAGAGTT-3´ 
CX  5´-CCCTTACCCTTACCCTTACCCTAA-3´ 
 
Component volume [µl] 
RNase/DNase-free H2O 29.6 
50 × dNTP mix 1 
10 × TRAP buffer 5 
TS-FAM primer (10µM) 0.5 
CX primer (10µM) 0.5 
5 × Solution Q 10 
Taq Polymerase (2U) 0.4 
ITAS 10fg/µl 1 
Sample  2 
Total volume 50 
 
2.3.1.5 Telomerase activity assay using real-time quantitative PCR 
Telomerase activity was measured using a modified real-time quantitative PCR based 
telomeric repeat amplification protocol (Q-TRAP) as previously described [Herbert et al., 
2006]. Q-TRAP reaction was performed in 384-well clear optical reaction plate (MicroAmp, 
Applied Biosystems, USA) with a final reaction volume of 12µl containing 2µl cell extract 
(0.1µg protein), 50ng of telomerase primer TS, 50ng of anchored return primer ACX and 
SYBR Green PCR Master Mix (QuantiTect, QIAGEN, Germany) as shown in Table 2. 
SYBR Green is a dye which binds to the double-stranded DNA and gives signal durging real-
time PCR reaction. Using the 7900HT Fast Real-Time PCR System (Applied Biosystems, 
USA), samples were incubated for 30min at 30°C for telomerase mediated extension reaction 
(if present), 95°C for 15min followed by 40 cycles of 94°C for 15sec, 60°C for 60sec. The 
threshold cycle value (Ct) of each sample was determined from amplification log plots (the 
change in fluorescent signal was plotted against cycle number) and compared to standard 
curves. The standard curve was generated from serial dilutions of telomerase-positive human 
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lung cancer cell line A549 cell extracts with 1.0, 0.2, 0.1, 0.05, 0.01 and 0.002µg protein 
respectively. The Ct values of standard control were plotted against log [protein] to calculate 
the linear equation. Inactivated samples were created by heating at 85°C for 10min. 
Telomerase activity of each sample was converted into relative telomerase activity (RTA) 
compared to A549 cells (telomerase activity of 1µg protein of A549 cell extracts was defined 
as 1). Standards, inactivated samples and lysis-buffer controls were assayed on each Q-TRAP 
assay plate. Lysis-buffer and heat-inactivated samples were used as negative controls to check 
for contaminations. TS and ACX primers were synthesized by Biomers (Ulm, Germany). The 
sequences are shown in Table 2. All measurements were performed in triplicates.  
Table 2: Primers sequences and PCR component with 1× reaction of Q-TRAP 
Primer Sequence 
TS  5´-AATCCGTCGAGCAGAGTT-3´ 
ACX  5´-GCGCGGCTTACCCTTACCCTTACCCTAACC-3´ 
 
Component Volume [µl] 
RNase/DNase-free H2O 1.5 
SYBR Green Master Mix 6.25 
EGTA (10mM) 1.25 
ACX primer (100ng/µl) 0.5 
TS primer (100ng/µl) 0.5 
Sample  2 
Total volume 12 
2.3.1.6 Statistical analysis 
Spearman test was used to determine statistical correlations between different methods. 
p<0.05 (two-sided) was considered as statistically significant. Data were analyzed using 
Graphpad Prism version 4.0 (GraphPad Software Incorp., San Diego, CA). 
 
2.3.2 Results and discussion 
2.3.2.1 Capillary electrophoresis based TRAP assay for telomerase measurement 
The capillary electrophoresis based TRAP assay was performed with fluorescence labeled TS 
primer and analyzed with GeneScan Analysis software. Fig. 1A displays the 
electropherograms of decreasing concentrations of A549 cell lysates. The extension products 
are in the range of 50bp to 140bp with 6bp intervals as shown in blue. The internal size 
standards are shown in red. 
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Fig. 1: TRAP-CE measurement of telomerase activity 
(A) Electropherograms of diluted A549 lung carcinoma cell lysates (0.8, 0.4, 0.2, 0.1, 0.05, 0.025, 
0.0125 and 0.00625µg protein, respectively). PCR products were separated by fluorescence capillary 
electrophoresis and collected data were analyzed with GeneScan Analysis software. Internal size 
standards GeneScan-500 ROX (35, 50, 75, 100, 139, 150, 160, 200, 250 and 300bp) are shown as red. 
Extension products, ranging from about 50 bp to 140bp with 6bp repeats, are shown in blue. The ITAS 
standard appears at 150bp. (B) Electropherograms of the positive control TSR8 and negative control 
CHAPS buffer. (C) The titration curve was generated with quantified values from electropherograms 
of (A). Fragment sizes were determined using the internal size standard. The quantity of extension 
product was calculated for each sample as the total integral (area under the curve) of FAM-labeled 
peaks corresponding to the extension products in relation to the area of ITAS peak. The TA can be 
calculated according to the equation TA= Peak area
 total / Peak area ITAS. TA values of different A549 
concentrations were plotted as a function of log [protein]. (D) Electropherograms of lung carcinoma 
cell lines A549, H23 and H460 extracts with same protein content. (E) Samples were quantified 
according to the electropherograms of Fig.D. Data present the mean +SD of 3 independent 
experiments. 
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A plot of the calculated TA values against the log[protein] of A549 cells used in the TRAP 
assay is shown in Fig. 1C. Each point is the result of an individual CE separation 
corresponding to the Fig. 1A. When the protein content was lower than 0.4µg, increased 
protein content showed elevated telomerase activity. Telomerase activity reached a plateau 
phase when the protein content was higher than 0.4µg and subsequently the tested telomerase 
activity declined. The telomerase activities of the diluted A549 cells did not give a linear 
regression line (Fig. 1C). Therefore, the protein content used in measurements might 
influence the final results and a pre-test is needed to adjust the proper protein content. Fig. 1B 
shows the electropherograms of different samples with size standards. A549 represents a cell 
line with positive telomerase activity. Negative control CHAPS-buffer did not show extension 
products except the ITAS peak (150bp) and the primer-dimer peak (~30bp).  
A549 cells with 0.00625µg protein content (Fig. 1A) shows similar electropherograms as 
negative CHAPS-buffer control (Fig. 1B) indicating that ~0.00625µg is the lower limit of 
TRAP-CE measurement. Fig. 1D illustrates the TRAP-CE measurement of different cell lines. 
All samples had the same protein content (0.1µg) in the PCR reaction. The telomerase activity 
after calculation is given in Fig. 1E. H460 had highest telomerase activity compared to the 
other two cell lines. The results of these three cell lines were comparable to the Q-TRAP 
measurement (Fig. 2D). 
2.3.2.2 Real-time quantitative PCR based TRAP assay for telomerase measurement 
The amount of cellular protein in A549 lung carcinoma cell lysates was determined and then 
analyzed for telomerase activity using Q-TRAP assay. The dilution series for A549 cell line is 
illustrated in Fig.2A.  
The green line represents the threshold in the amplification plot. The threshold cycle (Ct) of 
each sample was determined according to this green line. From curve 1 to 6, with decreasing 
protein concentration, the Ct values of the samples increased. If the amount of protein lysates 
is greater than 1µg, it can interfere with the PCR reaction and will increase Ct values [Herbert 
et al., 2006]. Therefore in our experiments the standard curve started from 1µg. Fig. 2B 
shows the relative standard curve calculated according to the data from Fig. 2A. Ct values of 
the samples were plotted against log [protein] to calculate the liner equation. The r2, which 
should be greater than 0.9, was 0.9919 in this experiment indicating a good correlation 
between Ct and log [protein]. The Y-intercept (as c in the equation y = bx + c) and the slope 
(as b in the equation y = bx + c) of the regression line were used to calculate the relative 
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telomerase activity (RTA) of unknown samples. Using this relative standard curve method, 
different samples assayed in the same experiment can be compared.  
 
 
Fig. 2: Real-time quantitative PCR based TRAP assay (Q-TRAP) measurement of telomerase 
activity 
(A) Real-time amplification plot of diluted A549 lung carcinoma cell lysates (1, 0.2, 0.1, 0.05, 0.01 
and 0.002µg protein corresponding to curve 1 to 6 respectively). The change in SYBR Green 
fluorescent signal was plotted against cycle number. The threshold cycle value (Ct) represents the 
cycle where fluorescence is first detected above the baseline signal plus 10 standard deviations (SD) 
(10 SD=10 to the power 1). The dilutions of cell lysates result in increased Ct values. (B) The standard 
curve was generated from the amplification plot of (A). The Ct values of standard control were plotted 
against log [protein] to calculate the linear equation (y = -3.3541x + 21.787). According to the linear 
equation the RTA of unknown samples were calculated as RTAunknown= 10[(Ct sample–21.787)/(-3.3541)]. (C) 
Real-time amplification plot of lung carcinoma cell lines A549, H23 and H460 cell extracts with same 
protein content (0.1µg). (D) Samples were quantified according to the amplification plot in (C) and the 
standard curve in (B). Data present the mean + SD of 3 different measurements. 
 
Telomerase activity of various samples also revealed individual curves as shown in Fig. 2C 
(the standard curves were not shown in this figure). The relative telomerase activities of these 
samples were quantified by the standard curve run in the same experiment and calculated as 
described above (Fig. 2D). H460 cells showed higher telomerase activity and smaller Ct 
values compared to the other two cell lines. H23 cells showed lowest telomerase activity and 
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had the greatest Ct value. The results are only valid when all the negative controls show no 
significant amplification signals. 
In this study, we analysed samples of known protein concentrations (0.1µg protein was used 
for each sample), the calibration curve showed a very good correlation (r2>0.95) and 
reproducibility between different experiments. It is easy and reliable to compare unknown 
samples within one experiment. The results between different PCR reactions can also be 
compared if the telomerase activity of the sample is normalized to a positive control (e.g. 
A549 cells) and expressed as a percentage of telomerase activity of the positive control. 
2.3.2.3 Comparison of telomerase assays 
To compare the TRAP-CE and Q-TRAP, telomerase activity was measured in primary lung 
cancer tissues which were obtained as surgical waste from patients. The two TRAP assays 
revealed a strong (r=0.7182) and significant (p=0.0168) correlation (Fig. 3).  
 
Fig. 3: Correlation between TRAP-CE and Q-TRAP assays for measurement of telomerase 
activity in primary lung cancer tissues 
Eleven primary lung cancer tissues were analyzed for telomerase activity by TRAP-CE and Q-TRAP.  
 
Compared to TRAP-CE, Q-TRAP has several advantages: it is specific and highly sensitive; it 
can provide linear telomerase detection down to low protein content; it can permit rapid 
analysis within less than 6h including protein isolation and determination. The real-time PCR 
reaction does not need post-PCR steps and the carryover contamination is reduced. One of the 
major advantages of the Q-TRAP assay is that it is not an end-point PCR as the results are 
generated during the exponential amplification phase which can avoid disturbing plateau-
related events (Fig. 2A and C). In the Q-TRAP the anchored return primer ACX was used to 
reduce primer-dimer interference and to prevent 3´ elongation of telomerase products [Kim et 
al., 1997]. We modified the reaction in a 384-well plate using the 7900HT Fast Real-Time 
PCR System, so more samples can be run in one set and the costs for each sample were also 
less. TRAP-CE as an end-point PCR reaction is time consuming, laborious and has a 
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relatively low throughput. It was reported that a several-fold difference in telomerase activity 
can not be easily discriminated by the conventional TRAP method [Hou et al., 2001]. In our 
experiments Q-TRAP can distinguish a two-fold difference in telomerase activity in A549 
cells (Fig. 2A). It was also reported that Q-TRAP can overestimate the telomerase activity in 
samples of very low-activity [Herbert et al., 2006]. Q-TRAP showed good linearity down to 
0.002µg protein (Fig. 2B), but attention is needed if samples with very weak telomerase 
activity (lower than 0.2% of A549 cells) are analyzed. The ideal protein content in the PCR 
reaction has to be evaluated at the beginning of the Q-TRAP assay. 
Because telomerase is a heat sensitive enzyme, samples have to be prepared at 4°C, snap- 
frozen with liquid nitrogen and stored at -80°C. Frequent thawing and freezing of the samples 
should be avoided. The protein extracts can be stored at -80°C for 10 years while the 
telomerase activity can be completely lost within 2 months when samples are stored at -20°C 
[Piatyszek et al., 1995]. The Q-TRAP assay can be used as a powerful tool for measurement 
of telomerase activity in various specimens. 
2.4 Part 2: Telomere measurement 
2.4.1 Materials and methods 
2.4.1.1 Preparation of genomic DNA 
Genomic DNA was isolated from cells using the QIAamp DNA Mini Kit (QIAGEN, Hilden, 
Germany). Cultured cells were harvested, counted and washed with PBS. Up to 5×106 cells 
were resuspended in 200µl PBS and added into a 1.5ml microcentrifuge tube which contained 
20µl Proteinase K and 40µl RNase A (10 mg/ml). After 200µl buffer AL (from kit) was 
added, the sample was incubated at 56°C for 10min. The following steps were done according 
to the QIAamp DNA Mini Kit protocol. The final DNA was eluted in Buffer AE(from kit) 
and stored at -20°C. DNA was quantified using a NanoDrop spectrophotometer (PEQLAB, 
Erlangen, Germany). For terminal restriction fragment length determination by Southern blot, 
5µg of genomic DNA were digested with 10U (2U/µg DNA) of the restriction enzyme Hinf I. 
2.4.1.2 Telomere measurement by terminal restriction fragment length determination 
Telomere length was determined by measurement of mean terminal-restriction fragment (TRF) 
lengths with southern blotting. Restriction enzyme Hinf I digested DNA was fractionated by 
electrophoresis on a 0.8% agarose gel and transferred to a positively charged nylon membrane. 
DNA was fixed on the membrane by UV-crosslinking. The membrane was pre-hybridized 
with pre-hybridization mix at 42°C for 30min and subsequently hybridized with digoxigenin -
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labeled 5´-(TTAGGG)7 telomere-specific probe overnight at 42°C. The membrane was 
washed twice with 2× sodium chloride-sodium citrate buffer (SSC)/0.1% sodium dodecyl 
sulfate buffer (SDS) for 15min at 42°C and further washed with 2×SSC for 5min at room 
temperature. Blocking solution was added to the membrane to prevent unspecific binding. 
The membrane was incubated with anti-DIG-alkaline phosphatase for 45 min. Finally, the 
immobilized telomere probe was visualized by a highly sensitive chemiluminescent substrate 
for alkaline phosphatase (CDP-star, Roche, Mannheim, Germany). The membrane was 
exposed to an X-ray film (Hyperfilm; GE Healthcare Bio-Sciences, Piscataway, NJ, USA) 
which was densitometrically scanned. TRF length analysis was performed on the scanned 
image with AIDA image analyzer software (Raytest, Straubenhardt, Germany). The mean 
TRF length was calculated by quantification of the signal intensities at each point above 
background integrated over the entire distribution of fragments. The average telomere length 
in each sample was calculated as weighted mean of the peak with the highest optical density 
compared to a standard molecular weight marker (Roche, Mannheim, Germany).  
2.4.1.3 Telomere measurement by real-time quantitative PCR 
Telomere measurement was performed by a quantitative real-time PCR described previously 
(Cawthon RM 2002). All samples were measured on the 7500 Real-Time PCR System with 
the SDS Version 1.2.3 software (Applied Biosystems, Foster City, USA). Endogenous control 
36B4 is a single copy gene which encodes the acidic ribosomal phosphoprotein P0 (Cawthon 
RM 2002). For 36B4 PCR reaction, the final volume of 20µl contains 35ng DNA, 300nM 
36B4u primer, 500nM 36B4d primer and 10µl SYBR Green PCR Master Mix (QuantiTect, 
QIAGEN, Germany).  
For telomere content PCR reactions, the final volume of 20µl contains 35ng DNA, 270nM 
telomere forward primer, 900nM telomere reverse primer, 1mM MgCl2 and 10µl SYBR 
Green PCR Master Mix. The cycling conditions for both telomere and 36B4 PCR reaction 
were: 95°C for 15min followed by 40 cycles of 94°C for 15sec, 54°C for 60sec. The threshold 
cycle value (Ct) of each sample was determined from amplification log plots (the change in 
fluorescent signal was plotted against cycle number). The relative telomere length of the 
sample was calculated by the delta-delta Ct method (∆∆Ct). The relative quantities of 
telomere content and the single copy gene 36B4 were expressed as the level of dilution of the 
reference DNA sample. This will make the experimental and reference samples equivalent 
with regard to the number of cycles of PCR needed to generate a given amount of telomere 
PCR or single copy gene PCR product during the exponential phase of the PCR (Cawthon 
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RM 2002). The relative telomere (T) to single copy gene(S) ratio (T/S) is the ratio of the 
dilution factors in this experiment. H23 cells were used as reference DNA sample and its T/S 
ratio was set as 1. The relative telomere length of each sample was determined by dividing the 
T/S ratio of the sample to the T/S ratio of H23 cells. A sample of cord blood from a newborn 
baby was used as long telomere control in each run. Primers were all synthesized by Biomers 
(Ulm, Germany) and the sequences are shown in Table 3. All measurements were performed 
in triplicates.  
Table 3: Primers, sequences and 1× PCR reaction components for telomere measurement by 
real-time quantitative PCR  
Primer Sequence 
Telomere forward 5´-GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3´ 
Telomere reverse 5´-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3´ 
36B4u 5´-CAGCAAGTGGGAAGGTGTAATCC-3´ 
36B4d 5´-CCCATTCTATCATCAACGGGTACAA-3´ 
 
Telomere content PCR: 
Component volume [µl] 
RNase/DNase-free H2O 1.66 
Telomere forward primer (26.4µM) 0.21 
Telomere reverse primer (54.5µM) 0.33 
SYBR Green Master mix 10 
MgCl2 (25mM) 0.8 
Sample  7 
Total volume 20 
 
Endogenous control PCR: 
Component volume [µl] 
RNase/DNase-free H2O 2.47 
36B4u forward primer (30.8µM) 0.20 
36B4u reverse primer (30µM) 0.33 
SYBR Green Master mix 10 
Sample  7 
Total volume 20 
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2.4.2 Results and discussion 
2.4.2.1 Telomere measurement by terminal restriction fragment length determination 
Fig. 4A exhibits the telomere length determined by the mean telomere TRF using Southern 
blot. The mean TRF length was calculated by quantifying on the blot the signal intensities of 
each sample. The white line on each sample shows the maximum of the optical detected peak 
density. A standard molecular weight marker (λ-Hind III) was used to calculate the average 
TRF by comparing the weighted mean of the peak signal with the highest optical density to 
the weight marker. Fig. 4B illustrates the quantification results calculated from Fig. 4A. The 
cord blood has the longest telomere length (~15kb) and the H23 cell has the shortest telomere 
length (~3.6kb) in the tested samples. 
 
Fig. 4: Telomere length determined by measurement of mean TRF lengths with Southern blot 
(A) Southern blot of lung carcinoma cells and a cord blood sample. (B) Quantitative analysis of the 
TRF from the Southern blot of (A). 
2.4.2.2 Telomere measurement by real-time quantitative PCR 
Fig. 5A shows the real-time amplification plot of the Q-PCR. In each sample the T/S was 
used to normalize the telomere signal to a single copy gene in each sample to avoid the 
interindividual variation between different samples. In this study we chose single copy gene 
36B4 as the basis to normalize the quantitative telomere PCR signal [Cawthon et al., 2002; 
Boulay et al.,1999].  
We assumed that the PCR reaction was quite efficient, so the amount of the PCR product was 
considered to be doubled in each PCR cycle. The T/S ratio can be calculated as 2-∆Ct while 
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∆Ct= Ct(telomerase)- Ct(36B4). The other samples were normalized to H23 to get the relative 
T/S ratios. The relative T/S ratio of each sample is 2-∆∆Ct while ∆∆Ct =∆Ct(sample) - 
∆Ct(H23). By using this ∆∆Ct method, a relative T/S ratio of each sample was calculated to 
indicate the relative telomere length. Fig.5B shows the results after the ∆∆Ct method 
calculation. The cord blood from a newborn baby has the longest relative telomere length. 
Lung carcinoma cell line A549 and primary lung cancer cells 5705 have shorter telomere 
length.  
Fig. 5: Telomere length was determined by measurement of relative T/S ratios with Q-PCR  
(A) Real-time amplification plot of samples by the Q-PCR method. (B) Quantitative analysis of 
relative T/S ratio from lung carcinoma cell lines and a human cord blood sample. Data present the 
mean + SD of 3 different measurements. 
2.4.2.3 Comparison of telomere assays 
As shown in Fig.6, in the tested 6 samples, relative T/S ratios determined by Q-PCR and 
relative TRF lengths measured by Southern blot exhibited a strong (r =0.9856) and significant 
(p=0.0028) correlation.  
 
Fig. 6: Correlation between Southern blot and Q-PCR methods for measurement of telomere 
length in lung cancer cells 
Six samples from lung cancer cell lines were analyzed for telomere length by Shouthern blot (TRF 
length) and Q-PCR (relative T/S ratio).  
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Cawthon RM et al. reported a correlation (r2=0.677, p< 0.01) between these two methods in 
DNA analysis of blood samples from 95 individuals [Cawthon et al., 2002]. This could be 
confirmed in our experiments with much stronger correlation. The stronger correlation of our 
experiment might be explained by a more homogenous samples or a small sample size. Fig. 7 
gives the telomere lengths of A549 cells after 15 weeks of treatment with a telomerase 
inhibitor antisense 2´-O-methyl-RNA (OMR). Compared to the control, the group treated 
with the telomerase inhibitor exhibited a comparable telomere shortening by both 
measurements (Fig. 7B and C).  
Fig. 7: Comparison of telomere length shortening of A549 cells measured by Southern blot and 
Q–PCR methods  
Telomere length was determined by measurement of mean TRF lengths in Southern blotting and 
relative T/S ratios in Q-PCR. Untreated cells were used as control. A549 cells were treated with 
nanoparticles (NP) delivered telomerase inhibitor OMR for 15 weeks. (A)Southern blot of control and 
telomerase inhibitor (OMR+NP) treated A549 cells. (B) Quantitative analysis of the TRF from the 
Southern blot results of (A). (C) Quantitative analysis of the relative T/S ratio of control and 
telomerase inhibitor (OMR+NP) treated A549 cells by Q-PCR. Data present the mean +SD of 
triplicates. The T/S ratio of each sample was normalized to H23 cells. 
 
Southern blot measurement of TRF requires about 5µg DNA for each sample and it is very 
time-consuming (about 3 days). The reproducibility of the blotting is low. The genomic DNA 
has to be digested before performing Southern blot. It was reported that the relative mean 
TRF lengths of the samples can be influenced by different restriction enzymes [Cawthon et al., 
2002]. This limits the application of this method. The measurement of telomere lengths by Q-
PCR is a fluorescence based assay with closed tubes; it is a rapid (less than 2h for the real-
time PCR reaction), simple and high throughput method. Recently, it has been published that 
the absolute telomere length can be measured with the Q-PCR method by introducing a 84-
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mer oligonucleotide standard with known quantities [O'Callaghan et al., 2008]. The absolute 
telomere measurement allows a better comparison of results between different experiments 
and laboratories. Since both methods can provide similar results and the absolute telomere 
length is not necessary in our experiments, we did not use O'Callaghan’s method. The Q-PCR 
method we optimized can provide a rapid and useful tool for investigating telomere biology. 
2.5 Conclusion 
Our data suggest that both real-time quantitative PCR based assays for telomerase activity and 
telomere length measurements are simple and specific. Their rapid and reliable quantification 
can be used in a wide range of applications. 
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Parts of this chapter have been published as an original article in Journal of 
Pharmaceutical Sciences: 
Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, Schaefer UF, Lehr CM, 
Klotz U, Mürdter TE.  
Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal 
delivery of 2'-O-methyl-RNA. J Pharm Sci. 2009 May; 98(5):1765-74. 
 
*The results presented in this chapter were obtained by Meng Dong.  
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3.1 Abstract 
 
Background: A new promising approach for the treatment of non-small cell lung cancer 
(NSCLC) is based on the inhibition of telomerase in cancer cells. The antisense 
oligonucleotide 2´-O-methyl-RNA (OMR) targeting the RNA component of telomerase 
represents a selective telomerase inhibitor and a potential candidate for anticancer therapy.  
The poor cellular uptake and rapid nuclease-mediated degradation of oligonucleotides limit 
the application of OMR. To improve the cellular uptake and subsequent antitumoral 
efficiency of OMR in human lung cancer cells, we have compared five different transfection 
reagents. 
Methods: In NSCLC A549 cells the transfection reagents DOTAP, MegaFectin 60, 
SuperFect, FuGENE 6 and MATra-A were tested for cellular uptake of OMR and the impact 
to mediate telomerase inhibition. A FAM-labeled OMR was applied to assess the intracellular 
distribution of the OMR by confocal laser scanning microscopy (CLSM).Telomerase activity 
was measured by a modified telomeric repeat amplification protocol using capillary 
electrophoresis (TRAP-CE) at 24h, 48h and 72h after transfection. 
Results: In NSCLC A549 cells all five transfection reagents enhanced cellular uptake of 
OMR. Cationic liposomal transfection reagents DOTAP and MegaFectin 60 were most 
efficient in the delivery of OMR resulting in telomerase inhibition. DOTAP exhibited the 
lowest cytotoxicity and a strong induction of telomerase inhibition. 
Conclusion: Our data show that in human NSCLC cells DOTAP is the most suitable 
transfection reagent for OMR delivery, displaying relatively high transfection efficiency, low 
cytotoxicity and strong telomerase inhibition. Effective delivery of OMR offers a potent 
therapeutic option for the treatment of lung cancer based on telomerase inhibition. 
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3.2 Introduction 
In recent years telomerase has been considered as a promising drug target for anti-cancer 
therapy. Telomerase is an enzyme which adds telomeric repeats to the end of linear 
eukaryotic chromosomes. Telomerase activity is present in 80-90% of all human cancers 
including lung cancer which is the leading cause of cancer-related mortality [Jemal et al., 
2007; Harley, 2008]. Telomerase activity is detected in about 80% of non-small cell lung 
cancer (NSCLC) which is one of the main types of lung cancers [Taga et al., 1999]. Inhibition 
of telomerase activity is a novel therapeutic strategy for NSCLC treatment.  
Human telomerase contains two major components, the catalytic protein subunit human 
telomerase reverse transcriptase (hTERT) and the RNA template human telomerase RNA 
(hTR) [Feng et al., 1995; Nakamura et al., 1997]. Apparently, hTR is an ideal target for 
telomerase inhibition. The antisense oligonucleotide 2´-O-methyl-RNA (OMR) can directly 
bind to hTR and consequently could serve as a specific telomerase inhibitor [Pitts et al., 1998]. 
After screening different classes of telomerase inhibitors, it has been reported that OMR 
demonstrated a high potential for telomerase inhibition in A549 lung cancer cells [Pitrowska 
et al., 2005]. 
However poor cellular uptake and rapid nuclease-mediated degradation of oligonucleotides 
limit the application of antisense OMR. Specific delivery systems are required to enhance 
uptake of OMR and subsequent biological effects. In NSCLC A549 cells we have tested five 
different transfection reagents for their delivery of OMR, analyzed cellular uptake, toxicity 
and the impact to mediate telomerase inhibition. The cationic lipid reagents DOTAP and 
MegaFectin 60 were compared with two nonliposomal transfection reagents FuGENE 6 and 
SuperFect and with magnet assisted transfection (MATra-A) which uses magnetic force to 
deliver oligonucleotides into target cells. Cationic lipid reagents can enhance antisense 
oligonucleotide activity and can facilitate oligonucleotide cell internalization [Bennett et al., 
1992; Capaccioli et al., 1993]. DOTAP is a liposome formulation of the monocationic lipid 
(N-1-2,3-Dioleoyloxy)-N,N,N-trimethylammonium propane methylsulfate and it is efficient 
in both in vitro and in vivo applications of oligonucleotides [Simberg et al., 2004]. It has been 
reported that addition of cholesterol to the formulation of liposome can improve the 
transfection efficiency [Templeton et al., 1997; Liu et al., 1997]. In the presence of serum 
MegaFectin 60, a combination of DOTAP and cholesterol increase the delivery of DNA to 
cells [Crook et al., 1998]. It has been used for gene transfer in in vivo experimental anticancer 
treatment [Anwer et al., 2000]. SuperFect is based on a novel, activated-dendrimer 
technology which has been reported to be used in cellular delivery of antisense 
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oligonucleotides [Hollins et al., 2004; Sato et al., 2001; Bielinska et al., 1996]. FuGENE 6 
represents a multi-component formulation which has been applied as transfection reagent in 
many different cell lines [Jacobsen et al., 2004]. We have compared these five different 
transfection reagents to identify a suitable reagent for efficient delivery of OMR into NSCLC 
A549 cells. Cationic lipids such as DOTAP and MegaFectin 60 were found to be more 
efficient in the delivery of OMR into NSCLC A549 cells. Furthermore, DOTAP is the most 
suitable transfection reagent for the delivery of OMR in human lung cancer cells. 
3.3 Material and methods 
3.3.1 Cell culture 
Human non-small cell lung cancer (NSCLC) cells A549 were obtained from DSMZ 
(Braunschweig, Germany). They were cultivated in Roswell Park Memorial Institute (RPMI) 
1640 medium (Biochrom, Berlin, Germany) supplemented with 10% heat inactivated fetal 
calf serum (FCS), 2mM L-glutamine (Biochrom), 50U/ml penicillin and 50 µg/ml 
streptomycin (Gibco BRL, Karlsruhe,Germany) in 5% CO2 at 37°C. Cell viability was 
assessed by trypan blue exclusion test.  
3.3.2 Oligonucleotides 
An antisense 2´-O-methyl-RNA (OMR) with a phosphorothioate (ps) backbone 5´-2´-O-
methyl [C(ps)A(ps)GUUAGGGUU(ps)A(ps)G]-3´ was used as telomerase inhibitor in this 
study. 2´-O-methyl-RNA mismatch was 5´-2´-O-methyl [C(ps)A(ps)GUUAGAAUU(ps) 
A(ps)G]-3´. The fluorescence-labeled 2´-O-methyl-RNA (FAM-OMR) was 5´-FAM-2´-O-
methyl [C(ps)A(ps)GUUAGGGUU(ps)A(ps)G]-3´. All oligonucleotides were synthesized by 
MWG-Biotech AG (Ebersberg, Germany). The oligonucleotides were dissolved in sterile 
water, aliquoted and stored at -20°C for further processing. To ensure the stability and 
biological activity of the oligonucleotides, small aliquots were tested in the cell-free TRAP 
assay prior to the use in the cell culture experiments.  
3.3.3 Preparation of oligonucleotide transfection 
A549 cells were selected to determine the biological effect of telomerase inhibitor OMR after 
transfection. A549 cells were seeded in 6-well plates before treatment. One day after seeding 
the cells reached approximately 60-80% confluency and they were transfected with 4µM 
OMR using five different transfection reagents according to the manufacturer’s protocol. The 
ratio of oligonucleotide to transfection reagents is listed in Table 1. 
The first transfection reagent was DOTAP (N-[1-(2,3-Dioleoyloxy) propyl]-N,N,N-
trimethylammonium methyl-sulfate) (Roche, Penzberg, Germany). Oligonucleotides were 
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dissolved in HBS buffer (20mM HEPES, 150mM NaCl, pH 7.4) with a final concentration of 
0.1µg/µl and 100µl DOTAP/HBS buffer (30µl DOTAP reagent was added in a sterile 
Eppendorf tube and filled up to 100µl with HBS buffer) was added. The mixture was mixed 
gently by pipetting to avoid foaming and incubated in the dark for 15min at room temperature. 
The mixture with certain amount of cell culture medium was applied to the cells and replaced 
by normal cell culture medium after 6h treatment. 
The second transfection reagent was MegaFectin 60TM (Qbiogene, Illkirch, France). 
Following the kit protocol 153.8µl HEPES buffer was added to the lyophilized lipid and 
vortexed well until completely suspended to form the MegaFectin solution. Oligonucleotide 
was added to MegaFectin solution and incubated in the dark for 15min at room temperature. 
Certain amount of cell culture medium was added together with transfection mixture to the 
cells to make a final volume of 1.5ml for each well. Transfection mixture was replaced by cell 
culture medium 6h after treatment. 
The third transfection reagent was SuperFect (Qiagen GmbH, Hilden, Germany).  
Oligonucleotides were first added to pure RPMI medium with supplements. SuperFect 
reagent was added to the oligonucleotide solution and mixed well. The mixture was incubated 
in the dark for 10min at room temperature to allow transfection-complex formation. The cells 
were washed with PBS once before applying the transfection mixture. Certain amount of cell 
culture medium with supplements was added to the cells and the transfection mixture was 
loaded to the cells. The final volume was 1.5ml for each well. Transfection mixture was 
removed 3h after treatment and the cells were continually cultured with cell culture medium.  
The fourth transfection reagent was FuGENE6 (Roche, Penzberg, Germany). Certain amount 
of supplement-free RPMI medium was added into the Eppendorf tube, oligonucleotides were 
added together with FuGENE6 to the medium and mixed well. After 15min incubation in the 
dark at room temperature, the mix was applied to the cells and further replaced by cell culture 
medium after 6h treatment. 
The fifth transfection device was magnet assisted transfection (MATra-A) (IBA GmbH, 
Göttingen, Germany). Oligonucleotides were added into supplement-free cell culture medium 
and mixed well. Certain amount of MATra-A reagent was added to the oligonucleotide 
solution and mixed well. The mixture was incubated for 20min at room temperature. During 
incubation, cell culture medium was changed; the bead-mixture was added to the cells and 
mixed immediately. The cell culture plate was placed on the suitable magnet plate and 
incubated for 15 min at 37°C. The magnet plate was removed and a medium change was 
performed once. Cells were continually cultured until analysis. Fig.1 provides an overview of 
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all the transfection procedures. Untreated A549 cells, A549 cells treated separately only with 
OMR, with transfection reagent or with a mismatch oligonucleotide were used as controls. 
 
 
Fig. 1: Overview of the five transfection procedures (DOTAP, MegaFectin, FuGene6, SuperFect, 
MATra-A) 
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Table 1: Ratio of oligonucleotides to transfection reagents 
 Transfection 
reagent (µl) 
OMR 
(µg) 
DOTAP 5 1 
MegaFectin 5 1 
SuperFect 2 1 
FuGENE 6 1.5 1 
MATra-A 1 1 
 
3.3.4 Confocal laser scanning microscopy analysis 
The transfection efficiency was analyzed by confocal laser scanning microscopy (CLSM). 
A549 cells were seeded in Lab-Tek® chamber slides (Nalge Nunc International, Naperville, 
USA) at a density of 65 000 cells per well one day before the transfection. 24h after seeding, 
cells were transfected as described above with the fluorescence labeled OMR (FAM-
OMR).Cells were evaluated by confocal laser scanning microscopy 6h, 24h and 72h after 
treatment, respectively. After two times washing with PBS, cells were incubated with 
25µg/ml rhodamine-labeled ricinus communis agglutinin I (RCA I, Vector Laboratories, 
Burlingame, CA, USA) for 15min at 37°C which enables detection of cell membranes by 
binding to oligosaccharides ending in galactose. The cells were washed twice with PBS and 
fixed with 100% ethanol at -20°C for 10min. The cell nuclei were stained with 1µM TO-
PRO®-3 iodide (Molecular Probes Invitrogen, Eugene, OR, USA) in the dark for 10 min at 
room temperature. Cells were washed twice with PBS, the chamber and gasket were removed 
and slides were mounted with mounting medium (Vectashield® Mounting Medium, Vector 
Laboratories, Burlingame, CA) for analyzing by CLSM. Images were taken randomly from 
different areas. Cells which contained more than 5% FAM signal were considered as positive 
cells. For each image the uptake efficiency in percent was calculated by dividing the number 
of positive cells by the total cell number. A mean value of each sample was calculated from 
all 12 images. CLSM was performed with a Leica LCS (Leica Lasertechnik) instrument based 
on a Leica DM IRBE microscope equipped with argon and helium/neon lasers. The excitation 
(Ex.) and emission (Em.) wavelengths of the dyes were as follows: FAM (Ex. 488nm,Em. 
500-540 nm);RCAI (Ex.543nm, Em.560-610 nm);TO-PRO®-3 (Ex. 563nm, Em. 650-700 nm). 
3.3.5 Telomerase activity assay using capillary electrophoresis  
A549 cells were harvested, counted 24h and 72h after transfection. 106 cells were pelleted and 
washed with PBS. The cell pellets were either stored at -80°C or immediately resuspended in 
200µl ice-cold 3-[ (3-cholamidopropyl) dimethyl-ammonio]-1-propanesulfonate (CHAPS) 
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lysis buffer and incubated on ice for 30min. After the incubation, lysates were centrifuged at 
12 000×g for 20 min at 4°C and supernatants were aliquoted, snap-frozen and stored at - 80°C.  
Telomerase activity was measured using a modified protocol of the TRAPEZE Telomerase 
Detection Kit (Chemicon International, Hampshire,UK). Detailed process is described in 
Chapter 2: Part 1: Materials and methods: Telomerase activity assay using capillary 
electrophoresis.  
3.3.6 Statistical analysis 
The Student’s t-test was used to determine statistical differences between pairs of groups; 
p<0.05 (two-sided) was considered as statistically significant. Data were analyzed using 
Graphpad Prism version 4.0 (GraphPad Software Incorp., San Diego, CA). 
 
3.4 Results 
3.4.1 Evaluation of transfection efficiency by confocal laser scanning microscopy  
FAM-OMR was used to evaluate the uptake efficiency in A549 cells transfected with 5 
different transfection reagents. CLSM images were taken 6h, 24h, 48h and 72h after 
transfection. DOTAP and MegaFectin 60 showed much higher transfection efficiencies than 
the other three reagents. FAM-OMR was present mainly in the cytoplasm of DOTAP 
transfected cells (Fig.2-DOTAP) and 6h after transfection the transfection efficiency reached 
about 74% (Table.2). The nuclear staining signal was found in about 25% of cells and the 
fluorescent signal increased to more than 50% 24h after transfection. The uptake efficiency 
remained stable and FAM-OMR was still present in about 70% of the cells 48h and 72h after 
transfection (Table.2).  
CLSM images showed that about 68% of the cells contained the FAM-OMR 6h after 
transfection with MegaFectin (Table. 2). FAM-OMR was mainly localized in the perinuclear 
area of the cytoplasm and some nuclei exhibited a spotted staining (Fig.2-MegaFectin). The 
transfection efficiency was still around 60% at 72h and did not change significantly (Table. 2). 
Seventy-two hours after transfection high amount of FAM-OMR were still localized in the 
cytoplasm but no nuclear localization was obvious.  
Transfection with FuGENE6 led to a poor uptake of FAM-OMR. Transfection efficiency was 
about 44% at 6h after transfection (Fig.2-FuGENE6). The transfection efficiency dramatically 
reduced at the following time points and reached only 12% at 72h after transfection (Table.2). 
The FAM-OMR was mainly found in the cytoplasm, a nuclear signal was only observed in 
very few cells.  
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Fig. 2: Uptake of FAM-labeled OMR in A549 cells visualized by CLSM 
A549 cells were transfected with 4µM FAM-OMR using MegaFectin 60, DOTAP, FuGENE6, 
Superfect and MATra-A. CLSM images were taken 6h, 24h, 48h and 72h after transfection. FAM-
OMR has a fluorescence signal shown in green. Cells were counterstained with RCAI (membrane, red) 
and TOPRO-3 (nucleus, blue). The second row of each treatment shows the transverse (XZ axis) and 
vertical (YZ axis) cross sections of a single zoomed cell from corresponding upper image for each 
time point. Images were analyzed using a 63× objective. Scale bars represent 20µm. 
 
SuperFect displayed lower transfection efficiency than DOTAP and MegaFectin. However, 
these differences did not reach statistical significance due to high variabilities. The FAM-
OMR was present in only 59% of the cells 6h after transfection (Table.2). The majority of the 
FAM-OMR was localized in the cytoplasm but there were more cells showing fluorescent 
signal in the nuclei compared to the other transfections. The transfection efficiency remained 
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stable after 6h, but the nuclear localization increased with time and reached a plateau at 72h 
(Fig.2-SuperFect).  
MATra uses magnetic nanoparticles delivering oligonucleotides into target cells by magnetic 
force. MATra was able to mediate delivery of FAM-OMR into A549 cells and resulted in a 
transfection efficiency of 53% 6h after transfection (Table.2). But the CLSM images also 
revealed that only low amounts of the OMR were present in the cytoplasm (Fig.2-
MATra).The transfection efficiency of MATra increased slightly after 6h, and then stayed 
around 60% until 72h after transfection.  
Table 2: Transfection efficiency of five transfection reagents 
The efficiency is given as % positive cells of total number of cells (mean value ± SD). Differences are 
compared to FuGENE6. * p < 0.05; ** p < 0.01. 
 
DOTAP MegaFectin SuperFect MATra-A FuGENE 6 
6   74 ± 18       68 ± 13 59 ± 12    53 ± 17  44 ± 20 
24 76 ± 15** 66 ± 17* 51 ± 19    60 ± 17* 26 ± 8 
48 69 ± 20** 65 ± 20*  54 ± 20*  56 ± 14** 14 ± 1 
72 71 ± 15** 60 ± 29*  52 ± 9 **  60 ± 19** 12 ± 2 
 
3.4.2 Evaluation of telomerase inhibition by capillary electrophoresis 
Transfection of mismatch-OMR using various transfection reagents did not demonstrate 
telomerase inhibition at all tested time points. As shown in Fig. 3, transfection of OMR with 
five different reagents exhibited different inhibitory effects. Twenty-four hours after 
transfection with DOTAP, MegaFectin and SuperFect an efficient and similar telomerase 
inhibition can be noted (at least 75%). Transfection with MATra-A and FuGENE6 resulted in 
weaker telomerase inhibition which was about 50% for MATra-A and 36% for FuGENE6 
(p<0.05 vs. DOTAP). Forty-eight hours after transfection, DOTAP and MegaFectin showed 
effective telomerase inhibition as after 24h. Cells transfected with SuperFect restored some 
telomerase activity. Compared to DOTAP, a weaker inhibition was observed for SuperFect, 
MATra-A and FuGENE6. Seventy-two hours after transfection, only DOTAP remained 
inhibitory and in the cells only about 16% of telomerase activity was left. The cells treated 
with the other transfection reagents demonstrated increased telomerase activity which was 
significantly different compared to DOTAP (Fig. 3). Transfection with MegaFectin resulted 
in 71% inhibition of telomerase 72h after transfection. Transfection of OMR with SuperFect 
reduced telomerase activity by 52%. MATra-A reduced telomerase activity 24h after 
Transfection    
        reagent Time after 
transfection (h) 
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transfection by about 49% but this inhibition was not maintained up to 72h. In contrast, after 
transfection with FuGENE6 almost no telomerase inhibition could be observed. 
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Fig. 3: Inhibition of the telomerase activity in A549 cells 24, 48 and 72h after transfection with 
4µM OMR using DOTAP, MegaFectin 60, SuperFect, MATra-A and FuGENE6 
Telomerase activity was determined by a modified TRAP-CE assay. Telomerase activity of cells 
treated with transfection reagents alone was set to 100%. Data represent the mean +SD from at least 
three independent experiments. * p< 0.05 compared to DOTAP at corresponding time point. 
 
3.5 Discussion 
The poor cellular uptake of oligonucleotides limits the application of the telomerase inhibitor 
OMR [Loke et al., 1989]. We have compared five different transfection reagents to mediate 
the delivery of OMR to NSCLC A549 cells and monitored the cellular telomerase activity. 
Overall the liposomal transfection reagents showed better transfection efficiency of OMR and 
more effective telomerase inhibition than the other reagents.  
It has been reported that 4µM OMR in combination with transfection reagents did not cause 
greater cytotoxicity compared to the transfection reagent alone [Beisner et al., 2009]. 
FuGENE 6 had a significantly higher cytotoxicity compared to the other four transfection 
reagents; the cell viability was only about 50% 72h after transfection while the cells treated 
with other transfection reagents had about 70% to 80% of cell viability [Beisner et al., 2009]. 
The liposomal transfection reagents DOTAP and MegaFectin demonstrated not only low 
cytotoxicity but also a relatively high binding efficiency with OMR.  
The lipoplex size is a major factor which influences the lipofection efficiency in vitro [Ross et 
al., 1999]. It has been shown that the cationic lipids DOTAP and MegaFectin have particle 
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sizes in the range of 600 and 800nm while those of SuperFect, FuGENE 6 and MATra-A are 
about 200nm. After combined with OMR, the particle size of FuGENE6 was almost doubled; 
the size of MegaFectin and DOTAP increased and reached more than 1µM [Beisner et al., 
2009]. OMR and DOTAP formed a complex of 1400nm which was found to be most efficient 
for uptake. The liposomal transfection reagents achieved better transfection efficiency than 
smaller complexes in the range from 10 to 300nm. Suspensions of the liposomal transfection 
reagents DOTAP and MegaFectin showed a very broad size distribution. After adding OMR, 
the size distribution changed significantly for DOTAP and FuGENE 6 but remained the same 
for MegaFectin [Beisner et al., 2009]. All five transfection reagents had highly positive 
surface charges. After adding the negatively charged OMR, the zeta potential of the reagents 
decreased. This indicates an interaction of the OMR with the positively charged particle 
surface, especially with DOTAP whose zeta potential value was reduced below zero [Beisner 
et al., 2009]. Because MegaFectin is a special DOTAP/cholesterol lipid formulation it was 
expected that MegaFectin could be more efficient than DOTAP alone. However, DOTAP 
showed better transfection efficiency, lower cytotoxicity and stronger telomerase inhibition 
and therefore represent the best compound among the tested transfection reagents for OMR. 
SuperFect is an actived-dendrimer-based reagent which has potential cellular delivery of 
antisense oligonucleotides [Hollins et al., 2004; Sato et al., 2001; Bielinska et al., 1996]. It 
has been also reported to be used in gene delivery in vitro [Tang et al., 1996]. SuperFect had 
similar cytotoxicity as DOTAP, but the transfection efficiency and telomerase inhibition was 
lower than DOTAP.  
FuGENE 6 has been used because of its low toxicity and high level of transfection in many 
different cell lines [Jacobsen et al., 2004]. It can enhance the cellular uptake of 
oligonucleotides in cell cultures and the antisense phosphorothioate oligoncleotides complex 
with FuGENE 6 induced telomerase inhibition in HeLa cells [Tao et al., 1999; Tamura et al., 
2000]. However, the transfection efficiency of FuGENE 6 was dramatically reduced 72h after 
transfection compared to other transfection reagents. In our experiments it also exhibited 
relatively high toxicity and low telomerase inhibition. This is probably due to the low binding 
efficiency between OMR and FuGENE 6. FuGENE 6 can not be regarded as the best choice 
for OMR delivery into A549 cells. 
MATra-A is a magnetofection-based transfection technique which uses magnetic 
nanoparticles as delivery system. It has been described as a highly efficient tool for antisense 
oligonucleotide delivery in vitro and in vivo [Krötz et al., 2003; Gersting et al., 2004]. In our 
experiments we also observed low cytotoxicity of MATra. But the transfection efficiency was 
Chapter 3: Telomerase Inhibition by Liposomal Delivery of OMR 
 
50 
low and it resulted in 51% inhibition of telomerase 24h after transfection, but 72h after 
transfection the telomerase inhibition was reduced to only 10%. The relatively weak 
inhibitory effect might be due to the strong interaction of OMR with the magnetic 
nanoparticles which probably prevents an effective action of OMR on telomerase inhibition 
[Beisner et al., 2009]. 
Inhibition of telomerase inducing telomere shortening is a novel target in anticancer therapy. 
Because sufficient telomere shortening needs a lag period, a long-term treatment might be 
necessary and a sustained telomerase inhibition is required. The half life of telomerase is 
about 24h [Holt et al., 1996]. For a long-term application cells have to be transfected every 3 
or 4 days, so the telomerase inhibition should persist for more than 72h. From our data, only 
liposomal delivery of OMR can mediate efficient telomerase inhibition for 72h. 
Imetelstat (GRN163L), a lipid modified 13-mer oligonucleotide that binds directly with high 
affinity to hTR resulting in direct, competitive inhibition of telomerase enzymatic activity, has 
entered phase I/II clinical trials. So far no direct toxicity could be observed in long-term 
studies. However it has been shown in a mouse model that GRN163L shows no difference in 
drug accumulation between healthy lung tissues and lung tumors [Dikmen et al., 2005]. This 
might cause effects on normal cells and could limit its clinical application. More research has 
to be done to investigate the delivery and effects of OMR in anticancer therapy. 
3.6 Conclusion 
Our data show that the cationic lipid transfection reagent DOTAP is most suitable for OMR 
delivery because of its high transfection efficiency, low cytotoxicity and strong telomerase 
inhibition in human NSCLC cells. Therefore, DOTAP can be used for in vivo studies and 
hopefully also for anticancer therapy in patients with lung cancers. 
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Telomerase Inhibition and Telomere Shortening by  
Nanoparticles Delivery of 2´-O-Methyl-RNA  
in Human Lung Cancer Cells 
 
 
 
 
 
Parts of this chapter have been published as an original article in the journal Lung 
Cancer: 
Beisner J, Dong M, Taetz S, Nafee N, Griese EU, Schaefer UF, Lehr CM, Klotz U, Mürdter 
TE. 
Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition 
and telomere shortening in human lung cancer cells. Lung Cancer. 2010 Jun;68 (3):346-54.  
 
*The results (except 4.4.1) presented in this chapter were obtained by Meng Dong. 
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4.1 Abstract 
 
Background: Lung cancer is the leading cause of cancer-related mortality. Non-small cell 
lung cancer (NSCLC) accounts for more than 80% of all lung cancers and carries a very low 
5-year survival rate. Telomerase activity is detected in 80% of NSCLC. Inhibition of 
telomerase in cancer cells is a promising approach for treatment of NSCLC. The antisense 
oligonucleotide 2´-O-methyl-RNA (OMR) binding to the RNA component of telomerase acts 
as a selective telomerase inhibitor. We analyzed the biological effects of chitosan-coated 
poly(lactide-co-glycolide) (PLGA) nanoparticle mediated delivery of telomerase inhibitor 
OMR in human lung cancer cells. 
Methods: Antisense oligonucleotides OMR were complexed with chitosan-coated PLGA 
nanoparticles to form OMR-nanoparticle-complexes (OMR-nanoplexes) and loaded to human 
NSCLC cells (A549, Calu-3, NCI-H23 and NCI-H460) and primary lung fibroblasts. For 
long-term experiments, the A549 cells were treated every 3-4 days with OMR-nanoplexes 
over 100 days. The cellular uptake of OMR was investigated by FACS analysis and confocal 
laser scanning microscopy (CLSM). Cytotoxicity of the treatment was measured by the ATP 
test. Telomerase inhibition was measured by real time PCR based telomeric repeat 
amplification protocol (Q-TRAP). Telomere length shortening after the long-term treatment 
was measured by real-time PCR. 
Results: Cellular uptake of OMR-nanoparticles was dramatically enhanced compared to the 
uptake of OMR alone as shown by FACS analysis. The internalization of OMR was further 
demonstrated by CLSM. OMR-nanoplexes treatment did not exhibit acute cytotoxicity in 
human lung cancer cells and nearly no influence in primary lung fibroblasts. Human NSCLC 
A549 cells did not show apoptosis 72h after treated with OMR-nanoplexes. Telomerase 
activity was continuously reduced by approximately 80% during a long-term experiment. 
Furthermore, in A549 cells the OMR-nanoplexes resulted in significant telomere shortening 
of about 50% in A549 cells. 
Conclusion: In human lung cancer cells nanoparticle mediated delivery of OMR induced 
effective telomerase inhibition and telomere shortening. Therefore it represents a great in vivo 
potential for the treatment of lung cancer. 
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4.2 Introduction 
Lung cancer is the leading cause of cancer-related mortality all over the world [Jemal et al., 
2007]. Small cell lung cancer and non-small cell lung caner (NSCLC) are the two main types. 
NSCLC accounts for approximated 80% of all lung cancer cases. The treatment of NSCLC 
including surgery at early stages, chemotherapy combined with radiation for some advanced 
cancers provides minor improvement in survival as the 5-year survival rate is only about 15% 
[Molina et al., 2008; Non-small Cell Lung Cancer Collaborative Group. 1995]. More efficient 
approaches are needed to target selectively the cancer cells.  
Telomerase has become one of the promising drug targets for anti-cancer therapy. Telomerase 
is a ribonucleoprotein synthesizing telomeric repeats to the end of telomeres [Morin, 1989] 
which cap the end of linear eukaryotic chromosomes thus protecting the end of chromosomes 
from deterioration. Human telomerase contains two major components, the human telomerase 
RNA (hTR) which serves as a template for the addition of telomeric repeats to the telomere 
DNA [Nakamura et al., 1997] and the human telomerase reverse transcriptase (hTERT) which 
works as the catalytic protein subunit [Feng et al., 1995; Meyerson et al., 1997]. Telomerase 
activity has been detected in human cancer cells as well as in germ line cells and stem cells, 
but not in most somatic cells [Kim et al., 1994]. Telomerase is positively expressed in 80-
90% of tumors [Harley, 2008]. It can prevent telomeres from shortening during each cell 
cycle and leads to immortalization of cancer cells. Telomerase activity has been detected in 
approximately 80% of NSCLC [Taga et al., 1999; González-Quevedo et al., 2002] and 
telomerase activity is associated with advanced stages and poor prognosis of NSCLC patients 
[Albanell et al.,1997; Marchetti et al., 1999]. Targeting telomerase is an attractive approach in 
NSCLC therapy. Compared to other anti-cancer methods, targeting telomerase is relative 
universal and specific for cancer cells as normal cells will not be affected [Harley, 2008]. 
Different strategies to inhibit telomerase have been developed and tested [Shay et al., 2006]. 
The antisense oligonucleotide 2´-O-methyl-RNA (OMR) with a phosphorothioate backbone 
has been reported as a potent and sequence-selective telomerase inhibitor [Pitts et al., 1998; 
Herbert et al., 1999]. It binds to the complementary hTR template which is an ideal target for 
inhibition oligonucleotides and further influences the synthesis of telomeric repeats 
[Zimmermann et al., 2007]. Previously we have shown that OMR can inhibit in vitro the 
telomerase activity in NSCLC A549 cells [Beisner et al., 2009]. However, the poor cellular 
uptake of oligonucleotides limits the application of OMR [Loke et al., 1989]. Biodegradable 
nanoparticles have been shown to be an efficient drug delivery system [Kumar et al., 2004; 
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Nafee et al., 2007]. In the present study, we developed positively charged chitosan-coated 
PLGA nanoparticles for the delivery of OMR and analyzed in human lung cancer cells the 
biological effects of nanoparticle mediated delivery of OMR. 
4.3 Material and methods 
4.3.1 Cell culture 
Human NSCLC cell line A549 were obtained from DSMZ (Braunschweig, Germany), Calu-3 
cells were from the American Type Culture Collection (ATCC, Rockville, MD, USA), NCI-
H23 (ATCC Number: CRL-5800TM) cells were ordered from LGC Standards (Wesel, 
Germany), NCI-H460 (ATCC Number: HTB-177TM) cells were purchased from LGC 
Standards (Wesel, Germany). A549, NCI-H23 (H23) and NCI-H460 (H460) cells were 
cultivated in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
heat inactivated fetal calf serum (FCS), 2mM L-glutamine, 50U/ml penicillin and 50µg/ml 
streptomycin. Calu-3 cells were cultivated in Minimum Essential Medium (MEM) with Earl’s 
Salts and L-glutamine (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat 
inactivated FCS, 1% MEM non-essential amino acids (NEA, BioChromag, Berlin, Germany), 
1mM sodium pyruvate, 50U/ml penicillin and 50µg/ml streptomycin. Cell viability was 
assessed by the trypan blue exclusion test.  
4.3.2 Oligonucleotides 
The telomerase inhibitor used in this study is an antisense 2´-O-methyl-RNA(OMR) with a 
phosphorothioate (ps) backbone 5´-2´-O-methyl [C(ps)A(ps)GUUAGGGUU(ps)A(ps)G]-3´. 
The mismatch OMR is 5´-2´-O-methyl [C(ps)A(ps)GUUAGAAUU(ps)A(ps)G]-3´. The 
fluorescence-labeled OMR (FAM-OMR) is 5´-FAM-2´-O-methyl [C(ps)A(ps)GUUAGGG-
UU(ps)A(ps)G]-3´ and the digoxigenin-labeled OMR (Digo-OMR) is 5´-2´-O-methyl 
[C(ps)A(ps)GUUAGGGUU(ps)A(ps)G]-digoxigenin-3´. All the oligonucleotides were 
synthesized by Biomers (Ulm, Germany). Nuclease-free water (QIAGEN GmbH, Hilden, 
Germany) was used to dissolve the oligonucleotides and the oligonucleotides were aliquoted 
and stored at -20°C for further processing. To ensure stability and biological activity of the 
oligonucleotides, small aliquots were tested in the cell-free TRAP assay prior to the use in the 
cell culture experiments.  
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4.3.3 Chitosan-coated PLGA nanoparticles preparation and characterization  
Chitosan-coated PLGA nanoparticles were prepared by an emulsion-diffusion-evaporation 
method described previously [Kumar et al., 2004; Nafee et al. 2007]. In brief, 5ml of PLGA 
was dissolved in ethyl acetate (20mg/ml) and added dropwise under stirring to 5ml of an 
aqueous solution containing 2.5% (w/v) polyvinyl alcohol (PVA) and 0.3% (w/v) cationic 
polymer chitosan. The emulsion was stirred for 1h at room temperature and homogenized 
using an UltraTurrax T25 (Janke & Kunkel GmbH & Co-KG, Staufen, Germany) at 13,500 
rpm for 10min. The homogenized emulsion was diluted with MilliQ-water to 50ml under 
constant stirring. Stirring was continued over night at room temperature to form the 
nanoparticle suspension which contained 3mg/ml of chitosan.  
Nanoparticles were characterized directly after preparation in respect to size, polydispersity 
index (PdI) and surface charge. Photon correlation spectroscopy was used to determine 
average size and PdI. Surface charge was assessed as zeta potential in a ZetaSizer Nano ZS 
(Malvern Instruments Ltd., Worcestershire, UK). Samples were diluted in MilliQ-water for 
analyses. All measurements were performed in triplicates. Nanoparticle concentration was 
determined gravimetrically after lyophilization. 
4.3.4 Preparation of oligonucleotide-nanoparticle-complexes (nanoplexes) transfection  
The oligonucleotide was mixed with the nanoparticle solution in cell culture medium and 
vortexed thoroughly. The mixture was incubated for 15min at 37°C in a water bath to form 
oligonucleotide-nanoparticle-complexes (nanoplexes). The content ratio of nanoplexes is 
1:100 (weight oligonucleotide / weight nanoparticles). Oligonucleotides were always used at a final 
concentration of 4µM in the nanoplexes. Six hours after treatment the nanoplexes were 
replaced by cell culture medium and cells were further cultured. Cells were loaded with 
OMR-nanoplexes, OMR or mismatch-OMR-nanoplexes; FAM-OMR or FAM-OMR-
nanoplexes separately. Nanoparticles were labeled with the fluorescent dye DiI (1,1´-
Dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate) from Sigma-Aldrich Chemie 
GmbH, Taufkirchen, Germany. The DiI-labeled nanoparticles (DiI-NP) were also loaded with 
FAM-OMR to form nanoplexes. In short-term experiments, the cells were cultured for 6h, 
24h, 48h or 72h before analyzing. In long-term experiments over 100 days, subsequently cells 
were seeded in 6-well plates at a density of 200,000 cells/well and treated every 3-4 days with 
OMR-nanoplexes. One day prior to transfection cells were trypsinized, collected and further 
seeded in 6-well plate at the same density 200,000 cells/well. The remaining cells were 
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collected and used for determination of telomerase activity and telomere length. Population 
doubling (PD) was calculated using the formula PD= lg (n cells harvested /n cells initially seeded) / lg2. 
4.3.5 Fluorescence-activated cell sorting (FACS) analysis 
For uptake analysis, after treatment cells were collected and washed twice with PBS and 
resuspended in 500µl PBS. For apoptosis analysis, cells were incubated with 5µl Fluorescein-
conjugated Annexin V(Annexin V-FITC) and 10µl of Propidium Iodide (PI) in 100µl binding 
buffer (FITC Annexin V, BD Pharmingen, Sandiego, CA) at room temperature for 15min in 
the dark and analyzed by FACScan fluorescence-activated cell sorter (Becton-Dickinson, 
Heidelberg, Germany). A minimum of 10,000 individual cells was analyzed per sample. The 
right population was gated from the dot plots, the fluorescence threshold was defined in 
reference to non-treated cells. The percentage of cell-associated fluorescence was analyzed by 
CellQuest software (Beckton-Dickinson, Heidelberg, Germany).  
4.3.6 Confocal laser scanning microscopy  
The cells were seeded in Lab-Tek® chamber slides (Nalge Nunc International, Naperville, 
USA) at a density of 65,000cells per well one day before the treatment. Cells were loaded 
with either FAM-OMR alone or FAM-OMR-nanoplexes 24h after seeding. Then cells were 
evaluated by CLSM 6h, 24h and 72h after treatment, respectively. After two times washing 
with PBS, cells were incubated with 25µg/ml rhodamine-labeled ricinus communis agglutinin 
I (RCA I, Vector Laboratories, Burlingame, CA, USA) for 15min at 37°C which enables 
detection of cell membranes by binding to oligosaccharides ending in galactose. Cells were 
washed twice with PBS and fixed with 100% ethanol at -20°C for 10min. Cell nuclei were 
stained with 1µM TO-PRO®-3 iodide (Molecular Probes Invitrogen, Eugene, OR, USA) for 
10min at room temperature in the dark. After two washing steps with PBS, the chamber and 
gasket were removed and slides were mounted with mounting medium (Vectashield® 
Mounting Medium, Vector Laboratories, Burlingame, CA) for analyzing by CLSM. CLSM 
was performed with a Leica LCS instrument (Leica Lasertechnik) based on a Leica DM IRBE 
microscope equipped with argon and helium/neon lasers. The emission (Em.) and excitation 
(Ex.) wavelengths of the dyes were as follows: FAM (Ex. 488nm, Em. 500-540 nm); RCA I 
and DiI (Ex. 543nm, Em. 560-610 nm); TO-PRO®-3 (Ex. 563nm, Em. 650-700 nm).  
4.3.7 Quantification of oligonucleotides uptake  
A549 cells were seeded in 24-well plates at a density of 50,000 cells / well. Cells were treated 
with FAM-OMR or FAM-OMR-nanoplexes. Six hours after treatment, the transfection 
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mixtures were collected and replaced by cell culture medium. Twenty-four hours after 
treatment, the cell culture medium was collected and the cells were trypsinized and kept as 
cell lysates. The original transfection mixes before loaded on cells, the transfection mixes at 
6h, the cell culture medium at 24h and the cell lysates were serially diluted. 300µl per well of 
the dilution were loaded in a 96-well plate. The level of presented FAM was measured by a 
microtiter plate reader (Victor Multilabel Counter 1420, Wallac-PerkinElmer, Waltham, MA, 
USA). The FAM level of transfection mixes at 0h were set as 100%, the fluorescence of all 
the other groups were normalized to the results of transfection mixes at 0h. All measurements 
were performed in triplicates. 
4.3.8 Cytotoxicity assay 
A standardized ATP-based tumor chemosensitivity assay (ATP-TCA) was applied to 
determine cell viability (DCS Innovative Diagnostik Systeme, Hamburg, Germany). Cells 
were seeded at a density of 104 cells/well in 96-well plates and 24h later cells were treated 
with nanoplexes as described in 4.3.4. Seventy-two hours after transfection, cells were lysed 
by addition of 50µl/well of ATP cell extraction reagent. After 30min shaking at lowest speed, 
50µl of the lysates from each well were transferred to a new well of a white 96 MicroWellTM 
plate (Nalgene Nunc International, Naperville, IL, USA) followed by addition of luciferin-
luciferase reagent. Luminescence corresponding to the level of ATP present was measured by 
a microtiter plate reader (Victor Multilabel Counter 1420, Wallac-PerkinElmer, Waltham, 
MA, USA). Luminescence measurements are directly related to ATP levels and allow the 
measurement of the percentage of inhibition by reference to untreated control wells included 
in each plate. The absorbance of untreated cells was set as 100%. All measurements were 
performed in quadruplicates and each experiment was repeated at least three times. Cell death 
was also determined by Annexin V-FITC staining and analyzed by FACS as described in 
FACS analysis section. 
4.3.9 Telomerase activity assay using real-time quantitative PCR 
Cultured cells were harvested, counted and 106 cells were pelleted and washed with PBS. The 
cell pellets were either stored at -80°C or immediately resuspended in 200µl ice-cold 3-[(3-
cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS) lysis buffer and 
incubated on ice for 30min. The lysates were centrifuged at 12,000×g for 20min at 4°C and 
the supernatants were aliquoted, snap-frozen and stored at -80°C.  
Telomerase activity was measured using a modified real-time quantitative PCR based 
telomeric repeat amplification protocol (Q-TRAP) assay described previously [Herbert et al., 
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2006]. We modified this method to reduce costs and to increase throughput using a 384-well 
reaction plate with a final reaction volume of 12µl. The detailed processes are described in 
Chapter 2: Part 1: Materials and methods: Telomerase activity assay using real-time 
quantitative PCR.  
4.3.10 Telomere measurement by real-time quantitative PCR 
Genomic DNA was isolated from cells using the QIAamp DNA Mini Kit (QIAGEN, Hilden, 
Germany). Cultured cells were harvested, counted and washed with PBS. Up to 5× 106 cells 
were resuspended in 200µl PBS and added into a 1.5ml microcentrifuge tube which contained 
20µl Proteinase K and 40µl RNase A (10mg/ml). After 200µl Buffer AL was added, the 
sample was incubated at 56°C for 10min. The following steps were done according to the 
QIAamp DNA Mini Kit protocol. The final DNA was eluted in Buffer AE, stored at -20°C. 
DNA was quantified using a NanoDrop spectrophotometer (PEQLAB, Erlangen, Germany). 
The telomere measurement was performed by quantitative real-time PCR described 
previously [Cawthon, 2002]. The details of the process are described in Chapter 2: Part 2: 
Materials and methods: Telomere measurement by real-time quantitative PCR.  
4.3.11 Statistical analysis 
Different groups were compared by Wilcoxon signed rank test or Wilcoxon matched pairs test. 
Results were considered statistically significant if p<0.05. All data were analyzed by 
Graphpad Prism version 4.0 (GraphPad Software Incorp., San Diego, CA).  
4.4 Results 
4.4.1 Characterization of chitosan-PLGA nanoparticles as a delivery system  
The diameter of nanoparticles was in the range of 150–170nm with a mean size of 160nm 
(±5nm).The chitosan-coated PLGA nanoparticle suspension contained 3mg/ml of chitosan. 
Nanoparticles were characterized by a positive surface charge with a zeta potential of 37mV 
(±5.9mV) and a polydispersity index (PdI) of 0.164 (±0.054). The concentration of 
nanoparticles in the aqueous suspension was 4.6mg/ml (±0.51mg/ml). The particles were 
spherical with a monomodal size distribution. The sizes of OMR-nanoplexes were 
comparable to those of the pure nanoparticle preparations. The surface of the nanoplexes 
decreased slightly with the addition of OMR indicating binding between oligonucleotide and 
cationic nanoparticles through electrostatic attraction [Nafee, 2008]. 
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4.4.2 Inhibition of telomerase activity by 2´-O-methyl-RNA-nanoparticle complexes 
Before the treatment the telomerase-inhibitory potential of OMR was first evaluated with the 
cell-free TRAP assay. Dilutions of OMR (10-12 to 10-5M), mismatch-OMR (10-12 to 10-5M) or 
nanoparticles (10-8 to 10-1µg/µl) were added to 0.1µg of telomerase-positive human lung 
cancer A549 lysates and the relative telomerase activity was measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Fig.1, in the cell-free TRAP assay, OMR showed an EC50 value of 1.536×10-8M 
(Fig.1A). Mismatch-OMR (2 mismatched bases) exhibited a slight inhibition (~25% to 38%) 
from 10-12 to 10-6M; more than 70% inhibition was observed with 10-5M (Fig.1C). 
Nanoparticles alone did not interfere with TRAP assay at all tested concentrations (Fig.1B).  
4.4.3 Nanoparticle mediated uptake of 2´-O-methyl-RNA into human lung cancer cells 
As shown in Fig. 2, uptake of FAM-OMR was strongly enhanced by nanoparticles mediated 
delivery. A549 and H23 cells treated with FAM-nanoplexes revealed a nearly complete shift 
in the fluorescence profile compared to the other treatments. Although Calu-3 cells exhibited 
less shift in the fluorescence profile, still more than 90% of the treated cells showed higher 
fluorescence intensities than the control population indicating an efficient delivery. FAM-
OMR without nanoparticles delivery had only less than 5% uptake efficiency. Treatment with 
nanoparticles alone also did not have an obvious effect on the cell population. All three 
NSCLC cells lines illustrated similar results. 
Fig. 1: Telomerase inhibitory potential of OMR 
(A), of nanoparticles as NP (B) and mismatch-
OMR(C) in cell–free TRAP assay 
Dilutions of oligonucleotides or nanoparticles were 
added to A549 human lung cancer lysates. 
Telomerase activity of lysates from untreated A549 
cells was considered as control and set to 100%. The 
data represent mean values ±SD (n=3).  
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Fig. 2: Uptake of FAM-labeled OMR –nanoplexes by human lung cancer cells 
Human A549, Calu-3 and H23 cells were treated with FAM-labeled OMR-nanoplexes (FAM-
OMR+NP), nanoparticles (NP) or FAM-labeled OMR (FAM-OMR). The corresponding non-treated 
cells were used as control. Cells were analyzed by FACS 24h after treatment and the proportion of 
FAM positive cells was expressed as the percentage of the total population. The percentage of positive 
cells is indicated in each histogram.  
The biological activity of OMR depends on its intracellular distribution within the cells. 
Therefore the intracellular localization of FAM-OMR was determined by CLSM. As shown 
in Fig. 3A, 6h after treated with FAM-OMR-nanoplexes, FAM-OMR was mainly 
accumulated in the membrane of all the tested cells (A549, Calu-3, H23 and H460). Calu-3 
cells had less accumulation compared to the other cells. In some A549 and H23 cells, a clear 
nuclear localization of the FAM-OMR was observed. 24h after treatment, most of the FAM-
OMR was present inside the cells and it was mainly located in the cytoplasm as small spots in 
the perinuclear area. More than 70% of A549 cells displayed positive staining for FAM-OMR. 
H460 cells still had a lot of dye accumulated in the cell membrane. Forty-eight hours after 
treatment, more FAM-OMR was delivered inside the cytoplasm of the cells. Calu-3 cells 
illustrated different cell morphology and less FAM-OMR uptake than the other three cell lines. 
After 72h following transfection, approximately 80% of A549 cells were stained with a 
spotted distribution within the cytoplasm but not within the nucleus. H23 cells exhibited 
similar results as A549. About 55% of H460 cells showed a positive fluorescent staining 
which was slightly lower than the other two cell lines; Calu-3 cells had only a minor 
fluorescent staining, but the positive Calu-3 cells showed similar distribution for the uptake of 
FAM-OMR (Fig. 3A).  
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Fig. 3: Intracellular localization of FAM-labeled OMR in A549, Calu-3, H23 and H460 cells 
visualized by CLSM 
Cells were imaged 6h, 24h, 48h and 72h after treatment with FAM-labeled OMR-nanoplexes (A), 
FAM-labeled OMR (B) or FAM-labeled OMR (FAM-OMR) and DiI-labeled nanoparticles (DiI-NP) 
formed nanoplexes (C). FAM-OMR had a green fluorescence signal. Cellular nuclei were stained with 
TOPRO-3 (blue). In (A) and (B), cell membranes were stained with RCA I (red). In (C) DiI-labeled 
nanoparticles had a red fluorescence signal. In (A) the second row of each cell line shows the 
transverse (XZ axis) and vertical (YZ axis) cross sections of a single zoomed cell from corresponding 
upper image for each time point. Images were analyzed by a 63×objective. Scale bars represent 20µm. 
 
As shown in Fig. 3B, at all time points after treatment with FAM-OMR, only very few cells 
had positive staining and most of the fluorescent signal was accumulated in cell membrane or 
cytoplasm. No nuclear uptake of FAM-OMR was observed. DiI-NP and FAM-OMR 
demonstrated a co-localization in A549 cells 72h after treatment (Fig. 3C). This demonstrated 
that OMR uptake mediated by nanoparticles occurred as OMR-nanoplexes and kept stable for 
A549 
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72h after treatment. From the overlay image in Fig.3C, the green signal of OMR and the red 
signal of the nanoparticle are co-localized and resulted in a yellow signal surrounding the cell 
nuclei.  
 
Fig. 4: Quantification of FAM-labeled OMR uptake in A549 cells 
A549 cells were treated with FAM-OMR-nanoplexes. The fluorescence level of original transfection 
mixes at 0h was set to 100%. All the values are shown as percentage of the fluorescence level of 
transfection mixes at 0h.  
 
We further quantified the nanoparticle mediated delivery of FAM-OMR in A549 cells with a 
microtiter plate reader. A549 cells were treated with either FAM-OMR alone or FAM-OMR-
nanoplexes. As shown in Fig. 4, about 64% of FAM-OMR still remained in the transfection 
mixes 6h after treatment. After 24h following transfection, the cell culture medium contained 
about 19% of FAM-OMR indicating that about 19% of original FAM-OMR was released 
back to the medium from 6h to 24h after the treatment. The cell lysates at 24h demonstrated 
that the cells took up more than 3% of FAM-OMR during the whole experiment. About 14% 
of the fluorescent signals were lost during the complete experiment (Fig. 4). Combined with 
the CLSM results in Fig.3A, this 3% FAM-OMR was mainly taken up by about 70% of A549 
cells at 24h following treatment. Compared to nanoparticle mediated delivery of FAM-OMR 
which had an uptake of about 3%, treatment with FAM-OMR showed only 0.55% uptake at 
24h. Nanoparticle mediated delivery enhanced the OMR uptake about 5-fold. 
4.4.4 Cytotoxicity of 2´-O-methyl-RNA-nanoparticle-complexes on cells 
Seventy-two hours after treatment, an ATP-based luminescence assay was used to determine 
cell viability in short-term experiments. We tested 4µM OMR which was efficient for 
telomerase inhibition. Treatment with OMR-nanoplexes had only slight toxic effects on all 
tested cells. A549 cells treated with nanoparticles alone showed about 87% viability 
compared to untreated control A549 cells (Fig. 5). There was no difference when the 
antisense OMR was replaced by a mismatch oligonucleotide or nanoparticles (p > 0.05). This 
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suggests that cytotoxic effects were mainly caused by nanoparticles. Similar results were 
observed with Calu-3 and H23 cells. In contrast, primary lung fibroblasts isolated from 
different NSCLC were not affected by the different treatments.  
In A549 cells apoptosis analysis by Annexin V-FITC staining showed that there was no 
difference for cell apoptosis among different groups 72h after treatment (Fig. 6). Untreated 
cells and all treated cells contained less than 10% apoptotic cells. The quantification of cell 
death by means of FACS analyses (Fig. 6) revealed similar results as the ATP test (Fig. 5).   
 
Fig. 5: Effect of OMR-nanoplexes on cell viability of human NSCLC cancer cells (A549, Calu-3 
and H23) and human primary lung fibroblasts 
Cells were treated with OMR-nanoplexes (OMR+NP), mismatch-nanoplexes (Mis+NP) or 
nanoparticles alone (NP). Cell viability was determined by the ATP test 72h after treatment. The ATP 
test results of untreated cells were considered as controls and set to 100%. Data represent the mean 
+SD from three independent experiments. In case of primary lung fibroblasts, cells were isolated from 
three different tumors and each one was tested at least twice. 
 
 
 
Fig. 6: Cell death indices determined by Annexin V-FITC staining with FACS analysis 
A549 cells were treated with OMR-nanoplexes (OMR+NP), nanoparticles alone (NP) or OMR. 
Untreated A549 cells were used as control. Cells were incubated with Annexin V-FITC and analyzed 
by FACS 72h after treatment. Cells in M2 phase are undergoing apoptosis.  
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4.4.5 Telomerase inhibition by 2´-O-methyl-RNA-nanoparticle complexes 
In human lung cancer cell line A549 and H23 cells the telomerase inhibitory effect of OMR 
delivered by chitosan-coated PLGA nanoparticles are illustrated in Fig.7. Cells were treated 
with complexes of 4µM OMR or mismatch-OMR and nanoparticles. Seventy-two hours after 
treatment cells were analyzed for telomerase activity using the Q-TRAP assay. Both cell lines 
showed comparable results for telomerase inhibition. The cells treated with OMR-nanoplexes 
demonstrated significant reduction of telomerase activity compared to cells treated with OMR 
alone or mismatch-OMR-nanoplexes (Fig.7). In A549 cells, OMR alone did not illustrate 
telomerase inhibition; nanoparticles delivery of OMR inhibited more than 60% of telomerase 
activity; mismatch-OMR-nanoplexes exhibited only 30% reduction of telomerase activity and 
there was a significant difference between these two treatments (Fig.7A). In H23 cells, 
nanoparticles delivery of OMR inhibited more than 50% of telomerase activity; mismatch-
OMR-nanoplexes showed only 20% reduction of telomerase activity and a significant 
difference between these two treatments was also observed; OMR alone did not have 
telomerase inhibition (Fig.7B). 
  A                                                                   B 
 
Fig. 7: Inhibition of telomerase activity after nanoparticle delivery of OMR in (A) A549 cells and 
(B) H23 cells  
Cells were treated with OMR, OMR-nanoplexes (OMR+NP) or mismatch-OMR-nanoplexes (Mis+NP) 
separately. Telomerase activity was determined by Q-TRAP 72h after treatment. Telomerase activity 
of untreated cells was used as control and set to 100%. Data represent the mean +SD from at least 
three independent experiments. t-test: *** p <0.001; ** p <0.01; * p <0.05. 
4.4.6 Long-term treatment with 2´-O-methyl-RNA-nanoparticle complexes resulting in 
progressive telomere shortening 
In order to investigate whether nanoparticle mediated delivery of OMR induces telomere 
shortening, A549 cells were treated with OMR-nanoplexes at 3 or 4 days intervals for more 
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than 100 days. Telomerase activity was measured at different time points by the Q-TRAP 
assay. OMR-nanoplexes induced a significant reduction of telomerase activity at all tested 
time points.  
   A 
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Fig. 8: Long-term effect of nanoparticle delivered OMR (OMR+NP) in A549 cells  
Cells were treated every 3 or 4 days with 4µM OMR-nanoplexes. (A) Inhibition of telomerase activity 
determined by the Q-TRAP. Untreated cells at day0 was considered as control and set to 100%. (B) 
Telomere length shortening of primary lung fibroblast and OMR-nanoplexes treated A549 cells 
(OMR+NP (A549)). Untreated A549 cells during long-term culture were considered as control. 
Fibroblasts were analyzed at different passages (P3, P7, P10 and P12), A549 cells were analyzed at 
different days (d0, d63 and d102). Cord blood from a newborn baby was taken as a positive control 
(Cord blood). Data represent the mean +SD from 3 measurements. t-test: * p<0.05. H23 cells were 
used as reference DNA sample and its T/S ratio was set as 1. All data were normalized to H23. (C) 
Population doubling (PD) of A549 cells at different time points during long-term treatment. 
Cumulative PD was plotted against time. PD was calculated using the formula PD= lg (n cells harvested /n 
cells initially seeded) / lg2. 
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After 5 weeks treatment telomerase activity was reduced to approximately 30% and further 
reduced to about 20% after 7 weeks. This effect was relatively stable during long-term 
treatment (Fig.8A). 
OMR-nanoplexes treatment for 102 days significantly reduced A549 cell telomere length by 
about 50% (Fig.8B). The telomere length of untreated control group did not change 
significantly during long-term culture. Because primary lung fibroblasts have relative low or 
no detectable telomerase activity, we used fibroblasts as a telomere shortening positive 
control in our experiment. As given in Fig.8B, telomere length of fibroblasts reduced 
according to the cell passage, it shortened about 50% at passage 12 compared to passage 3. 
Fibroblasts also stopped proliferating when they reached passage 12 or 13 indicating that 
without sufficient telomerase activity, telomere length will be shortened during each cell 
passage and finally cells stopped growing when the telomere length reached a critical level.  
Cell growth of A549 cells was inhibited by OMR treatment leading to a reduced number of 
population doublings (Fig.8C). After 102 days, the control cells reached about 100 PD but the 
OMR-nanoplexes treated cells achieved only 65 PD. 
In summary we have shown that nanoparticle mediated delivery of OMR induced a 
significant telomere shortening in A549 cells indicating that continuous inhibition of 
telomerase will cause a reduction in telomere length. 
4.5 Discussion 
Telomere shortening can trigger cell senescence. Tumor cells normally have short telomeres, 
so telomere maintenance is a key event in the immortalization and proliferation of tumor cells 
[Hahn et al., 1999; Bodnar et al., 1998]. Expression of telomerase stabilizes telomere length 
of most human tumors. Since telomerase activity is essential for continuous cancer cell 
proliferation, an efficient inhibition of telomerase offers a promising strategy for cancer 
therapy. We have demonstrated that in different human NSCLC cell lines chitosan-coated 
nanoparticles enhanced the delivery of the telomerase inhibitor OMR and telomerase was 
inhibited. Long-term experiments indicated that such treatment can inhibit continuously 
telomerase and this resulted in effective telomere shortening. Our data demonstrated that 
chitosan-coated nanoparticles can be used to mediate the delivery of OMR to cancer cells and 
they might also be used as a delivery system for gene therapy [Prabha et al., 2002]. 
It has been shown that OMR can bind to hTR which serves as a template for the addition of 
telomeric repeats to the end of telomere DNA. In human prostate cancer cells and in 
immortalized human breast epithelial cells it can inhibit the telomerase activity [Pitts et al., 
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1998; Folini et al., 2005; Herbert et al., 1999]. With the phosphorothioate modification, 
stability of OMR is increased and resistance to degradation by nucleases is enhanced. It can 
bind specifically to complementary RNA improving the selectivity of antisense effects [Pitts 
et al., 1998; Agrawal et al., 1997]. Our data have shown that in human NSCLC A549 and 
H23 cells nanoparticle mediated delivery of OMR inhibited more than 50% of telomerase 
activity 72h after treatment. Telomerase inhibition was sequence-dependent as mismatch-
OMR was quite ineffective. In the cell-free TRAP assay, the EC50 of OMR was 1.5×10-8M; 
different concentration of NP did not influence the results; mismatch-OMR showed less 
telomerase inhibitory effect at low concentration; on contrast more than 70% telomerase 
inhibition was observed only in concentration greater than 10-5M indicating an unspecific 
inhibition. In the cell uptake experiments we used 4µM of OMR or mismatch-OMR and only 
approximately 3% of oligonucleotides have been taken up into the cells. So the final amount 
of oligonucleotides inside the cells can not influence the TRAP assay. The lower telomerase 
activity of the treated cells was due to functional inhibition of telomerase and not caused by 
free oligonucleotides in the cells. During long-term treatment telomerase activity of A549 
cells was inhibited to approximately 30% and remained stable for the tested period of 102 
days. We also observed decreased cell proliferation of human lung cancer cells. These results 
suggest that effects on telomere length do not require complete inhibition of telomerase. 
Although decreased cell proliferation rate and reduced telomere length have been observed 
during long-term treatment, A549 cells did not reach proliferate crisis. It has been reported 
that human epithelial carcinoma cell A431 started crisis after 162 days treatment with the 
telomerase inhibitor GRN163 when telomeres had shortened from an initial length of ~4.5kb 
to an average length of 1.8kb [Asai et al., 2003]. The primary lung fibroblasts also stopped 
growing at about passage 12 to 13 when they reached a very short telomere length. In long-
term experiment, 102 days after treatment in A549 cells telomere length shortened to about 
50% of the original length; this suggests that longer treatment will be necessary to reach the 
crisis of A549 cells. The inhibitory potentials of OMR might also depend on the initial 
telomerase activity and telomere length of the tumor cells.  
In our study, the various NSCLC cells showed different telomerase activities and telomere 
lengths; they also exhibited a variable response to the nanoparticle mediated delivery of OMR, 
e.g. Calu-3 cells had less uptake efficiency compared to the other tested cell lines according to 
FACS analysis (Fig. 2). This was further proved by CLSM imaging as Calu-3 cells showed 
much less FAM-OMR uptake (Fig. 3A). This might be explained by the cell morphology of 
Calu-3 cells, as these cells mainly formed colonies during proliferation which can reduce 
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uptake efficiency. Stronger telomerase inhibition was observed in cells with elevated 
telomerase activity. So such treatment will be more effective in cells with high telomerase 
activity and shorter telomere length. Telomere length of NSCLC tumors is relatively short and 
telomerase activity is high. However the individual distribution is quite broad [Hsu et al., 
2004; Hirashima et al., 2000]. Thus pre-selection of patients will be advisable for the clinical 
application of telomerase inhibitors. Patients whose tumors have short telomeres might 
benefit more from this kind of therapy. On the other hand, for patients it might take several 
months to destroy the tumor cell population. Therefore, a combination with chemotherapy or 
radiotherapy may lead to more efficient and rapid progress in cancer treatment.  
In A549 cells the quantification of OMR uptake showed that 6h after treatment with FAM-
OMR-nanoplexes, more than 60% of FAM-OMR still remained in the transfection mixtures, 
24h after treatment about 14% of FAM-OMR was released into the cell culture medium. This 
proportion might derive from the cells or the surface of the cell culture wells. Twenty-four 
hours after treatment, only about 3% of FAM-OMR stayed in the cell lysates. It also includes 
FAM-OMR attached to the cell membrane. Actually, functional OMR inside the cells was 
less than 3% of the original amount. About 18% FAM-OMR were lost during the complete 
experiment. This might be caused by the absorption to the cell culture wells, by the 
degradation of fluorescence dye FAM, or by the volume lost during pipetting. 
ATP test and Annexin-V staining demonstrated that nanoparticle delivery of OMR had low 
cytotoxicity and did not induce apoptosis after short-term treatment. This might be explained 
by the different action mode of OMR if compared to classical antisense oligonucleotides. It 
was reported previously that antisense oligonucleotides directed against hTERT induced 
apoptosis or apoptotic cell death a few days after treatment [Folini et al., 2005; Jiang et al., 
2003; Wang et al., 2006]. In contrast, the antisense OMR caused telomerase inhibition by 
specific targeting the RNA template which does not interfere with the transcriptional 
regulation of hTR.  
For in vivo application OMR has some limitations because of its poor uptake efficiency into 
the cells. Biodegradable PLGA nanoparticles have been reported as suitable drug delivery 
system in several areas [Costantino et al., 2006; Lamprecht et al., 2001; Dillen et al., 2004]. 
But the negatively charged PLGA nanoparticles can not interact with the negatively charged 
OMR limiting their application. However the positively charged chitosan-coated PLGA 
nanoparticles with cationic surface modification can overcome this problem and serve as an 
efficient delivery system for antisense oligonucleotides [Nafee et al., 2007]. Our results 
demonstrated that chitosan-coated PLGA nanoparticles have a high delivery efficiency of 
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OMR in human lung cancer cells. The high efficiency may provide a promising potential of 
cancer therapy for in vivo application. 
Telomerase inhibitors will mainly target cancer cells which show telomerase activity, while 
normal cells will not be influenced because of a lack of telomerase activity. Likewise, 
telomerase positive human germ line cells and stem cells may not be affected by telomerase 
inhibitors because they have longer telomeres and they are predominantly quiescent 
[Zimmermann et al., 2007; Shay et al., 2006]. Nanoparticle delivery of the telomerase 
inhibitor OMR can increase its therapeutic potential. The cationic chitosan-coated PLGA 
nanoparticles have the advantage of being biodegradable, tailorable and exhibiting low 
cytotoxicity. It can be assumed that they have a great potential for in vivo application. More 
studies have to be performed to evaluate whether nanoparticle mediated delivery of 
telomerase inhibitors could be used for clinical applications of lung cancer therapy. 
4.6 Conclusions 
Our data demonstrate that in human lung cancer cell lines nanoparticle delivery of the 
telomerase inhibitor OMR can induce efficient telomerase inhibition and telomere shortening. 
The results provide evidence that telomerase inhibitors delivered by nanoparticles have a 
great potential for in vivo application of anticancer therapy. 
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Tissue Slice Model of Human Lung Cancer to Investigate Telomerase 
Inhibition by Nanoparticle Delivery of Antisense 2´-O-Methyl-RNA 
 
 
 
 
 
 
 
 
 
This chapter has been submitted for publication as an original article in International 
Journal of Pharmaceutics: 
Dong M, Philippi C, Loretz B, Nafee N, Schaefer UF, Friedel G, Ammon-Treiber S, Griese 
EU, Lehr CM, Klotz U, Mürdter TE.  
Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle 
delivery of antisense 2´-O-methyl-RNA.  
 
*The results presented in this chapter were obtained by Meng Dong. 
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5.1 Abstract 
 
Background: Telomerase activity is detected in about 80% of non-small cell lung cancers 
(NSCLC). The chitosan-coated poly(lactide-co-glycolide) (PLGA) nanoparticles delivery of 
antisense 2´-O-methyl-RNA (OMR) binding to the telomerase RNA template represents a 
promising approach for anticancer therapy. We used primary lung cancer cells and a tissue 
slice model to evaluate the effect of nanoparticle delivery of OMR in human lung cancers.  
Methods: We isolated and cultured primary cells and 0.2mm thick tissue slices from freshly 
excised tumor samples of NSCLC patients. Oligonucleotides were complexed with chitosan-
coated PLGA nanoparticles (nanoplexes) to treat primary cells and tissue slices. FACS 
analysis and confocal laser scanning microscopy (CLSM) were used to investigate uptake of 
FAM-labeled OMR. Cell viability in tissue slices was assessed by CLSM. Real-time PCR 
based telomeric repeat amplification protocol was used to investigate telomerase activity. 
Tissue structure, cell proliferation and telomerase expression were assessed by 
immunohistochemistry in paraffin-embedded tissues.  
Results: In both cells and tissue slices, OMR cellular uptake was strongly enhanced by 
nanoplexes delivery. More than 80% of human primary lung cancer cells showed uptake of 
OMR-nanoplexes 72h after treatment. Telomerase activity was inhibited by approximately 
45% in cancer cells and by about 40% in tissue slices. In tissue slices treatment with OMR-
nanoplexes did not exhibit acute cytotoxicity. Tissue architecture, cell proliferation and 
telomerase expression were also not influenced.  
Conclusion: Nanoparticle mediated delivery of OMR can inhibit telomerase in primary 
cancer cells isolated from NSCLC. Further, we could prove that OMR-nanoplexes penetrate 
into tissue and the delivered antisense OMR is able to inhibit telomerase activity in tumor 
tissue slices. 
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5.2 Introduction 
Antisense oligonucleotides have great potential for cancer treatment. However, the poor 
cellular uptake is a limiting factor that may contribute to the lack of functional efficacy in 
anticancer therapy [Akhtar et al., 1992; Fattal et al., 2009]. Biodegradable nanoparticles have 
shown to be a promising drug delivery system. The cationic chitosan-coated poly(lactide-co-
glycolide) (PLGA) nanoparticles are able to interact with oligonucleotides through 
electrostatic interaction to form naoplexes that show relatively low cytotoxicity on the cells 
[Bersner et al., 2010; Nafee et al., 2007; Katas et al., 2008]. Delivery of oligonucleotides, 
including tissue disposition, degradation and elimination are important factors for their 
efficacy in vivo [Agrawal, 1999]. A solid tumor has a complex structure consisting of tumor 
cells, stromal cells and associated extracellular matrix [Tredan et al., 2007]. The tumor 
microenvironment plays a role in drug resistance in tumor tissues [Morin, 2003] and may 
influence the efficient delivery of oligonucleotides to the tumor cells. Therefore, it is 
important to understand the effect of nanoparticle delivery of antisense oligonucleotides on 
tumor response in the intact tumor microenvironment of individual tumors.  
The ex vivo tissue slice culture model as a three dimensional system has been used to 
investigate pharmacological properties of anticancer drugs [Sonnenberg et al., 2008; 
Umachandran et al., 2006; Vaira et al., 2010; van der Kuip et al., 2006]. This model could 
maintain both organ and cellular architecture, keep the original cancer microenvironment and 
preserve the integrity of the tumor-stroma interaction [Umachandran et al., 2006; Vaira et al., 
2010]. The thin tissue slice (200µm thickness) allows a smooth diffusion of oxygen, nutrients 
and antibodies. The viability in tissue slices can be maintained for at least 4 days in normal 
culture condition [van der Kuip et al., 2006]. This three dimensional model provides a tool 
that fills the gap between the current results based on monolayer culture of cancer cell lines 
and the reality in human solid tumors.  
Lung cancer is the leading cause of cancer death worldwide in both men and women [Jemal et 
al., 2010]. Non-small cell lung cancer (NSCLC) is the main type and constitutes about 80% of 
all lung cancers. One promising approach to treat NSCLC is based on the inhibition of 
telomerase activity in cancer cells [Dong et al., 2010]. Telomerase is an enzyme that adds 
telomeric repeats to the end of linear eukaryotic chromosomes. The human telomerase 
consists of a telomerase RNA (hTR), a telomerase reverse transcriptase (hTERT) and other 
associated proteins. The catalytic protein subunit hTERT uses hTR as a template for adding 
telomeric repeats to the telomere DNA strand [Blackburn, 1991]. Telomerase is not active in 
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most somatic cells but is expressed in human germ line cells, stem cells and many cancer cells. 
As a consequence of telomerase activity the cells can become immortal and keep dividing 
[Kim et al., 1994; Wright et al., 1996]. Telomerase activity is detected in about 80% of 
NSCLC and is correlated with a poor prognosis [Hiyama et al., 1995; Taga et al., 1999]. The 
telomerase RNA template hTR is an ideal target for inhibition by oligonucleotides [Harley, 
2008; Philippi et al., 2010]. The antisense oligonucleotide 2´-O-methyl-RNA (OMR) with a 
phosphorothioate backbone can specifically inhibit hTR leading to progressive telomere 
shortening [Herbert et al., 1999; Pitts et al., 1998].  
Previously, we have demonstrated that delivery of antisense OMR with chitosan-coated 
PLGA nanoparticles induced efficient telomerase inhibition in human NSCLC cells [Beisner 
et al., 2010] and has a potential to be used as inhalation therapy. However, these results were 
based on established lung cancer cell lines and therefore may not totally reflect the behavior 
of tumor cells in original tumor tissues. In contrast, freshly isolated primary lung cancer cells 
in short-term culture retain many characteristics of cancer cells in primary tumors and show 
biological properties more closely related to the original tumors than cancer cell lines. But it 
is still a two dimensional culture system and can not reflect the solid tumor architecture as the 
tissue slice that can be used to study the tumor response to nanoparticle delivery systems in 
the complex environment of a primary cancer tissue. In the present study, we used freshly 
isolated human tumor tissue slices and primary lung cancer cells from NSCLC patients to 
evaluate the nanoparticle delivery of OMR and its biological effect on telomerase inhibition. 
 
5.3 Material and methods 
5.3.1 Lung tumor materials 
Fresh tissues of primary lung tumors were obtained as surgical waste from patients newly 
diagnosed for lung cancer at the Klinik Schillerhöhe. Immediately after surgical resection, 
tumor tissues were maintained on ice until further processing. Fifteen tumor tissues were used 
for tissue slice preparations and 33 tumor tissues were used for isolation of primary lung 
cancer cells. The investigation was approved by the local ethics committee (#396/2005V) and 
informed consent was obtained from all patients. 
5.3.2 Primary cells isolation, cultivation and characterization  
The minced NSCLC tissue was enzymatically digested using a tissue disaggregation buffer 
(1mM NaH2PO4, 5.4mM KCl, 120mM NaCl, 5.6mM glucose, 2.5mM MgCl2×6H2O, 20mM 
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HEPES, pH7.2) supplemented with 167U/ml collagenase, 250U/ml DNase and 0.25mg/ml 
protease for 90min at 37°C [Sonnenberg et al., 2008]. Digested tissue suspension was passed 
through a 70µm mesh nylon filter (BD Falcon) to remove cell clumps. Primary lung cancer 
cells were isolated from cell suspension using the magnetic-activated cell sorting (MACS) 
system. Cells were incubated with monoclonal CD326 (EpCAM) antibody conjugated to 
microbeads (human Anti-HEA (Ep-CAM) Microbeads, Miltenyi Biotec, Bergisch Gladbach, 
Germany) for 30min at 4°C and passed through a positive selection column (MACS Cell 
Seperation Column, Miltenyi Biotec, Bergisch Gladbach, Germany). The CD326 positive cell 
populations were selected as primary lung cancer cells and cultivated with Airway Epithelial 
Cell Growth Medium with SupplementMix (PromoCell, Heidelberg, Germany), 50µg/ml 
gentamicin (PromoCell, Heidelberg, Germany) and 0.05µg/ml amphotericin B (PromoCell, 
Heidelberg, Germany) in Collagen IV 24-well plates (BD Biosciences, Bedford, USA). 
CD326 negative cells were cultured as primary lung fibroblasts in RPMI1640 medium 
supplemented with 20% heat inactivated fetal calf serum (FCS), 1mM sodium pyruvate, 2mM 
L-glutamine, 10mM HEPES, 1% 2-mercaptoethanol, 0.5% non-essential amino acids (NEA, 
BioChromag, Berlin, Germany), 0.02mg/ml asparagin, 50U/ml penicillin and 50µg/ml 
streptomycin. Cell viability was assessed by trypan blue exclusion test. Primary cells were 
further identified by fluorescence-activated cell sorting (FACS) for epithelial specific antigen 
(ESA) expression. 
5.3.3 Tissue slice preparation and cultivation 
Preparation of tissue slices was performed as described previously [van der Kuip et al., 2006]. 
Briefly, tissue slices (thickness: 200µm, diameter: 5mm) were cut by a Krumdieck microtome. 
Slices were individually submerged in the same medium used for primary lung cancer cell 
culture in 24-well plates. Each well contained one slice. Incubation was performed at 37°C in 
a constant atmosphere of 5% CO2. Treatment started 24 hours after the slice preparation.  
5.3.4 Oligonucleotides 
The telomerase inhibitor is an antisense 2´-O-methyl-RNA(OMR) with a phosphorothioate(ps) 
backbone 5´-2´-O-methyl [C(ps)A(ps)GUUAGGGUU(ps)A(ps)G]-3´. The mismatch OMR is 
5´-2´-O-methyl [C(ps)A(ps)GUUAGAAUU(ps)A(ps)G]-3´. The fluorescence-labeled OMR 
(FAM-OMR) is 5´-FAM-2´-O-methyl [C(ps)A(ps)GUUAGGGUU (ps)A(ps)G]-3´ and the 
digoxigenin-labeled OMR (Digo-OMR) is 5´-2´-O-methyl [C(ps)A(ps)GUUAGGGUU(ps) 
A(ps)G]-digoxigenin-3´. All oligonucleotides were synthesized by Biomers (Ulm, Germany). 
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To ensure the stability and biological activity of the oligonucleotides, small aliquots were 
tested in the cell-free TRAP assay prior to use.  
5.3.5 Preparation and characterization of chitosan-coated PLGA nanoparticles 
Chitosan-coated PLGA nanoparticles were prepared by an emulsion-diffusion-evaporation 
method described previously [Kumar et al., 2004; Nafee et al., 2007]. In brief, 5ml of 2% 
PLGA (Polysciences Inc, Warrington, USA) were dissolved in ethyl acetate. The organic 
phase was added dropwise to 5ml of an aqueous solution of 2.5% (w/v) stabilizer polyvinyl 
alcohol (PVA) (Sigma Chemical Co., St. Louis,USA) and 0.3% (w/v) cationic polymer 
chitosan (NovaMatrix, Drammen, Norway) under stirring and was further stirred for 1h. The 
emulsion was homogenized using an UltraTurrax T25 (Janke & Kunkel GmbH & Co-KG, 
Staufen, Germany) for 10min. MilliQ-water was added up to 50ml to the homogenized 
emulsion. Organic solvent was removed by continuous stirring overnight at room temperature 
to obtain a suspension of nanoparticles. 
Size, polydispersity index (PdI) and Zeta potential of nanoparticles were measured directly 
after preparation. Size of nanoparticles was in the range of 228–235nm with a mean size (±SD) 
of 230nm (±4nm). The surface charge of nanoparticles measured as zeta potential was +32mV 
(±6mV). The PdI was 0.13 (±0.054). Nanoparticle concentration was determined 
gravimetrically after lyophilization to be 4.8mg/ml (±0.79mg/ml). Particles were further 
confirmed by atomic force microscopy (AFM) as spherical with a monomodal size 
distribution. 
5.3.6 Preparation of oligonucleotide-nanoparticle-complexes (nanoplexes) for transfection  
Certain amounts of oligonucleotides were dissolved in cell culture medium to a final 
concentration of 4µM. A suspension of nanoparticles was added and mixed. Then the mixture 
was incubated for 15min at 37°C to form oligonucleotide-nanoparticle-complexes 
(nanoplexes). The content ratio of nanoplexes was 1:50 (weight oligonucleotide/weight nanoparticles) 
for primary cells treatment and 1:100 (weight oligonucleotide/weight nanoparticles) for treatment of 
tissue slices. Primary cells and tissue slices were treated with OMR-nanoparticle-complexes 
(OMR-nanoplexes), OMR alone or mismatch-OMR-nanoplexes; either FAM-OMR alone or 
FAM-OMR-nanoparticle-complexes (FAM-OMR-nanoplexes); either Digo-OMR alone or 
Digo-OMR-nanoparticles-complexes (Digo-OMR-nanoplexes), separately. Six hours after 
treatment the mixture was replaced by cell culture medium. Tissue slices or primary cells 
were further cultured for 24h or 72h. 
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5.3.7 Fluorescence-activated cell sorting (FACS) analysis 
For characterization, primary cells were incubated with anti-ESA-FITC (1:20; Biomeda, 
Foster City, CA) at room temperature for 20min in the dark. For binding and/or uptake 
analysis, primary cells were collected and washed twice with PBS after treatment. The 
resuspended cell pellets were analyzed by FACScan fluorescence-activated cell sorter 
(Becton-Dickinson, Heidelberg, Germany) and 10,000 events were counted for each sample. 
Data were analyzed using CellQuest software (Becton-Dickinson, Heidelberg, Germany). 
5.3.8 Confocal laser scanning microscopy analysis 
One day after cells were seeded in Lab-Tek® chamber slides (Nalge Nunc International, 
Naperville, USA) primary cells were treated either with FAM-OMR alone or FAM-OMR-
nanoplexes. Cells were observed at 6h, 24h and 72h after treatment, respectively. After 
washing with PBS, cell membranes were stained with 25µg/ml Rhodamine-labeled Ricinus 
Communis Agglutinin I (RCA I, Vector Laboratories, Burlingame, CA, USA) for 15min at 
37°C. The cells were fixed with 100% ethanol at -20°C for 10min. The cell nuclei were 
stained with 1µM TO-PRO®-3 iodide (Molecular Probes Invitrogen, Eugene, OR, USA) for 
10min at room temperature in the dark. Sections were mounted with mounting medium 
(Vectashield® Mounting Medium, Vector Laboratories, Burlingame, CA) for analyzing by 
CLSM.  
One day after tissue slices were prepared, they were treated with either FAM-OMR alone or 
FAM-OMR-nanoplexes. Twenty-four hours and 72h after treatment, tissue slices were 
washed with PBS and incubated with 25µg/ml RCA I for 15min at 37°C. After washing with 
PBS, they were incubated with 6.25µM DRAQ5TM (Biostatus Limited, Lörrach, Germany) for 
10min at room temperature in the dark and immediately examined by CLSM. Images were 
taken randomly from different areas. For every taken image the efficiency of uptake in 
percent was calculated by dividing the number of positive cells by the total cell number. A 
mean value of each sample was calculated from 12 images. 
To identify cytotoxicity within the non-fixed tissue slices, we used a three-color fluorescent 
viability assay as described previously [van der Kuip et al., 2006]. Briefly, tumor tissue slices 
were incubated simultaneously with 0.5µM tetramethylrhodamine methyl ester perchlorate 
(TMRM, Sigma-Aldrich, Deisenhofen, Germany) and 5µM DRAQ5TM for 20min at 37°C, 
followed by Picogreen in DMSO (Molecular Probes, Invitrogen) for additional 10min at 37°C 
and analyzed immediately without further washing steps using CLSM. Images were taken 
randomly from different areas. Cells which showed signals from Picogreen in the nuclei were 
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considered as dead cells. For each image the viability was calculated by dividing the number 
of living cells by the total cell number. A mean value was calculated from 12 images. 
Experiments were repeated with tumor tissue slices from different patients. 
CLSM was performed with a Leica LCS (Leica Lasertechnik, Heidelberg, Germany) 
instrument based on a Leica DM IRBE microscope equipped with argon and helium/neon 
lasers. The excitation (Ex.) and emission (Em.) wavelengths were as follows: Picogreen and 
FAM (Ex. 488nm, Em. 500-540nm); TMRM and RCAI (Ex. 543nm, Em. 560-610nm); TO-
PRO®-3 and DRAQ5TM (Ex. 563nm, Em. 650-700nm). 
5.3.9 Telomerase activity assay using real-time quantitative PCR 
Primary cells were harvested and counted. 500,000 cells were further pelleted and washed 
with PBS. The cell pellets were either stored at -80°C or immediately resuspended in 100µl 
ice-cold 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS) lysis 
buffer and incubated on ice for 30min. Tissue slices were isolated using the FastPrep system: 
300 µl CHAPS buffer with 200 U Recombinant Ribonuclease Inhibitor (RNaseOUTTM, 
Invitrogen, Carlsbad, CA) were added into a Lysing Matrix D tube with spheres (MP 
Biomedical, Solon, OH). Two frozen tissue slices were transferred into the tube and 
homogenized by a FastPrep FP120 cell disrupter (Thermo Savant Bio101, Cedex, France) 
for 20sec at speed setting of 6.0 at 4°C. After short centrifugation the tubes were left on ice 
for 30 min. The upper phase was transferred to a new tube and centrifuged at 12,000×g for 
20min at 4°C. The supernatants were aliquoted, snap-frozen and stored at -80°C.  
Telomerase activity was measured using an optimization of the modified real-time 
quantitative PCR based telomeric repeat amplification protocol (Q-TRAP) assay described by 
Herbert et al. [Herbert et al., 2006]. The details of the process are described in Chapter 2: 
Part2: Materials and methods: Telomere measurement by real-time quantitative PCR. 
5.3.10 Immunohistochemical staining 
After treatment, tissue slices were fixed in 4% buffered formalin and embedded in paraffin for 
further investigation. The fixed tissue slices were cut in 3µm serial sections by Rotary 
Microtome (Leica RM2255, Germany). Paraffin sections were stained with hematoxylin and 
eosin (HE) for histopathological examination. Immunohistochemical staining for KI67 (1:75, 
Monoclonal Mouse Anti-human KI67 Antigen, Clone MIB-1, Dakocytomation, Glostrup, 
Denmark) and hTERT (30µg/ml, Rabbit Anti-hEst2 IgG, Alpha Diagnostic International, San 
Antonio, USA) were performed using the Dako Envision Kit according to the manufacturer’s 
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manual. Immunohistochemical staining for Digo-OMR was performed using Mouse-anti-DIG 
antibody (ZytoVision, Bremerhaven, Germany). Epitope retrieval was achieved as follows: 
prior to staining with KI67 and mouse-anti-DIG, sections were treated for 30min with citric 
acid buffer pH6.0 (Dako, Glostrup, Denmark) in a steam heater. For hTERT staining, sections 
were treated for 15min with Tris/EDTA buffer pH9.0 (Dako, Glostrup, Denmark) in a 
pressure cooker. Counterstaining was performed with hematoxylin. Images were taken by a 
DigitalMicroscope (Leica DM 4000B) and analyzed by Leica Application SuiteV3. 
Immunohistochemical assessments were performed independently by two observers 
(MD,TM). The percentage of positive KI67 was calculated by relating the number of positive 
cells to the total cell number.  
5.3.11 Statistical analysis 
Different groups were compared by Wilcoxon signed rank test or Wilcoxon matched pairs test. 
Results were considered statistically significant if p<0.05. All data were analyzed by 
Graphpad Prism version 4.0 (GraphPad Software Incorp., San Diego, CA). 
 
5.4 Results 
5.4.1 Cultivation and characterization of primary cells 
The isolated cells were put into culture in an attempt to get primary lung cancer cells. The 
mean cell viability after isolation was 81.4% ± 11% (mean ± SD). From 9 out of the isolated 
33 tissue samples, primary lung cancer cells proliferated and enough cells were obtained for 
further experiments after 3 to 5 passages. Telomerase activity was detected in 29 out of these 
33 NSCLC specimens. Before treatment, cells were tested for the expression of epithelial 
specific antigen (ESA) by FACS analysis (Fig.1A). At least 75% of cells showed positive 
expression for ESA in these tested primary cells. The ESA positive cells were used for further 
studies.  
5.4.2 Preparation and cultivation of tissue slices 
Different numbers of viable tissue slices were obtained from 14 out of 15 telomerase positive 
primary lung cancer samples. In one case the tissue was contaminated with bacteria. Tissue 
slices from 8 telomerase positive samples were used for evaluating inhibition by the Q-TRAP 
assay. Six samples were applied for FAM-OMR uptake efficiency tests, 3 samples for Digo-
OMR uptake efficiency tests, 6 samples for viability tests, 8 samples for 
immunohistochemical staining. 
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Fig. 1: (A) Characterization of primary lung cancer cells 
FACS analysis of human lung cancer cells for ESA expression. The control histogram represents 
negative control antibodies. Experiments were performed for each cultured primary lung cancer cells 
and a representative experiment is shown. 
(B) Uptake of OMR-nanoplexes in primary lung cancer cells and primary lung fibroblasts 
Human primary lung cells were treated with FAM-OMR-nanoplexes (FAM-OMR+NP), nanoparticles 
(NP) or FAM-OMR were analyzed by FACS 24h after treatment. The corresponding non-treated 
primary cells were used as control. Figures show the histographic results of primary lung cancer cells 
(left panel) and primary lung fibroblasts (right panel). Experiments were repeated 3 times with 
different primary cells and a representative experiment is shown. 
(C) Localization of nanoparticles delivered FAM-OMR in primary lung cancer cells and 
fibroblasts visualized by CLSM 
Images were taken 6h, 24h and 72h after treated with FAM-OMR-nanoplexes. FAM-OMR has a 
fluorescence signal shown in green. Fig. 1, 2 and 3 display the images of primary lung cancer cells. 
Figures 4, 5 and 6 show the images of primary lung fibroblasts. Cells were stained with RCA I (red) 
and TO-PRO®-3 (blue) before microscopic observation (63× objectives). Scale bars represent 20µm. 
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Experiments were performed for each cultured primary lung cancer cells and a representative 
experiment is shown. 
5.4.3 Nanoparticle delivery of 2´-O-methyl-RNA in primary lung cancer cells and tissue 
slices 
FACS was used to quantify the binding and/or uptake of nanoplexes prepared with FAM-
OMR in human primary lung cancer cells and fibroblasts 24h after treatment. The treatment 
of cells with FAM-OMR-nanoplexes revealed a markedly stronger shift in the fluorescence 
profile of the cell population reflecting a higher cell binding and/or uptake compared to OMR 
alone in both primary lung cancer cells and fibroblasts (Fig.1B). The percentage of cells 
above the fluorescence threshold was 99.1% ± 1.13% (mean ± SD, n=3) for fibroblasts and 
90.9% ± 2.77% (mean ± SD, n=3) for primary lung cancer cells. The cell population showed a 
slight shift to higher fluorescence with FAM-OMR in the absence of nanoparticles in both cell 
types, the population shift was more pronounced in primary lung cancer cells compared to 
fibroblasts. But compared to the dramatic shift after FAM-OMR-nanoplexes treatment, the 
shift was negligible and might be caused by unspecific binding. As expected, treatment with 
nanoparticles alone did not show any effects.  
The localization of FAM-OMR in primary cells and tissue slices was determined by CLSM. 
The uptake of nanoplexes into cells appeared to be a stepwise process. In primary lung cancer 
cells, the FAM-OMR was accumulated on the membrane of cells after 6h of incubation 
(Fig.1C-1). Only few cells showed an uptake of FAM-OMR, less than 5% of cells exhibited 
fluorescence in nuclei. An uptake into the primary cells was observed 24h after treatment; the 
FAM-OMR appeared inside the cells and was mainly located in the cytoplasm as small spots 
in the perinuclear area (Fig.1C-2). More than 80% of cells displayed fluorescence signals 
within the cells and approximately 20% of those cells within the nuclei 72h after treatment 
(Fig.1C-3). CLSM proved that the high fluorescence intensities in FAM-OMR-nanoplexes 
treated primary lung cancer cells as observed by FACS is due to an intracellular uptake rather 
than an adsorption of nanoplexes to the cell surface. In primary lung fibroblasts, the FAM-
OMR accumulated mostly on the cell membranes during the whole observation time. The 
fluorescence signal localization showed almost no difference 6h, 24h and 72h after 
transfection (Fig.1C-4 to Fig.1C-6). Although primary lung fibroblasts treated with FAM-
OMR-nanoplexes demonstrated high fluorescence intensities by FACS analysis, the cells did 
not take up the nanoplexes; thus the fluorescence signal is due to an adsorption of nanoplexes 
to the cell surface.  
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Fig. 2: (A to F) Localization of nanoparticles delivered FAM-OMR in cells of tissue slices 
visualized by CLSM 
Fig. A and B show tissue slices treated with FAM-OMR alone (FAM-OMR). Fig. C and D show tissue 
slices treated with FAM-OMR-nanoplexes (FAM-OMR+NP). Fig.E and F illustrate the transverse and 
vertical sections of a single zoomed cell from C and D respectively. FAM-OMR has a fluorescence 
signal shown in green. Cells were stained with RCA I (red) and DRAQ5TM (blue) before microscopic 
observation (63× objective). Scale bars represent 20µm. 
(G to L) Localization of nanoparticles delivered digoxigenin-labeled OMR in cells of tissue slices 
visualized by immunohistochemistry 
Fig. I and J show tissue slices treated with digoxigenin-OMR (Digo-OMR). Fig. K and L show tissue 
slices treated with Digo-OMR-nanoplexes (Digo-OMR+NP). Fig. G and H show control tissue slices 
without treatment. Fig.G, I and K are areas mainly contain tumor cells. Fig. H, J and L are areas 
mainly contain fibroblasts. Scale bar represents 20µm (100× objectives). 
(M) Uptake efficiency of nanoparticles delivery of FAM-OMR in human lung tissue slices 
For each tissue slice, images were taken from 12 different areas and with each area at least 20 cells 
were counted. Uptake efficiency is given as % positive cells of total number of cells. Data represent 
the mean +SD from 6 independent experiments (*, p<0.05). 
Chapter 5: Tissue Slice Model for Nanoparticles Delivery of OMR 
83 
In tumor tissue slices, the uptake of nanoplexes started after 6h of incubation (data not shown), 
more than 50% of cells showed uptake in the following incubation time (Fig.2C to F). The 
FAM-OMR-nanoplexes were able to pentrate the whole tissue slice and showed equally 
distribution. Interestingly, the uptake of FAM-OMR nanoplexes showed a spotted distribution 
within the nucleus, which is different to the uptake into primary lung cancer cells. Nanoplexes 
significantly enhanced efficiency of uptake: Compared to FAM-OMR-nanoplexes, uptake of 
FAM-OMR alone was only minor and did not improve over time (Fig. 2A to B). There was a 
significant difference for the uptake efficiency between FAM-OMR alone and FAM-OMR-
nanoplexes treatment both, 24h and 72h after treatment (Fig.2M). The results were further 
confirmed by immunohistochemical staining for Digo-OMR uptake into tissue slices 
following treatment with Digo-OMR-nanoplexes. The digoxigenin signal mainly present in 
the tumor cells but not in stromal cells indicated that tumor cells showed nanoparticle 
mediated uptake of Digo-OMR (Fig.2G to L). 
5.4.4 Cytotoxicity of nanoparticles delivery of 2´-O-methyl-RNA  
After treatment with nanoplexes, viability of primary lung cancer cells was reduced by 30 ± 
12% if compared to untreated controls. There was no difference in cytotoxicity among the 
OMR-nanoplexes, mismatch-OMR-nanoplexes and nanoparticles alone. Compared to 
established cancer cell lines, primary lung cancer cells were more sensitive to the culture 
condition and the treatment. The slight cytotoxic effects were mainly caused by the treatment 
with nanoparticles not by the oligonucleotide transfection. To limit this effect, we decided to 
use a nanoplexes ratio of 1:50 instead of 1:100 (weight oligonucleotide/weight nanoparticles) for 
primary cells. As all experiments were carried out with 4µM OMR, the amount of 
nanoparticles used was halved. 
In Fig.3A and B viable cells displayed red fluorescence of TMRM which bounds to active 
mitochondrial membranes, whereas nuclei of dead cells showed green fluorescence from 
Picogreen. Nuclei of cells were stained with DRAQ5TM, which is a cell membrane permeable 
DNA-interactive agent. A high percentage of living cells was identified in tissue slices 72h 
after treatment and no difference was found between nanoplexes treated specimens and the 
untreated controls. This was confirmed by quantification of Picogreen negative cells in 
relation to total cells in 6 different tumor samples. The mean ratio of living cells was more 
than 80% and no significant difference was seen for viability between both groups (Fig.3C) 
indicating that treatment with nanoplexes did not have an acute cytotoxic effect on the tissue 
slices.  
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Fig. 3: Cytotoxicity of nanoparticles delivery of OMR in tissue slices determined by CLSM 
Fig.A shows control tissue slices without treatment (control). B shows tissue slices treated with OMR-
nanoplexes (OMR+NP). Living cells were stained with TMRM (red) and dead cells were stained with 
Picogreen (green), all cells nuclei were stained with DRAQ5TM (blue) before microscopic observation 
(40×objectives). Experiments were performed with 6 tissue slices from different patients and a 
representative experiment is shown. C exhibits the quantification of cell viability in tissue slices from 
CLSM images. For each tissue slice, images were taken from 12 different areas and with each area at 
least 20 cells were counted. Cell viability is given as % Picogreen negative cells of total number of 
cells. Data represent the means +SD from 6 independent experiments. 
 
 
5.4.5 Impact of 2´-O-methyl-RNA-nanoparticle-complexes on cell proliferation and 
telomerase expression in tissue slices  
Hematoxylin and eosin (HE) histological examination of paraffin embedded tissue slices 
showed that there was no obvious difference in the morphology between the nanoplexes 
treated and the untreated tissue slices 72h after treatment (Fig.4A and B). Nuclear hTERT 
expression was detected by immunohistochemistry in tissue slices with or without nanoplexes 
treatment using an affinity purified antibody which binds to a 16 amino acid peptide sequence 
within hTERT. After 72h of cultivation, immunohistochemical staining indicated positive 
hTERT expression in tissue slices (Fig.4C and D). The cell proliferation in tissue slices was 
analyzed using proliferation marker KI67 (Fig. 4E and F). The morphology from HE staining 
and the hTERT expression did not show any difference between nanoplexes treated and 
control tissue slices. However, there was a slight decrease of Ki67-positive tumor cells 
following treatment with nanoplexes. 
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Fig. 4: Evaluation of nanoparticles delivery of OMR on morphology, proliferation and 
telomerase expression in human tissue slices 
Images of paraffin embedded tissue slices were taken 72h after treated with OMR-nanoplexes 
(OMR+NP). Untreated tissue slices were used as control. A and B show representative example of 
Hematoxylin and eosin (HE) staining of sections from control and OMR+NP treated tissue slices. C 
and D exhibit representative examples of hTERT expression stained with Anti-hEst2 IgG antibody. E 
and F show representative examples of cell proliferation with KI67 staining in control and OMR+NP 
treated tissue slices (40× objectives). Scale bar represents 50µm. 
 
5.4.6 Inhibition of telomerase activity by 2´-O-methyl-RNA-nanoparticle-complexes in 
primary lung cancer cells and tissue slices 
The real-time quantitative PCR based TRAP assay allows a more rapid and quantitative 
determination of telomerase activity in cells or tissue extracts compared to assays based on 
electrophoresis. We modified this method to be of low-cost and high-throughput using 384-
well reaction plates with only 12µl total PCR reaction volume.  
We analyzed the functional effect of OMR delivered by chitosan-coated PLGA nanoparticles 
on telomerase activity in primary lung cancer cells from passage 3 to 5. Primary cells were 
treated with OMR-nanoplexes or mismatch-OMR-nanoplexes for 6h and telomerase activity 
was measured 72h after treatment. Following treatment with OMR-nanoplexes telomerase 
activity was inhibited by approximately 45% (p=0.0313). Primary cells treated with 
mismatch-OMR-nanoplexes showed only a slight reduction (~15%) of telomerase activity 
indicating a specific inhibition of telomerase by the OMR-nanoplexes (Fig.5A). 
Chapter 5: Tissue Slice Model for Nanoparticles Delivery of OMR 
86 
Fig. 5: (A) Telomerase inhibition by nanoparticle delivery of OMR in primary lung cancer cells 
Cells were treated with either OMR-nanoplexes (OMR+NP) or mismatch-OMR-nanoplexes 
(Mis+NP).Telomerase activity was measured by Q-TRAP 72h after treatment. Telomerase activity of 
untreated cells (control) was set to 100%. Telomerase activity of treated cells were normalized by 
corresponding control cells and shown as percentage. Data represent the mean +SD from 6 
independent experiments (* p<0.05). 
(B) Inhibition of telomerase activity by nanoparticle delivery of OMR in lung tissue slices 
Tumor tissue slices were treated with OMR-nanoplexes (OMR+NP), OMR (OMR) or nanoparticles 
(NP). The telomerase activity was measured by Q-TRAP 24h after treatment. Telomerase activity of 
untreated tissue slices (control) was set to 100%. Telomerase activity of treated tissue slices were 
normalized by corresponding control tissue slices and shown as percentage. Data represent the mean + 
SD from 8 independent experiments with different patients (** p<0.01; * p<0.05. n=5 for NP treated 
group, n=8 for all the other groups). 
We further analyzed the effect of OMR delivered by chitosan-coated PLGA nanoparticles on 
telomerase activity in the tissue slices. Tissue slices from 8 different telomerase positive 
tumor samples were treated for 6h with 4µM of OMR alone or OMR-nanoplexes. 24h after 
treatment, OMR-nanoplexes treatment reduced telomerase activity by about 40% (p=0.0078) 
in tumor tissue slices. The group treated with OMR alone only showed a slight of about 15% 
inhibition of telomerase activity (p=0.0156) (Fig.5B). Treatment with nanoparticles alone did 
not show significant telomerase inhibition effect on tumor tissue slice. 
5.5 Discussion 
In contrast to normal cells, tumor cells have relatively short telomeres but often an increased 
telomerase activity [Zimmermann et al., 2007]. This makes the inhibition of telomerase an 
interesting option for anticancer therapy. When the telomere length is reduced to a certain 
critical value, cells go to apoptosis and eventually die. However, tumor cells normally have 
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high telomerase activities which can maintain telomere length during proliferation [Harley et 
al., 2008; Kim et al., 1994]. The efficient inhibition of telomerase can drive tumor cells into 
apoptosis, while telomerase negative normal somatic cells are not targeted and affected. Other 
telomerase positive cells, such as germ line cells and stem cells, also remain unaffected 
because of their longer telomere lengths and slower cell division rates compared to tumor 
cells [Zimmermann et al., 2007; Shay et al., 2006]. Previously we have demonstrated that 2'-
O-methyl-RNA (OMR) acts as a specific telomerase inhibitor and chitosan-coated PLGA 
nanoparticles enhance the delivery of OMR inducing telomerase inhibition and telomere 
length shortening in human NSCLC cells [Beisner et al., 2009; Beisner et al., 2010]. All these 
results have been based on human lung cancer cell lines which do not reflect perfectly the 
original tumor in vivo. Therefore we used primary lung cancer cells and tumor tissue slices to 
evaluate the telomerase inhibition by nanoparticle delivery of antisense OMR. 
Primary lung cancer cells were directly isolated from the tumor lesion. During short-term 
culture, they undergo less transformation and show biological properties related more closely 
to the original tumor [Burdall et al., 2003]. But it is quite difficult to establish a primary lung 
cancer cell culture which is suitable for in vitro experiments. In order to improve attachment 
and growth, we used collagen IV coated wells. A special airway epithelial cell culture 
medium was used to keep their characteristics and to avoid contamination with fibroblasts. 
Nevertheless, cells within this culture system have only a limited lifespan. The primary cancer 
cells have longer population doubling times compared to established cancer cell lines; most of 
the cells proliferated even more slowly after 5 passages. In addition, these primary cancer 
cells were more sensitive to the condition of culture and environmental changes. Especially 
during the transfection procedure when cells were treated with nanoplexes but also 
nanoparticles alone, we observed decreased cell viability. We therefore decided to reduce the 
amount of nanoparticles during treatments and increased the content of nanoplexes ratio from 
1:100 to 1:50 (weight oligonucleotide / weight nanoparticles). Under these conditions, we were able to 
perform the experiments without a remarkable decrease of  cell viability. Telomerase activity 
of primary cancer cells was inhibited by about 40% with OMR-nanoplexes prepared in a ratio 
of 1:50, which was similar to A549 cells treated with OMR-nanoplexes of a ratio of 1:100 as 
reported previously [Beisner et al., 2010]. The original telomerase activities of these primary 
cells were highly variable within specimens from different patients. Cells which expressed 
high telomerase activity had longer lifespan (Spearman test, r=0.428, p=0.037).  
Cell morphology, cell-cell, cell-matrix and tumor-stroma interactions in cell culture models 
are different compared to the ones in tumor tissue [van der Kuip et al., 2006] and these 
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interactions are also specific for each individual tumors in vivo [Morin, 2003]. Although more 
closely related to the original tumor tissue than cell lines, primary cancer cell culture is still a 
two dimensional culture system and lacks most of these interactions. Compared to monolayer 
culture, the multicellular tumor spheroids were more resistant to anticancer drugs [Morin, 
2003]. Moreover, the extracellular matrix forms a tight network that can prevent the 
penetration of drugs into the tumor [Morin, 2003; Tannock et al., 2002; Fattal et al., 2009] or 
affect the sensitivity of the tumor cells to these drugs [Morin, 2003; Dalton, 1999]. Therefore, 
the ex vivo tissue slice model is a suitable system to evaluate drug response and actual 
efficacy in human tumors.  
Previous studies have shown that tumor tissue slices recover from the preparation process 
within 24h and are fully viable for at least 4 days. Therefore, treatment with nanoplexes was 
commenced after 24h and viability was evaluated up to 72h post treatment. We could show 
that both, small molecules and antibodies can freely penetrate the slices with 200 µm 
thickness [van der Kuip et al., 2006]. However, no data were available on larger particles. For 
a successful in vivo treatment of solid tumors, nanoplexes have to penetrate the tumor tissue 
to affect all tumor cells. The results achieved with viable tumor tissue slices showed that 
nanoplexes were able to permeate through the whole tumor tissue slice which is has a 
thickness of about 200µm. Taking into account the architecture of solid tumors with its 
vascularization this distance should exceed to the nearest blood vessel.  
In our study, a comparison of the morphology of the original tumor tissue with tissue slices by 
HE staining showed that neither the slicing procedure nor the treatment with nanoplexes 
changed the architecture of the tissue. In concordance, proliferation marker KI67 staining 
demonstrated no decrease in the fraction of proliferating tumor cells over 72h of incubation 
time. In addition, there was only a slight difference in KI67 positive cells between the treated 
and control groups after 72h. This is in agreement with the lack of acute toxicity of 
nanoplexes in lung cancer cell lines [Beisner et al., 2010]. In long-term experiments, the 
population doublings of A549 cells reduced about 40% after 2 weeks treatment, but no 
obvious difference could be observed at the first 3 days [Beisner et al., 2010]. This was 
expected as shortening of telomeres is a stepwise process needing several cell cycles to affect 
proliferation rate. The antisense 2´-O-methyl-RNA targeting only the telomerase RNA 
template does not interfere with transcriptional regulation of hTR [Pitts et al., 1998]. It 
inhibits telomerase activity by competing with the telomeres but does not influence the 
hTERT expression. Accordingly, we also observed that hTERT staining did not change in 
tissue slices during treatment. Previously, we have demonstrated that different treatments 
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such as OMR-nanoplexes, mismatch-OMR-nanoplexes or nanoparticles alone had no 
influence on cell viability of A549, Calu-3 cells and primary lung fibroblasts [Beisner et al., 
2010]. In contrast to primary lung cancer cells the cell viability in the tissue slice model was 
not affected by OMR-nanoplexes.  
Although primary lung fibroblasts showed high fluorescence intensities by FACS analysis 
after treatment with FAM-OMR-nanoplexes, the results of CLSM proved that these signals 
came from the adsorption of nanoplexes to the cell surface. The results of 
immunohistochemical staining for tissue slices following treatment with Digo-OMR-
nanoplexes also showed that the digoxigenin signal was mainly present in the tumor cells not 
in the stroma cells. This indicated that stromal cells did not reveal a very good uptake of 
nanoplexes. This might explain that viability of primary lung fibroblasts was not affected by 
the treatment of nanoplexes [Beisner et al., 2010] and proves that fibroblasts were not 
influenced by this kind of treatment.  
Tissue slices from different NSCLC patients showed a broad distribution of telomerase 
activities. But the inhibition ratio of OMR-nanoplexes treatment did not demonstrate 
significant differences. The averaged telomerase inhibition was 36.5% ± 9.4% (± SD) 
indicating that the treatment works successfully on different levels of telomerase activity. 
Tumor tissue consists of different kinds of cells, such as cancer cells, fibroblasts, 
lymphoblasts, lymphocytes, endothelial cells and extracellular matrix. Among these 
components, only tumor cells exhibit high telomerase activity. When comparing telomerase 
activity of freshly isolated cancer cells and tumor tissue homogenate, the isolated cancer cells 
showed higher telomerase activity. This is explained by the fact that telomerase activity 
determined in tumor tissue slices was the average of tumor cells with high telomerase activity 
and stromal cells which do not express telomerase. 
5.6 Conclusion 
Inhibition of telomerase in tumor cells is a promising approach in the treatment of solid 
tumors. The antisense OMR directed against the RNA template is a potent inhibitor of 
telomerase. In the primary cancer cells isolated from NSCLC we could show that nanoparticle 
delivery of antisense OMR can inhibit telomerase activity. Using the tissue culture model we 
could prove that (1) OMR-nanoplexes penetrate into tumor tissue, (2) transfect tumor cells in 
their “natural” environment to deliver OMR and (3) that telomerase activities of these cells 
are inhibited by this OMR. Therefore the tissue slice model of human lung cancer appears to 
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be a useful tool for translating nanotechnology based delivery of telomerase inhibitor 
antisense oligonucleotides into more complex in vivo experiments. 
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Dong M, Ammon-Treiber S, Philippi C, Loretz B, Schaefer UF, Lehr CM, Klotz U, Mürdter 
TE. 
Inhalation of nanoplexes for the delivery of 2´-O-methyl-RNA in an isolated perfused rat lung 
model. 
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6.1 Abstract 
 
Background: The respiratory delivery of drugs to the lungs by inhalation has been 
investigated extensively and employed to treat diseases primarily localized in the lung, e.g. 
asthma. The respiratory tract might also be used as a route for administration of aerosolized 
targeted drugs in lung cancer therapy. 
Methods: An isolated perfused rat lung (IPL) was used as a model to investigate in pilot trials 
the uptake efficiency and distribution in the lung of a complex formed from digoxigenin 
labeled oligonucleotides and chitosan-coated poly(lactide-co-glycolide) (PLGA) nanoparticles 
(nanoplexes) following inhalation. The aerosol of nanoplexes was produced and applied to the 
rat lung through a microsprayer needle directly placed into the bronchus of the lung. The rat 
lung was ventilated by negative pressure and perfused for about one hour at constant 
recirculating flow rate with a modified Krebs-Henseleit buffer supplemented with 2% bovine 
serum albumin. Perfusion parameters such as pulmonary artery pressure, pH of perfusion 
buffer, tidal volume, resistance and compliance were monitored continuously. Distribution of 
nanoplexes in the lung was assessed with a Mouse-anti-DIG antibody by 
immunohistochemical staining. 
Results: Following the inhalation of the aerosol of nanoplexes digoxigenin labeled 
oligonucleotides could be detected in all different parts of the lung. However, the distribution 
was heterogeneous and exhibited local differences. During the preparation of the IPL and the 
inhalation experiment, rat lung structure and cells in the lung did not show any changes in 
their anatomical and physiological properties. The biological function of the lung was not 
altered. 
Conclusion: An isolated perfused rat lung model was successfully applied to investigate the 
inhalative delivery of nanoplexes to the lung. Oligonucleotides transported by these 
nanoplexes could be localized throughout the complete lung. The inhalation of nanoplexes did 
not alter lung physiology. 
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6.2 Introduction 
The respiratory delivery of drugs to the lungs by inhalation has been investigated extensively 
and employed to treat diseases primarily localized in the lung. The respiratory tract can be 
used for the direct deliver of drugs to the diseased area and the inhalation of a drug will result 
in a quick onset of action. It allows topical effects for the aerosolized administration of 
targeted drugs in lung cancer therapy.  
Previously we have proved that delivery of an antisense oligonucleotide 2´-O-methly-RNA 
(OMR) with chitosan-coated poly(lactide-co-glycolide) (PLGA) nanoparticles can induce 
efficient telomerase inhibition and telomere shortening in human non-small cell lung cancer 
(NSCLC) cells [Beisner et al., 2010]. Nanoparticles mediated delivery of OMR by inhalation 
might offer a new mode for drug delivery in lung cancer therapy. 
The present study was designed to use the isolated perfused rat lung (IPL) as a model to 
investigate the pulmonary delivery and distribution of nanoplexes consisting of 
oligonucleotides (OMR) and chitosan-coated PLGA nanoparticles after inhalative application 
of an aerosol. The aerosol was formed with a microsprayer needle connected to a high 
pressure syringe. The IPL model was modified from the method described by Uhlig et 
al.[Uhlig et al., 1994]. The isolated lung was ventilated by negative pressure and was 
perfused at constant flow rate with recirculating buffer. Compared to other in vitro models, 
cells in the IPL are maintained in their “normal” anatomical and physiological environment 
and are not fragmented or dispersed. Therefore, transcellular transport and diffusion of agents 
are probably not altered [Niemeier, 1984]. This technique offers a versatile experimental 
system which supplements isolated organelle preparation [Rhoades, 1984] and allows the 
continuous assessment of lung mechanics [Uhlig et al., 1994]. Using the microsprayer device 
to generate a homogenous aerosol with particle sizes of 16 to 22 µm the inhalative application 
of nanoplexes can be studied with this model.  
6.3 Material and methods 
6.3.1 Animals 
Two male Wistar rats (Harlan, Horst, Netherlands) of 290g and 310g weight were used for the 
experiments. The rats were housed under controlled conditions with temperature 20-21°C, 
humidity 50-60%, light (12:12 light-dark rhythm) and free access to standard food (pellets) 
and tap water. The experiments were approved by the local authorities (Regierungspräsidium 
Tübingen, Germany). 
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6.3.2 Isolated perfused rat lung (IPL) preparation  
Rats were anesthetized with ketamine (Ketavet, 100mg/kg body weight) and xylazine 
(Rompun, 10mg/kg body weight) by intraperitoneal (i.p.) administration. Heparin-sodium 
(500IE/100g) was injected i.p. to avoid blood clotting during the preparation. 
After incision of the trachea and insertion of a tracheal cannula, positive pressure ventilation 
was started. Rats were exsanguinated by cutting the renal artery. Following cannulation of the 
pulmonary artery and the pulmonary vein, perfusion was started and the lung with trachea 
was carefully dissected together with the heart and suspended in a humidified glass chamber 
maintained at 37°C. Thereafter, perfusion was switched to recirculation (total recirculating 
volume: 270ml) with a flow rate of 20ml/min and ventilation was switched to negative 
pressure ventilation (70breaths/min, end-expiratory pressure: -2cm H2O, end-inspiratory 
pressure -8 cm H2O) with a deep insufflation (-20cm H2O) every five minutes to avoid 
atelectasis of the peripheral airways.  
The lungs were perfused through the pulmonary artery with filtered Krebs-Henseleit buffer at 
37°C consisting of 118mM NaCl, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM MgSO4 (x 7 H2O), 
2.5mM CaCl2 (x 2H2O), 24.9mM NaHCO3, 2% (w/v) albumin, 0.1% (w/v) glucose and 0.3% 
(w/v) HEPES. The pH of the perfusate was maintained between 7.3-7.4 by adding CO2. Data 
on lung mechanics (breath rate, tidal volume, end-inspiratory pressure, end-expiratory 
pressure, compliance, resistance, flow rate and pH of the perfusate, pulmonary artery pressure) 
were monitored continuously. Signs of edema formation were checked by visual inspections. 
Perfusion apparatus and the electronic equipment were purchased from Hugo Sachs 
Elektronik-Havard Apparatus GmbH (March-Hugstetten, Germany). 
6.3.3 Inhalation of nanoplexes 
A digoxigenin-labeled antisense oligonucleotide OMR (Digo-OMR) with a phosphorothioate 
(ps) backbone 5´-2´-O-methyl [C(ps)A(ps) GUUAGGGUU(ps)A(ps)G]-digoxigenin-3´ was 
used in this experiment (Biomers, Ulm, Germany). Certain amount of OMR was mixed with 
nanoparticles at ratio of 1:50 (weight oligonucleotide / weight nanoparticles) and incubated for 15min 
at 37°C to form Digo-OMR-nanoplexes. The process is described in detail in Chapter 5: 
Materials and methods. 
Automatic breath was turned off after 15min equilibration. Respiratory rate was decreased to 
30breaths/min for a short-term. A deep breath was activated manually; 100µl 0.9% NaCl 
solution was instilled through a microsprayer (Model IA-1C, with high pressure syringe 
model FMJ-250, PennCentury, INC., P.A., USA) during inspiration. Another deep breath was 
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initiated manually. Subsequently automatic breath was turned on and the respiratory rate was 
set back to 70 breaths/min. Ten minutes after NaCl application inhalation was repeated with 
100µl of nanoplexes solution. The lung was perfused continuously for another 30min. At the 
end 4% buffered formalin was perfused into the lung for fixation and the lung was embedded 
in paraffin for the preparation of histological sections. Fig. 1 shows the schematic diagram of 
the IPL inhalation experiment. 
 
Fig.1: Schematic diagram of IPL inhalation 
Arrows give the flow direction of perfusion buffer. The photo exhibits the rat lung with the trachea 
and the heart in a humidified glass apparatus.  
 
6.3.4 Immunohistochemical staining 
The paraffin fixed perfused lung tissues were cut in 3 µm serial sections by Rotary Microtome 
(Leica RM2255, Germany) and epitope retrieval pretreatment was achieved by heating in 
epitoe retrieval solution (ZytoVision, Bremerhaven, Germany). Immunohistochemical 
staining for Digo-OMR was performed using Mouse-anti-DIG antibody (ZytoVision, 
Bremerhaven, Germany) according to the manufacture’s instructions. The images were taken 
by a DigitalMicroscope (Leica DM 4000B) and analyzed by Leica Application Suite V3 
software. The details of the process are described in Chapter 5: Materials and methods: 
Immunohisochemical staining. 
 
6.4 Results and discussion 
Following the inhalation of an aerosol of nanoplexes rat lung structure and cells in the lung 
did not show changes in their anatomical and physiological properties. As the cover of the 
Chapter 6: IPL Model for Inhalative Delivery of Nanoplexes 
96 
perfusion cask was adapted for inhalation no continuous measurement of lung weight for the 
sensitive detection of oedema was feasible. However, the surface of the lung was uniformly 
white and no oedema formation was observed during the complete experiment. 
 
Fig.2: Localization of Digo-OMR-nanoplexes in rat lung visualized by immunohistochemistry 
(40× objectives) 
Rat lung was divided into 6 parts according to the lobes and labelled from 1 to 6. The left upper lobe 
was cut into two parts (5 and 6) because of the large size. Images were marked with the corresponding 
numbers. Paraffin sections were stained with Mouse-anti-DIG antibody. Counterstaining was 
performed with hematoxylin. Scale bar represents 50 µm. 
 
After inhalation Digo-OMR-nanoplexes (in brown colour) were observed in both parts of the 
rat lungs. However, the two parts did not exhibit similar localizations of Digo-OMR 
indicating that the distribution of nanoplexes following inhalation showed some differences. 
Fig.2 illustrates the detailed distribution of Digo-OMR-nanoplexes. Most of the nanoplexes 
were attached in form of a layer to the surface of bronchus, as shown in Fig.2-3. In the left 
upper lobe (Fig.2-5) numerous cells with positive signals can be seen. In the right lower lobe 
(Fig.2-1) positive signals can be observed on the inner surface of alveoli. This might be 
caused by the interaction of Digo-OMR-nanoplexes with the surfactant on the alveolar surface. 
Few signals were also found in other lobes indicating that the nanoplexes can reach almost the 
entire lung but with heterogeneous distribution. According to their morphology, cells 
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demonstrating an uptake of Digo-OMR-nanoplexes could be either macrophages or alveolar 
type II cells, but not alveolar type I cells. To identify exactly the cell type further 
immunohistochemical experiments are necessary.  
 
Fig.3: Time course of lung functions during perfusion of the IPL with inhalation of nanoplexes 
Red lines indicate the time when inhalation was applied. Aerosol of Digo-OMR-nanoplexes was 
administered for inhalation. The same amount of 0.9% NaCl solution was used as control for 
inhalation experiment. 
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The effects of the inhalation of nanoplexes on the physiology of the IPL are summarized in 
Fig.3. Lung perfusion requires a continuous exchange of medium within the vascular bed. As 
a marker of gas exchange, the biological function of the lung and pH changes were monitored 
continuously. Following the inhalation of 100µl of physiological saline the rate of pH 
increase was slightly decreased. This indicated a decreased capability of the lung to exhale 
carbon dioxide. Following the application of nanoplexes no further alteration of the pH profile 
was observed. Immediately after the inhalation of both, saline and nanoplexes, there was 
some decrease in tidal volume and compliance. However, both parameters recovered after 
subsequent deep breaths (Fig.3). Flow rate of the perfusion buffer was kept constant during 
the perfusion experiment. Constant pulmonary artery pressure indicated that there was no 
change in the vascular structure during IPL. 
Proper ventilation is very critical in the perfused lung; it provides the physiologic route for 
oxygenation. After the lung and heart was suspended in a sealed glass chamber negative 
pressure ventilation was applied. Positive pressure ventilation may cause destruction of lung 
architecture by overinflation followed by oedema formation and progressive atelectasis. 
Negative pressure ventilation is preferable since it can mimic more closely the in vivo 
situation [Uhlig et al., 1994]. 
The changes of the functional parameters around the time of inhalation (peaks next to the red 
lines in Fig.3) are caused by the two manually activated deep breaths before and after the 
inhalation in combination with the manipulations at the air inlet to introduce the microprayer 
needle. More experiments are needed to confirm the results of the pilot trials and to further 
investigate the biological function of the telomerase inhibitor OMR delivered by 
nanoparticles through inhalation in lung cancer patients. 
6.5 Conclusion  
An isolated perfused rat lung model was successfully used to investigate the inhalative 
delivery of nanoplexes to the lung. Topical uptake of oligonucleotides transported by these 
nanoplexes could be localized throughout the complete lung. The inhalation of nanoplexes did 
not impair pulmonary physiology. 
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7.1 Abstract 
 
Background: Previous studies have shown that telomerase activity is detected in about 80% 
of non-small cell lung cancers (NSCLC) and correlated with a poor prognosis. Cancer stem 
cells should have telomere-lengthenging mechanisms to maintain their replicative ability. 
Therefore tumors may arise from telomerase-positive stem cells. It is still not known if 
CD133 is an appropriate marker of organ-specific cancer stem cells or not. The telomerase 
dynamics in cancer stem cells also remain unclear. The aim of this study was to determine 
whether in NSCLC relationships exist between telomerase activity, tumor proliferation (KI67 
expression), cellular expression of hTERT, and cancer stem cell population (CD133 
expression). 
Methods: Thirty one primary NSCLC and 9 lung metastases from 40 patients (27 males, 13 
females) were analyzed. Telomerase activity of fresh tumor tissue was measured with a real 
time PCR based telomeric repeat amplification protocol (Q-TRAP). Paraffin sections were 
stained for hTERT, proliferation marker KI67 and stem cell marker CD133, and their 
interrelations were analyzed. 
Results: Telomerase activity was present in 29 (93.5%) of the 31 primary NSCLC and 8 
(89%) of the 9 lung metastases. Similar telomerase activity levels were detected between lung 
metastases and primary lung cancers. Metastases showed a trend of higher KI67 expression. 
No significant correlations were found in the expression of KI67, hTERT and CD133. There 
was a tendency that CD133 expression was correlated inversely with telomerase activity. 
Conclusion: The CD133 positive cells may show downregulation of telomerase activity. 
Significant correlations were not found in the expression of KI67, hTERT and CD133. Larger 
sample sizes and further research are required to identify cancer stem cells and to understand 
better the relationship between cancer stem cells and telomerase activity. 
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7.2 Introduction 
Lung cancer is the most common cause of cancer-related mortality all over the world. Non-
small cell lung cancer (NSCLC) is the most frequent form and constitutes approximately 80% 
of all lung cancers. The NSCLC includes adenocarcinoma, squamous cell carcinoma, adeno-
squamous carcinoma and large cell carcinoma.  
Previous studies have shown that telomerase activity was detected in more than 80% of 
NSCLC and correlated with a poor prognosis [Taga et al., 1999]. Human telomerase contains 
two major components: the catalytic protein subunit human telomerase reverse transcriptase 
(hTERT) replicating the ends of linear DNA, and the human telomerase RNA (hTR) that 
provides the template for the synthesis of human telomeric repeats [Feng et al., 1995; 
Nakamura et al., 1997]. It has been reported that hTERT and functional telomerase are both 
located primarily in the nucleolus [Smith et al., 2004]. Kyo S et al. found that functional 
hTERT was expressed in both the nucleus and cytoplasm of cancer cells and hTERT 
expression did not strictly reflect telomerase activity [Kyo et al., 2003]. Therefore we 
analyzed hTERT expression at the cellular level in lung cancer specimens by 
immunohistochemistry and compared it to telomerase activity from the same sample by a 
modified TRAP assay using real-time quantitative PCR. KI67 is a marker for cell 
proliferation which is present in the nucleus of proliferating cells [Cattoretti et al., 1992]. 
KI67 was demonstrated to have a weak correlation with hTERT expression [Smith et al., 
2004] and telomerase activity [Albanell et al., 1997].  
Cancer stem cells have been isolated from various tissues and cell lines [Singh et al., 2003; 
Al-Hajj et al., 2003; Tirino et al., 2009]. The cancer stem cell theory suggests that a rare 
fraction of cells with stem cell properties can drive tumorigenesis [Reya et al., 2001]. The 
failure of current cancer therapies may be due to the inefficacy of drugs on cancer stem cells 
[Dean et al., 2005]. Therefore the identification of cancer stem cells is very important for 
targeted cancer therapy. A variety of stem cell markers have been applied to differentiate 
cancer stem cells from solid tumors. These makers include CD34, CD133 and CD24 coupled 
with migration molecules such as CD29, CD44, integrin α2β1 and CD31 [Collins et al., 2001; 
Tirino et al., 2009]. Hoechst 33342 dye was also used to isolate side population cells which 
have distinguishing biological characteristics from the main population as a different 
approach [Brown et al., 2007]. CD133 is a membrane glycoprotein with unknown biological 
function. It is suggested to be a stem cell marker for normal and cancer tissues [Shmelkov et 
al., 2008]. It has been used for the identification and isolation of cancer stem cell populations 
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from malignant tumors of liver [Suetsugu et al., 2006], brain [Singh et al., 2003; Singh et al., 
2004], prostate [Collins et al., 2005], pancreas [Hermann et al., 2007], colon [O'Brien et al., 
2007] and lung [Eramo et al., 2008]. Cancer stem cells should have telomere-lengthenging 
mechanisms to maintain their replicative ability. However, the identification and purification 
of cancer stem cells are difficult in most solid tumors. In addition, telomere and telomerase 
dynamics in cancer stem cells remain unclear [Hiyama et al., 2007]. Armanios M et al. 
suggested that tumors may arise from telomerase positive stem cells [Armanios et al., 2005]. 
However it was reported that CD133 was not a selective marker of organ-specific stem and 
progenitor cells [Shmelkov et al., 2008]. Shervington A et al. found that telomerase activity is 
downregulated in cancer brain stem cells which express CD133. Therefore to identify cancer 
stem cells and to understand their relationships with telomerase activity are crucial for a more 
effective anti-cancer therapy.  
The aim of this study was to determine in NSCLC whether relationships exist between 
telomerase activity, tumor proliferation (KI67 expression), cellular expression of hTERT, and 
cancer stem cell populations (CD133 expression). 
 
7.3 Material and methods 
7.3.1 Tissues collection 
Fresh lung tumor tissues were obtained at the time of surgery from 40 patients (27 males, 13 
females; age range 36-88 years) newly diagnosed for lung cancer at the Klinik Schillerhöhe. 
Immediately after surgical resection, the main portion of tumor tissues were fixed in formalin 
and sent to pathology for further diagnosis. The remaining parts were snap-frozen with liquid 
nitrogen and stored at -80°C for analysis. The investigation was approved by the local ethics 
committee (# 396/2005V) and informed consent was obtained from the patients.  
7.3.2 Telomerase activity measurement of lung cancer tissues 
For each tissue specimen, one piece (50 to 100mg) was taken for determination of telomerase 
activity. Tissue pieces were isolated by FastPrep methods as described in Chapter 2: Part1: 
Materials and methods: Preparation of tumor tissue extracts. Telomerase activity was 
measured using a modified real-time quantitative PCR based telomeric repeat amplification 
protocol (Q-TRAP) assay as described previously [Herbert et al., 2006]. The detailed process 
is described in Chapter 2: Part1: Materials and methods: Telomerase activity assay using 
real-time quantitative PCR. The cutoff value for Q-TRAP assay was set as 0.01 (compared to 
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the activity of 1µg protein from NSCLC cell line A549 cells). The Q-TRAP result was 
considered as telomerase positive if the value was greater than 0.01. 
7.3.3 Immunohistochemical staining 
The paraffin fixed tissues were cut in 3 µm serial sections by Rotary Microtome (Leica 
RM2255, Germany) and stained with hematoxylin and eosin (HE) for histopathological 
examination. Immunostaining for KI67 (1:75, Monoclonal Mouse Anti-human KI67 Antigen, 
Clone MIB-1, Dakocytomation, Glostrup, Denmark), human telomerase reverse transcriptase 
(hTERT, 30µg/ml, Rabbit Anti-hEst2 IgG, Alpha Diagnostic International, San Antonio,TX) 
and CD133 (1:10, Monoclonal Mouse Anti-human CD133/1 (AC133) pure antibodies, 
Miltenyi Biotec, Bergisch Gladbach, Germany) were performed using the Dako REALTM 
EnvisionTM Kit(EnVision, Dako, Glostrup, Denmark) according to the manufacturer’s manual. 
A heat-induced epitope retrieval technique was employed as following: prior to staining for 
KI67 and CD133, sections were treated in a steam heater for 30 min with pH6.0 citric acid 
buffer (Dako, Glostrup, Denmark). For hTERT staining, sections were treated in a pressure 
cooker for 15 min with pH 9.0 Tris/EDTA buffer (Dako, Glostrup, Denmark). The detailed 
process of immunohistochemical staining is described in Chapter 5: Part1: Materials and 
methods: Telomerase activity assay using real-time quantitative PCR. 
7.3.4 Scoring methods 
Images of immunohistochemical staining were taken by a 40× objective with Digital 
Microscope (Leica DM 4000B) and analyzed by Leica Application Suite V3. For each sample, 
cells were counted from at least 4 randomly selected fields. The ratio of positive cells was 
calculated as the percentage of positively stained cells related to total cells. 
7.3.5 Statistical analysis 
GraphPad Prism Software  Version 4.0 (GraphPad Prism Incorp., San Diego, CA, USA) was 
used for statistic analysis. The Spearman correlation test was applied to measure associations 
between telomerase activity and expressions of KI67, hTERT, CD133. 
 
7.4 Results 
7.4.1 Telomerase activity and histopathology of lung tumors  
In 40 specimens, there were 31 primary NSCLC and 9 lung metastases from different origins. 
Telomerase activity was detected in 29 (93.5%) of the 31 primary NSCLC and in 8 (89%) of 
the 9 lung metastases. Some details are summarized in Table1. 
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Table 1. Comparison of tumor histology with telomerase activity in primary NSCLC and lung 
metastasis 
  Telomerase activity 
Histology Tumors numbers Negative Positive % positive 
Adenocarcinoma 14 2 12 85.7 
Squamous cell carcinoma 11 1 10 90.9 
Adeno-squamous carcinoma  4 0 4 100 
Large-cell carcinoma 2 0 2 100 
Metastasis 9 1 8 88.9 
 
 
Fig. 1: Telomerase activity of primary NSCLC (Adenocarcinoma, Squamous cell carcinoma, 
Adeno-squamous carcinoma and Large-cell carcinoma) and lung metastasis 
(Each point represents an individual tumor sample) 
 
Telomerase activities of all 40 analyzed lung tumor specimens are illustrated in Fig.1. The 
level of telomerase activity was in the range of 0.001 to 1.469 with an average value of 0.166 
(compared to the activity of 1µg protein of A549 cells). There was no significant difference 
among different lung tumor types. The telomerase activity of metastasis exhibited a similar 
distribution as primary lung cancers as shown in Fig.1. and Fig.3 (A).  
7.4.2 Relationships between telomerase activity and expressions of KI67, hTERT and 
CD133 
Fig. 2 illustrates the histological examination of paraffin embedded lung cancers of different 
tumor types and the cell proliferation in lung tumors analyzed as KI67 expression. Nuclear 
hTERT expression was detected by immunohistochemistry using an affinity purified antibody 
which binds to a 16 amino acid peptide sequence within hTERT. Although cancer stem cell 
marker CD133 is a 120kDa membrane glycoprotein, positive staining was not only observed 
on the cell membrane but also in both nucleus and cytoplasm (see Fig. 2-CD133).  
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Fig. 2: HE staining (20× objectives) and immunohistochemistry (40× objectives) of KI67, hTERT 
and CD133 expression in NSCLC 
Scale bars represent 100µm in 20× objectives and 50µm in 40× objectives. 
 
Positive KI67 expression with nucleus localization was found in all tumors with a range of 
2.4% to 49.6% (Fig. 3B). Metastasis showed a trend of higher KI67 expression but no 
significant differences were observed. In primary NSCLC cells and lung metastasis cells 
hTERT immunostaining was clearly visualized in both nucleus and cytoplasm (range: 4.5% - 
36.2%). Expressions of KI67 and hTERT were not related to tumor types. Only 35% of 
primary lung cancers (range: 0.12%-34.7%) and 33% of lung metastases (range: 1.3% - 
12.3%) showed positive immunostaining of CD133. As shown in Fig. 3D, CD133 exhibited a 
trend of lower expression in lung metastasis but this did not reach statistical significance.  
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Fig. 3: Telomerase activity (A) and KI67 (B), hTERT (C), CD133 (D) immunostaining 
quantification in NSCLC and metastasis (The horizontal lines indicate the medians of the samples) 
 
 
 
 
 
 
 
 
 
 
No significant correlation was found between hTERT expression and telomerase activity in 
31 primary NSCLC specimens (Fig.4), indicating that hTERT expression assessed by in 
immunostaining may not represent telomerase activity. Likewise, no significant correlations 
could be found between the expression of KI67, hTERT or CD133; telomerase activity and 
KI67 staining also did not show a significant correlation. 
Fig. 4: Relationship between 
hTERT immunostaining and 
telomerase activity in primary 
NSCLC 
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Fig. 5: Relationship between CD133 immunostaining and telomerase activity (A); distribution of 
CD133 immunostaining according to levels of telomerase activity (B) in primary NSCLC  
(The horizontal lines indicate the medians of the samples) 
  
An inverse trend (r =-0.32, p = 0.079) was detected between CD133 expression and 
telomerase activity (Fig. 5A). This finding was supported by separating CD133 expression 
into two groups according to low (0-0.05) and high (0.05-1.5) levels of telomerase activities. 
The group with high telomerase activity level showed lower CD133 expression (median: 
0.12%) if compared to the group (median: 3.86%) with low telomerase activity level (Fig. 5B). 
Positive CD133 expression was found in 79% of tumors of the low telomerase activity level 
group and in 53% of the high telomerase activity level group. This might indicate if CD133 is 
the appropriate marker for cancer stem cells, these cells would have lower telomerase activity.  
 
7.5 Discussion 
Telomerase activity is detected in most tumor tissues and has been considered as a potentially 
diagnostic marker for tumor progress. Albanell J et al. reported that telomerase activity was 
detected in 84.8% of primary NSCLC [Albanell et al., 1997]. In our study, telomerase activity 
was detected in 93.5% of the primary NSCLC specimens. This higher value can be explained 
by the modified Q-TRAP assay which we used for measurements of telomerase activity. The 
highly sensitive and specific new method can avoid end-point PCR problems and provides 
linear telomerase detection down to much lower levels than with the old assays. Specimens 
with lower than 0.010 (compared to the activity of 1µg protein of A549 cells) telomerase 
activity were defined as telomerase negative. Therefore the percentage of positive telomerase 
activity of NSCLC has been increased. 
KI67 is a proliferation associated antigen that is present only in proliferating cells. 
Immunological detection of KI67 is a useful method for detecting cellular proliferation in 
tissue samples [Cattoretti et al., 1992]. Telomerase activity was significantly associated with 
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KI67 expression in breast cancer [Mokbel et al., 1999], psoriasis lesional skin [Jang et al., 
2001], malignant melanomas [Miracco et al., 2000] and primary NSCLC [Albanell et al., 
1997]. In our study we did not observe a statistically significant correlation between 
telomerase activity and KI67 expression. This could be due to the small sample size or the 
heterogeneous nature of tumor samples.  
hTERT represents the catalytic subunit of telomerase. The expression of hTERT has 
important implications in cancer diagnostics and prognostics [Hiyama et al., 2001] and in 
human cancer tissues it correlated with telomerase activity [Hiyama et al., 2001]. A weak 
association between hTERT and KI67 expression was found in patients with curative 
resection of hepatic colorectal metastases [Smith et al., 2004]. In our study, no significant 
correlation was detected between hTERT expression and telomerase activity, or between the 
expressions of hTERT and KI67 in 31 primary NSCLC specimens. These negative findings 
might be due to the small sample size. Smith DL et al. suggested that nucleolar hTERT 
expression was a good reflection of functional telomerase activity. On the contrary, Kyo S et 
al. reported that functional hTERT was expressed in both the nucleus and cytoplasm of cancer 
cells and hTERT expression did not always reflect telomerase activity. Our results 
demonstrated that both nucleus and cytoplasm had strong hTERT expression in lung cancer 
specimens. Therefore our results confirm the theory of Kyo S et al.that hTERT expression 
does not always reflect telomerase activity. 
Recently, several studies indicated that a small population of cancer stem cells in tumors were 
responsible for tumor maintenance and spreading [Eramo et al., 2008; Singh et al., 2004]. 
CD133 antibody has been used for the identification and isolation of cancer stem cell 
population from malignant tumors. We found that only about 30% of lung tumor specimens 
showed a CD133 positive staining. This result is in agreement with the general concept that 
cancer stem cells are expressed in a very small percentage of the total tumor cell population 
[Tirino et al., 2009].  
It has been reported that cancer stem cells express high telomerase activity [Hiyama et al., 
2007]. According to our initial hypothesis we tried to identify in lung cancer specimens a 
correlation between CD133 and telomerase activity. However, we could only find a trend for 
an inverse correlation between CD133 expression and telomerase activity which most likely 
can be explained by the small sample size. Telomerase activity was downregulated in cancer 
brain stem cells which express CD133 [Shervington et al., 2009]. During differentiation cells 
proliferate and telomerase activity is upregulated. So non-differentiated CD133 positive 
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(CD133+) cells exhibit low telomerase activity. This might explain our results that the 
specimens with high telomerase activity exhibited low CD133 expression. Shmelkov SV et al. 
suggested that CD133 is not a specific marker of organ-specific stem and progenitor cells as 
both CD133+ and CD133- metastatic colon cancer cells initiate tumors. Meng X et al. 
reported both, CD133+ and CD133- subpopulations of lung cancer cell lines A549 and H446 
cells contain cancer-initiating cells. Therefore CD133 may not be a reliable marker for cancer 
stem cells in lung tumor specimens. Consequently, either CD133 is not the perfect marker for 
cancer stem cells or cancer stem cells have very low telomerase activity. 
High telomerase activity was correlated with poor prognosis in gastric cancer [Hiyama et al., 
1995], breast cancer [Kim et al., 1996] and neuroblastoma [Hiyama et al., 1995]. In NSCLC 
high telomerase activity was associated with increased cell proliferation and advanced 
pathologic stage [Albanell et al., 1997]. More investigations are needed to clarify the 
relationship between telomerase activity and prognosis in NSCLC. In such studies lymph 
node metastasis and survival data should be also considered. 
7.6 Conclusion 
In 40 lung tumor specimens no significant correlations were found between the expression of 
KI67, hTERT and CD133. Lung tumor metastasis showed a trend of higher KI67 expression. 
The weak inverse relation between CD133 expression and telomerase activity suggests that 
CD133 positive cells are associated with low telomerase activity. Larger sample sizes and 
further research are required to better understand the relationships between different markers 
of cancer stem cells and telomerase biology. 
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Chapter 8 
Summary and Outlook 
The experiments presented in this thesis focus on the inhibition of telomerase to provide data 
whether this approach is suitable for non-small cell lung cancer (NSCLC) therapy. An 
antisense oligonucleotide 2´-O-methyl-RNA (OMR) was used as a specific telomerase 
inhibitor. Several strategies were tested to deliver OMR to its target site in different models 
based on cell cultures, tissue slices and an isolated perfused rat lung.  
Telomerase activity and telomere length are the two biomarkers to evaluate the therapeutic 
potential of telomerase inhibitors. The real-time quantitative PCR based assays for measuring 
these two parameters were optimized to provide specific and quantitative data of various 
biological materials. Compared to current techniques, the new methods permit rapid and 
accurate analysis for large sample sets. 
In NSCLC A549 cells, five commercial available transfection reagents (DOTAP, MegaFectin 
60, SuperFect, FuGENE 6 and MATra-A) were tested for cellular uptake of OMR and 
telomerase inhibition. The cationic lipid DOTAP displayed a relatively higher transfection 
efficiency, a lower cytotoxicity and stronger telomerase inhibition if compared to the other 
four reagents. Furthermore, biodegradable and chitosan-coated poly(lactide-co-glycolide) 
(PLGA) nanoparticles were applied for delivering OMR into human lung cancer cells. 
Positively charged nanoparticles can form nanoplexes with the negatively charged OMR and 
can be taken up by cells. In the cells OMR was released and specifically blocked the 
telomerase RNA template region. In human NSCLC cell lines the nanoparticle delivery of 
OMR induced efficient telomerase inhibition. Telomerase activity was continuously reduced 
by approximately 80% and telomeres were shortened about 50% during long-term (102 days) 
treatment. Nanoplexes did not exhibit acute cytotoxicity in NSCLC cell lines and had almost 
no influence in primary lung fibroblasts. 
Freshly isolated primary lung cancer cells represent much better biological model related to 
the original tumors. However, they are very sensitive to culture conditions and environmental 
changes. Therefore these cells need to be treated with a reduced amount of nanoparticles to 
avoid toxicity. Telomerase activity was inhibited by about 40% 72h after treatment. Cell 
morphology, cell-cell or cell matrix interactions are different in isolated cells compared to 
tissues and therefore experiments with isolated cells have several limitations if used as models 
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for in vivo tumors. The ex vivo tissue slice model can overcome these problems presenting a 
suitable system to evaluate drug response in tumors. 
In tissue slice model, tumor microenvironment and integrity of the tumor-stroma interaction 
will be preserved. In this model 0.2 mm thick tissue slices were freshly excised from tumor 
samples of NSCLC patients. We could prove that OMR-nanoplexes can penetrate into tumor 
tissue, transfected tumor cells in their natural environment, and delivered the telomerase 
inhibitor OMR to its target. Furthermore, the released OMR could inhibit telomerase activity 
by about 40%. Tissue architecture, cell proliferation and telomerase expression were not 
influenced. However, due to the short survival time of tissue slices (about 4 days) no 
biological response can be expected. A long-term in vivo experiment using a tumor xenograft 
model is recommended to investigate such effects. 
An isolated perfused rat lung (IPL) model is one step closer to the in vivo situation especially 
for the inhalative delivery of nanoplexes. An IPL was used to investigate the delivery and 
distribution of an inhaled aerosol of OMR-nanoplexes. The aerosol was produced and applied 
through a microsprayer needle directly connected to the bronchus of the lung. Following the 
inhalation OMR-nanoplexes could be detected within the entire lung. The nanoplexes did not 
alter lung physiology.  
The cancer stem cells theories suggest that cancers may arise from a rare subpopulation of 
stem cell-like tumor cells and they are responsible for the failure of current cancer therapies. 
Cancer stem cells present a novel target for anticancer therapy. Therefore, it was tested 
whether in NSCLC relationships exist between telomerase, and markers of tumor proliferation 
or for cancer stem cell populations. In 40 tumor samples of patients with NSCLC no 
significant correlations between these factors could be found. Only stem cell marker CD133 
positive tumor cells showed a trend for downregulation of telomerase activity. Large samples 
sizes or more reliable stem cell markers are probably required to identify cancer stem cells 
and to better understand their relationship to telomerase activity.  
This thesis provides evidence that telomerase inhibitors delivered by nanoparticles have a 
considerable potential for in vivo application of anticancer therapy. Inhaled nanoplexes might 
be suitable agents for the topical treatment of lung cancer. 
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Chapter 9 
Zusammenfassung und Ausblick 
Die in dieser Arbeit vorgestellten Experimente konzentrierten sich auf die Hemmung der Telomerase-
aktivität für die Therapie des nichtkleinzellig Lungenkarzinoms (NSCLC). Als spezifischer 
Telomeraseinhibitor wurde ein Antisense Oligonukleotid 2´-O-methyl-RNA (OMR) eingesetzt. 
Verschiedene Strategien wurden getestet, um OMR an seinen Wirkort zu bringen. Dazu wurden 
Modelle eingesetzt, die auf immortalisierten Zelllinien, viablen Gewebeschnitten und isoliert 
perfundierten und ventilierten Rattenlungen basieren. 
Telomerase-Aktivität und Telomerlänge sind die beiden Biomarker zur Bewertung des therapeutischen 
Potenzials. Die auf Echtzeit-quantitativer Polymerase-Kettenreaktionen basierten Methoden zur 
Messung dieser zwei Parameter wurden optimiert, um spezifische und quantitative Daten von 
verschiedenen biologischen Materialien zu liefern. Im Vergleich zu den Standardtechniken 
ermöglichen diese neuen Methoden schnellere und genauere Analysen für große Stichprobemengen. 
In NSCLC-Zellen A549 wurden fünf Transfektionsreagenzien (DOTAP, MegaFectin 60, SuperFect, 
FuGENE 6 und Matra-A) für die zelluläre Aufnahme der OMR und die Auswirkungen auf Hemmung 
der Telomerase getestet. Das kationische Lipid DOTAP zeigte die höchste Transfektionseffizienz, 
niedrigere Zytotoxizität und stärkere Telomeraseinhibition im Vergleich zu den anderen vier 
Reagenzien. Außerdem wurden die biologisch abbaubaren, mit Chitosan beschichteten Polylaktat-
coglykolat- (PLGA) Nanopartikel für die Aufnahme von OMR in humane Lungenkarzinomzellen 
untersucht. Die positiv geladenen Nanopartikel können mit der negativ geladenen OMR Komplexe 
(Nanoplexe) bilden, die von Zellen aufgenommen werden. OMR werden in den Zellen aus den 
Nanoplexen freigegeben und binden an die RNA-Untereinheit der Telomerase. Durch Nanopartikel in 
die Tumorzellen eingeschleuste OMR hemmte die Telomerase effizient. Wiederholte Behandlung mit 
Nanoplexen über 102 Tage reduzierte die Telomerase-Aktivität in A549 Zellen kontinuierlich um 80% 
und verkürzte die Länge der Telomere auf etwa 50%.  Nanoplexe zeigten eine nur sehr geringe akute 
Cytotoxizität. Darüber hinaus hatte diese Behandlung auf die Viabilität von primären Fibroblasten, die 
aus humanen Lungengeweben isoliert wurden, keinen Einfluss.  
Im Vergleich zu Zelllinien repräsentieren frisch isolierte primäre Lungenkrebszellen besser die 
biologischen Eigenschaften der ursprünglichen Tumoren. Allerdings sind sie schwierig zu kultivieren 
und reagieren empfindlich auf die Kulturbedingungen und Veränderungen der Umwelt. Deshalb 
wurden diese Zellen mit einer verringerten Menge an Nanopartikeln behandelt (Gewicht 
Oligonukleotid / Gewicht Nanopartikel 1:50). 72 Stunden nach dem Experiment war die Telomerase-
Aktivität im Mittel zu 60% gehemmt. Zellmorphologie, Zell-Zell und Zell-Matrix-Interaktionen sind 
in den isolierten Zellen unterschiedlich im Vergleich zum ursprünglichen Gewebe. Deshalb ist die 
Übertragbarkeit von Experimenten mit isolierten Zellen auf in vivo Tumoren limitiert. Die ex vivo 
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Kultivierung viabler Schnitte von Tumorgewebe kann solche Probleme überwinden und ist ein 
geeignetes System, die Reaktion von Tumorzellen auf eine medikamentöse Behandlung im 
Gewebeverband zu evaluieren. 
Im Gewebeschnittmodell werden Tumor-Mikroumgebung und die Integrität der Tumor-Stroma 
Interaktion bewahrt. Hierfür wurden 0,2 mm dicke Gewebeschnitte frisch aus Tumorproben von 
NSCLC-Patienten hergestellt. Wir konnten weisen, dass OMR-Nanoplexe in das Tumorgewebe 
vordringen, Tumorzellen in ihrer "natürlichen" Umgebung transfizieren und die Telomerase  um ca. 
40% hemmen können. Architektur des Gewebes, Zellproliferation und Expression der Telomerase 
wurden nicht beeinflusst. Aufgrund der kurzen Beobachtungszeit von 4 Tagen sind bei der 
Gewebekultur jedoch keine biologische Reaktion zu erwarten. Um diese zu untersuchen, werden in 
vivo Experimente mit einem Tumor Xenograft Modell empfohlen. 
Insbesondere für die Untersuchung einer inhalativen Applikation ist das Modell der isoliert 
perfundierten und beatmeten Rattenlunge einen Schritt näher an der in vivo Situation. Dieses Modell 
wurde erfolgreich eingesetzt, um die Aufnahme und Verteilung des inhalativen Aerosols von OMR- 
Nanoplexen zu untersuchen. Das Aerosol wurde mittels einer direkt in die Bronchien der Lunge 
eingeführten Microsprayer-Nadel erzeugt. Nach der Inhalation konnten OMR-Nanoplexe in der 
gesamten Lunge detektiert werden. Die Inhalation von Nanoplexen beeinflusste die 
Lungenphysiologie nicht. 
Die Stammzellen-Theorien besagen, dass Krebserkrankungen aus einer seltenen Subpopulation von 
stammzellartigen Tumorzellen entstehen können und diese für das Versagen der gegenwärtigen 
Krebstherapien verantwortlich sind. Daher kommen Krebsstammzellen in den Fokus für neue 
Therapiestrategien. Deswegen wurde getestet, ob in NSCLC eine Beziehung zwischen Telomerase, 
und Markern der Tumorproliferation oder Markern für Tumor-Stammzellen bestehen. In 41 
Tumorproben von Patienten mit NSCLC wurde keine signifikante Korrelation zwischen diesen 
Faktoren gefunden. Tumorzellen, die postiv für den Stammzellmarker CD133 waren, zeigten eine 
Tendenz zur geringeren Expression von Telomerase. Es sind wahrscheinlich große Probenmengen 
oder besser Stemmzellmarker erforderlich, um Krebsstammzellen zu identifizieren und  die Beziehung 
zwischen Krebsstammzellen und Telomeraseaktivität besser zu verstehen.  
Die hier beschriebenen Experimente geben klare Hinweise darauf, dass die durch Nanopartikel 
unterstützte Behandlungsverfahren mit Telomeraseinhibitoren auf Oligonukleotid-Basis ein großes 
Potenzial für die in vivo Anwendung in der Krebstherapie haben. Inhalative verabreichte Nanoplexe 
könnten ein geeignetes Mittel zur topischen Behandlung von Lungenkrebs werden. 
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Abbreviations 
 
AFM atomic force microscopy  
ATCC American Type Culture Collection 
BCA assay bicinchoninic acid assay 
BSA bovine serum albumin  
CHAPS 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate  
CLSM Confocal Laser Scanning Microscopy 
Digo-OMR   Digoxigenin-labeled 2'-O-Methyl-RNA  
Digo-OMR-nanoplexes    Digo-OMR-nanoparticle-complexes 
DiI  1,1´-Dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate 
DiI-NP DiI-labeled nanoparticle 
Em. emission    
ESA    epithelial specific antigen 
Ex. excitation   
FACS  Fluorescence-activated cell sorting 
FAM 6-carboxy-fluorescein  
FAM-OMR   FAM-labeled 2'-O-Methyl-RNA 
FAM-OMR-nanoplexes FAM-OMR-nanoparticle-complexes  
FCS fetal calf serum  
FISH fluorescence in situ hybridization  
h hours  
H23 NCI-H23  
H460 NCI-H460    
HE   hematoxylin and eosin  
hTERT   human telomerase reverse transcriptase   
hTR human telomerase RNA 
IPL isolated perfused rat lung  
ITAS internal telomerase assay standard 
MEM Minimum Essential Medium  
min minutes 
Mismatch-OMR-nanoplexes Mismatch 2'-O-Methyl-RNA-nanoparticle-complexes  
nanoplexes oligonucleotide-nanoparticle-complexes    
NSCLC Non-small cell lung cancer  
OMR   2'-O-Methyl-RNA  
OMR-nanoplexes   2'-O-Methyl-RNA-nanoparticle-complexes  
Abbreviations 
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PD   population doubling   
PdI   polydispersity index  
PI Propidium Iodide   
PLGA poly(lactide-co-glycolide)  
ps phosphorothioate  
PVA polyvinyl alcohol 
Q-PCR real-time quantitative PCR   
Q-TRAP  Real-time quantitative PCR based telomeric repeat amplification 
protocol   
RCA I Rhodamine-labeled Ricinus Communis Agglutinin I  
RPMI Roswell Park Memorial Institute  
RTA relative telomerase activity 
SCLC Small cell lung cancer 
SD standard deviations 
SDS sodiem dodecyl sulfate buffer 
sec seconds  
SSC sodium chloride-sodium citrate buffer 
TA telomerase activity   
TMRM tetramethylrhodamine methyl ester perchlorate  
TNM system Tumor node metastasis system  
TRAP telomeric repeat amplification protocol 
TRAP-CE Telomeric repeat amplification protocol using capillary electrophoresis 
TRF terminal restriction fragment  
∆∆Ct delta-delta Ct method  
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